




Strategy Into Solutions

2026 Annual Report



Who We Are

Kimball Electronics was founded in 1961 and incorporated in 1998. We deliver a package of value that includes durable, high-reliability electronics, higher-level and final assemblies, and contract development and manufacturing organization (“CDMO”) solutions. Through our Kimball Solutions platform, we provide integrated manufacturing solutions that combine electronics manufacturing services, medical disposables, drug delivery solutions, precision molded plastics, and end-to-end product lifecycle support. Our CDMO solutions support the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. The acquisition of Helvoet Polymer Technologies B.V. (“Helvoet”) on July 1, 2026* expanded our capabilities in precision molded plastics, complex tooling, and medical device component manufacturing, enhancing our ability to provide comprehensive solutions to customers across the medical and pharmaceutical markets. Customers and industry trade publications regularly award us for our design, engineering, and manufacturing expertise that, coupled with robust processes and procedures, helps us ensure that we deliver the highest levels of quality, reliability, and innovative service throughout the entire lifecycle of our customers’ products. Our Customer Relationship Management (“CRM”) model is key to providing our customers with convenient access to our highly integrated global footprint, enabled by our largely standardized operating system and procedures.

We offer our services globally on a contract basis, and we manufacture products to our customers’ specifications. Our services primarily include:

- Production and testing of printed circuit board assemblies (PCBAs);
- Higher-level and final assembly of medical, automotive, and industrial products;
- Design services and support, including innovative Design for Excellence solutions;
- Supply chain services and support;
- Rapid prototyping and new product introduction support;
- Product design and process validation and qualification;
- Industrialization and automation of manufacturing processes;
- Reliability testing (testing of products under a series of extreme environmental conditions);
- Aftermarket services;
- Production and assembly of medical devices, medical disposables including packaging, and other non-electronic products;
- Drug delivery devices and solutions with and without electronics;
- Class 7 and 8 clean room assembly, cold chain and product sterilization management;
- Design engineering and production of precision molded plastics; and
- Complete product lifecycle management.

Our Global Presence

Our global footprint supports our customers’ specialized manufacturing needs. Whether the requirement is in-region support for an end market, access to a lower cost market, or proximity to a customer team, Kimball has a solution.

North America

Jasper, Indiana
(*Manufacturing and World Headquarters*)
Indianapolis, Indiana (*2 plants*)
Reynosa, Mexico (*2 plants*)

Europe

Poznan, Poland
Timisoara, Romania
Amsterdam, The Netherlands
Tilburg, The Netherlands

Asia

Nanjing, China
Laem Chabang, Thailand
Pune, India

Financial Highlights

(Amounts in thousands, except per share data)

Net Sales

Operating Income, as reported (GAAP)

Stock Compensation Expense

SERP

Restructuring Expense

Asset Impairment (Gain on Disposal)

Acquisition Costs

Adjusted Operating Income (non-GAAP)

Adjusted Operating Income (non-GAAP)

Depreciation & Amortization

Adjusted EBITDA (non-GAAP)

Net Income, as reported (GAAP)

Stock Compensation Expense, After-Tax

Restructuring Expense, After-Tax

Asset Impairment (Gain on Disposal), After-Tax

Acquisition Costs, After-Tax

Adjusted Net Income (non-GAAP)

Diluted Earnings per Share, as reported (GAAP)

Stock Compensation Expense

Restructuring Expense

Asset Impairment (Gain on Disposal)

Acquisition Costs

Adjusted Diluted Earnings per Share (non-GAAP)

Cash Flow from Operations

Capital Expenditures⁽¹⁾

Share Owners’ Equity

Fiscal Year Ended June 30,

2026

2025

\$ 1,431,378

\$ 1,486,727

\$ 66,057

\$ 45,535

8,232

6,519

666

614

4,977

10,990

(14,721)

(2,391)

524

-

\$ 65,735

\$ 61,267

\$ 65,735

\$ 61,267

38,705

36,994

\$ 104,440

\$ 98,261

\$ 27,960

\$ 16,984

6,242

4,944

3,610

8,314

(11,164)

(2,086)

397

-

\$ 27,045

\$ 28,156

\$ 1.13

\$ 0.68

0.25

0.19

0.15

0.33

(0.45)

(0.08)

0.01

-

\$ 1.09

\$ 1.12

\$ 72,267

\$ 183,937


\$ 51,675

\$ 33,675

\$ 585,132

\$ 569,884

Diversified Portfolio of End Markets and Market Services



Automotive (-7%)**

- Electronic Power Steering
- Electronic Braking Systems
- Body Controls



Medical (+4%)**

- Sleep Therapy and Respiratory Care
- AED
- Surgical Devices
- In Vitro Diagnostics
- Image Guided Therapy
- Drug Delivery/Auto-injectors
- Patient Monitoring
- Blood Separation



Industrial (-5%)**

- Climate Controls
- Smart Metering
- Off-Highway/Commercial Equipment
- IoT & Factory Automation
- Energy Generation & Storage
- Public Safety

* Percentage of net sales

**Percentage change compared to fiscal year 2025. Medical increased more than 10% when normalizing for a one-time sale of consigned inventory in fiscal 2025. See fiscal 2026 Earnings Release for Non-GAAP reconciliation.

* The acquisition of Helvoet Polymer Technologies B.V. (“Helvoet”) on July 1, 2026, which occurred after our fiscal year end, is reported as a subsequent event (in the 10-K in Note 22–Subsequent Event of Notes to Consolidated Financial Statements).

⁽¹⁾ Capital Expenditures include purchases of capitalized software.

“I am filled with a sense of pride and accomplishment for the transformation that occurred in fiscal 2026 as we continued to position our Company for the future.”

— Richard D. Phillips, Chief Executive Officer

To Our Share Owners

As I write to you today, reflecting back on my third full year as CEO, I am filled with a sense of pride and accomplishment for the transformation that occurred in fiscal 2026 as we continued to position our Company for the future. It is humbling, and a privilege, to lead an organization with more than six decades of manufacturing excellence, a genuine commitment to long-term relationships, and Guiding Principles that shape how we serve our customers, support our people, give back to our communities, and create value for our Share Owners. I truly appreciate the trust that you have placed in me with this opportunity.

Finishing Strong and Building Momentum

Fiscal 2026 was a year of transition that included celebrating milestones such as our 65th anniversary as a Company, cutting the ribbon at the grand opening for our Post Road medical facility in Indianapolis, and kicking off a phased rebranding campaign to Kimball Solutions. Then, at the dawn of our new fiscal year, we welcomed Helvoet Polymer Technologies on July 1, 2026. Throughout the year, our teams navigated uneven demand and geopolitical uncertainty, but ended with a strong finish, momentum, and an outlook projecting a return to top-line growth in fiscal 2027. We also strengthened our balance sheet, generated strong cash flow, and used it to pay down debt while investing in future growth as a differentiated, global, contract development and manufacturing organization.

Financial highlights in fiscal 2026 included:

- Revenue of \$1.4 billion, with medical sales increasing more than 10%*
- Adjusted operating income margin of 4.6% of net sales
- Cash generated from operating activities of \$72 million
- Borrowings of \$117 million, the lowest level of debt in more than four years
- Returned \$12 million to you, our Share Owners, by repurchasing 447,000 shares of common stock

*Normalizing for a one-time sale of consigned inventory in fiscal 2025.

Celebrating Milestones and Our New Brand

In addition to our 65th anniversary, the fiscal year was also highlighted by other important milestones around the Company. Our facility in Romania surpassed 10 years of operation in Timisoara, while China recognized 20 years in Nanjing. Both locations had very strong results in fiscal 2026 with each of them predominantly serving regional Automotive markets as a Tier 2 supplier.

We also celebrated the grand opening of our Post Road medical manufacturing facility in Indianapolis with a ribbon-cutting and open house. This 308,000-square-foot building is more than twice our existing footprint in Indy and will support current production of medical devices, single-use surgical instruments, and selected drug delivery devices, such as auto-injectors. It also has plenty of additional space for us to expand into new end markets or support growth with medical companies actively looking for incremental capacity to keep pace with the robust growth in the industry. Our clean room and controlled manufacturing footprint has more than doubled and we have plastic injection molding infrastructure to triple current operations. Equipment from our existing campus is actively being moved into the new building with selected qualifications expected to start in the fall and production to commence within fiscal 2027.

This facility is also the first location to feature the new Kimball Solutions name in its signage. In fiscal 2026, we launched a campaign to update our brand — a strategic move reflecting the evolution beyond traditional Electronics Manufacturing Services — with an expanded portfolio of capabilities that includes design and engineering support, supply chain management, precision molded plastics for medical applications, and higher-level and final product assemblies for the verticals we serve. It also embodies our customer-centric approach for long-lasting partnerships, providing end-to-end solutions from design and prototyping to new product introduction, manufacturing, and aftermarket support. The rebrand will occur in a phased rollout at our locations around the world and is expected to be completed at the end of fiscal 2027, pending a Share Owner vote that will occur this November. I thank you in advance for your



support. We believe this is yet another example of our commitment to innovation and the vision to deliver comprehensive solutions worldwide.

Advancing Our Medical CDMO Strategy

On July 1, 2026, we acquired Helvoet Polymer Technologies, a European-based medical CDMO with operations in Tilburg, The Netherlands, and Pune, India. Helvoet brings highly automated micro-molding and precision injection-molding capabilities supporting microfluidics, in vitro diagnostics, and drug delivery applications. Approximately 70% of its revenue serves medical end markets, and its long-standing customer relationships, technical expertise, and strong leadership team are highly complementary to Kimball.

Our first priority is to unlock top-line synergies across the combined organization. Helvoet enhances our presence in Europe, gives us immediate access to the emerging market in India, and provides a new avenue to leverage the facility in Indianapolis. We are taking a measured and thoughtful approach to integration. Customer interest has been strong and collaboration between the teams is underway. Together, we can pursue larger and more complex programs, expand customer relationships, and support medical companies across product lifecycles.

Returning to Growth

As we enter fiscal 2027, our outlook reflects a return to organic sales growth and the accretive contribution from Helvoet. Medical is expected to drive the top line with a robust increase in our base business and the addition of medical sales from the highly concentrated customer portfolio of Helvoet. The combination should result in medical representing more than one-third of our total

portfolio, which is in line with our stated objective to balance revenue across the verticals. Of course, we also look to grow Automotive and Industrial, which are expected to have stabilizing trends in the year.

Our capital allocation strategy will continue to invest where we have differentiated capabilities, attractive growth opportunities, and the potential to earn appropriate returns. In support, we have aligned our efforts to attract investors focused on the medical industry with banking partners and equity research analysts with a similar focus but new to the Kimball story.

The strategy matters, but execution will always depend on our people and our culture. Throughout the year, our team demonstrated perseverance and collaboration, maintaining a focus on our customers, supporting one another, and continuing to improve the business. I am grateful for their commitment and proud of how they represent “The Kimball Way” around the world. Our strategic journey continues to build, and so does my excitement for the future of the Company. I thank you for your continued support.

We invite you to stay informed by visiting www.kimballelectronics.com. For more detailed information about fiscal 2026, we encourage you to read the Form 10-K that follows.

Ric Phillips

Ric Phillips
Chief Executive Officer and Director
Kimball Electronics, Inc.



Kimball Solutions Indianapolis

In February 2026, Kimball Solutions officially opened the Indianapolis Post Road facility, a significant milestone in the company's long-term medical growth strategy. Designed specifically to serve the unique needs of medical and life sciences customers, the 308,000-square-foot campus brings together advanced capabilities including injection molding, clean room manufacturing, complex assembly, automation, sterilization support, and cold chain logistics within a single integrated operation. This facility will strengthen Kimball Solutions' ability to support customers from early-stage development through commercial-scale production while delivering the quality, reliability, and regulatory excellence required in the medical market.

MEDICAL MARKET

Strategy Into Solutions

The opening of our Indianapolis Post Road facility in February of 2026 and the acquisition of Helvoet during July of 2026 are milestones in the same strategic journey — expanding our global footprint, deepening our technical capabilities, and creating a stronger medical manufacturing platform for our customers. Together, these investments enhance our ability to support customers across the product lifecycle, from precision components and complex assemblies to scaled global production, while reinforcing our commitment to quality, innovation, and long-term partnerships. As the medical market continues to evolve, these strategic investments position us to help customers navigate increasing complexity, accelerate innovation, and bring life-improving technologies to patients around the world.



Transformation Into a Global Medical CDMO

July 1, 2026, marked one of the most significant milestones in the company's medical growth strategy with the acquisition of Helvoet Polymer Technologies. The addition of manufacturing operations in the Netherlands and India expanded Kimball Solutions' global footprint while adding highly complementary capabilities in diagnostics, microfluidics, drug delivery, precision polymer technologies, and clean room manufacturing. Together with the opening of the Indianapolis medical facility earlier in the year, the acquisition strengthens our ability to support customers with a broader range of technologies, greater geographic flexibility, and enhanced manufacturing expertise. This strategic combination creates a more comprehensive medical manufacturing platform that is designed to support innovation, improve supply chain resiliency, and help customers bring complex medical products to market around the world.



CDMO

Contract Development and Manufacturing Organization reflects our ability to support customers from product development through commercial manufacturing.



“Our investments in Indianapolis and Helvoet are ultimately about creating more value for our customers. Together, they expand the capabilities, capacity, and geographic reach available to our customers, enabling us to support increasingly complex medical products with greater flexibility, deeper technical expertise, and a more comprehensive manufacturing solution.”

— Kathy R. Thomson, Chief Commercial Officer



170+

Employees in our Indianapolis facilities and expanding

1M+

Current injection-molded components per week in our Indianapolis facilities and expanding

308,000 ft²

Total office and manufacturing space at the Post Road facility



MEDICAL MARKET

Real Solutions for Everyday Life

During fiscal 2026, our medical business continued to validate the strength of our strategy, delivering growth while expanding our role as a trusted partner for complex healthcare products. By combining electronics manufacturing services, higher-level assembly capabilities, global supply chain expertise, and advanced manufacturing solutions, we helped customers bring innovative medical technologies to market with speed, quality, and reliability.

Supported by robust quality systems and deep experience in regulated medical manufacturing, we partner across the product lifecycle to deliver scalable solutions that meet the industry's highest standards for quality, compliance, and patient safety. Through continued investment in capabilities, capacity, and customer partnerships, we are transforming strategy into solutions and strengthening our position as a leading medical manufacturing partner.



\$412.8M

MEDICAL MARKET
NET SALES

Strategy Into Solutions

Moving Production Without Disruption

As part of a major medical manufacturing transfer initiative, Kimball Solutions successfully executed one of its largest and most complex global production transitions, demonstrating the organization's ability to move highly regulated manufacturing operations while maintaining uninterrupted customer supply. The effort required the seamless transfer of production, supply chain management, quality systems, regulatory responsibilities, materials, and manufacturing processes to a new global location while preserving product integrity, compliance, and operational performance.


Through disciplined program governance, copy-exact manufacturing replication, supplier qualification, process validation, and extensive cross-functional collaboration, the team established a scalable manufacturing footprint designed to support long-term growth. The transfer included six production lines, over 500 final assemblies, and more than 1,300 supply chain components, while maintaining business continuity across a product portfolio representing more than \$100 million in revenue. This achievement highlights Kimball Solutions' proven expertise in executing complex, multi-site manufacturing transfers with precision, reinforcing customer confidence and delivering the quality, reliability, and regulatory excellence required in the medical market.



From Components to Complete Solutions

Kimball Solutions combines advanced electronics manufacturing, higher-level system assembly, and world-class quality management to support the production of complex medical technologies used in life-saving diagnostic and therapeutic procedures worldwide. Our teams apply disciplined manufacturing controls, robust validation processes, and comprehensive supply chain management to ensure every product meets the exacting standards of the medical industry. The result is a trusted manufacturing partnership that enables customers to deliver innovative healthcare solutions with the quality, reliability, and regulatory excellence that patients and providers depend on every day.

~31M
Patients impacted globally



7.6M+

Medical assemblies, devices, and units manufactured for medical solutions in fiscal 2026

27 years

of experience manufacturing medical electronics and life-improving healthcare technologies

29%

of annual revenue is medical solutions products





INDUSTRIAL MARKET

Real Solutions for Powering, Protecting, and Connecting Communities

During fiscal 2026, our industrial business continued to build on a strong foundation of innovation, diversification, and customer partnership. By combining electronics manufacturing services, higher-level assembly capabilities, global supply chain expertise, and advanced manufacturing solutions, we helped customers bring increasingly complex products to market with greater speed, efficiency, and reliability. Industrial growth initiatives remained focused on key markets including off-highway equipment, climate and energy systems, IoT and factory automation, and public safety, while expanding our role in higher-value assembly and complete system integration.

Leveraging our experience in high-reliability manufacturing and challenging operating environments, we partner with customers to deliver scalable solutions that improve performance, simplify supply chains, and support long-term growth. Through continued investment in capabilities, strategic market expansion, and collaborative customer relationships, we are transforming strategy into solutions and strengthening our position as a trusted manufacturing partner across the industrial marketplace.



\$361.7M

INDUSTRIAL MARKET
NET SALES

Strategy Into Solutions

Complete System Manufacturing

We continued to advance our complete system manufacturing capabilities during fiscal 2026, building on our long-standing expertise in complex subassembly production. Over the past year, we expanded our portfolio of higher-level, complex assembly products, enabling us to support customers with more integrated solutions, simplify their supply chains, and accelerate the path from concept to production.



9.5M+

Public safety assemblies produced in fiscal 2026, helping keep communities safe through reliable electronics.

58 years

of high-power electronics manufacturing expertise, delivering reliable solutions for demanding industrial, automation, energy, and electrification applications

25%

of annual revenue is industrial solutions products


Powering the Next Generation of Off-Highway Equipment

As off-highway industrial equipment becomes smarter, more connected, and increasingly electrified, manufacturers are looking for partners who can help bring greater complexity and innovation to market. Kimball Solutions is supporting this evolution through advanced electronics manufacturing and higher-level assembly capabilities designed for demanding applications in agriculture, construction, commercial equipment, and other rugged environments. Building on decades of experience serving the automotive market, the company leverages its expertise in quality, reliability, and complex electronics manufacturing to support continued growth in off-highway and commercial equipment applications. By combining engineering expertise, global manufacturing resources, and integrated assembly solutions, Kimball Solutions helps customers accelerate product development, enhance performance, and meet the growing demands of automation, connectivity, and sustainable operation in the next generation of industrial equipment.



10,000+

Off-Highway electronic control assemblies enabled



AUTOMOTIVE MARKET

Real Solutions for the Road Ahead

While automotive market conditions remained challenging, Kimball Solutions continued to earn opportunities to support additional customer manufacturing programs and future vehicle launches. These programs demonstrate the strength of the company's customer partnerships and its reputation for delivering high-quality manufacturing solutions for complex automotive applications.

Fiscal 2026 marked continued progress toward diversifying the automotive portfolio beyond traditional product concentrations. Strategic efforts focused on expanding into adjacent growth areas including domain controllers, advanced braking technologies, power electronics, and other next-generation vehicle systems.



\$656.9M

AUTOMOTIVE MARKET
NET SALES

Strategy Into Solutions

Quality at the Core of Innovation

Since 1985, Kimball Solutions has built a legacy of manufacturing high-reliability electronic systems for many of the industry's leading vehicle platforms. With decades of experience producing steering control electronics and other safety-critical automotive products, the company has evolved alongside the rapid advancement of vehicle technology while maintaining a steadfast commitment to quality, operational excellence, and customer success. Today, Kimball Solutions leverages its global manufacturing footprint and advanced capabilities to support the next generation of automotive innovation.



Driving Success Together

For more than 15 years, Kimball Solutions has partnered with a global automotive technology leader, supporting the evolution of critical vehicle control and motion systems across multiple regions. This enduring relationship is built on a foundation of operational excellence, continuous improvement, cost innovation, and trusted collaboration. During fiscal 2026, the partnership continued to grow through expanded manufacturing opportunities and customer recognition for delivering measurable value in a highly competitive market. These achievements reflect the strength of a relationship that has evolved beyond supplier-customer interactions into a strategic partnership focused on quality, responsiveness, and long-term success.



15 years
of collaboration, quality, and
long-term commitment



4 awards
for exceptional partnership
and performance from our
Automotive customers in
fiscal 2026

41 years
of manufacturing automotive
electronics for safety-critical
vehicle applications

46%
of annual revenue
is automotive
solutions products



PEOPLE & CULTURE

Our People are the Real Solutions

Our Guiding Principles say it plainly: our customer is our business, and our people are the company. Kimball has been built upon a tradition of pride in craftsmanship, mutual trust, personal integrity, respect for the dignity of the individual, a spirit of cooperation, and a sense of family and good humor. That is exactly how our strategy becomes solutions for our customers. We cultivate a leadership style built on personal autonomy and empowerment, individual initiative and teamwork, employee involvement and continuous improvement, and open, non-defensive communication. In a year marked by softening demand, difficult decisions, and the closure of a facility, we kept watch over the hearts and minds of our people, and they answered by staying, by leading, and by holding the line on quality. We emphasize human-centered and purpose-driven methodologies to foster a work environment where our people can thrive, because the distance between a plan and a solution is always measured in the judgment of the person closest to the problem. Our people are the company. Our people are the real solutions.

Strategy Into Solutions

Celebrating Milestones Across Our Global Footprint

65

Calendar Year 2026 marks several significant milestones for Kimball, including the 65th anniversary of the company and its Jasper, Indiana location, 20 years of operations in China, and 10 years in Romania. These anniversaries reflect the strength of our global team, the trust of our customers, and a legacy of manufacturing excellence that continues to span generations and geographies.



We target one percent of adjusted net income annually to community investment through financial contributions, in-kind donations, and employee volunteering. We also, through a smaller portion of giving funds, aid charitable organizations whose reach extends well beyond the geographies where we operate. For additional information about our annual giving initiatives, please refer to our [Guiding Principles Report](#), published each spring and covering the previous calendar year.



1% adjusted net income annual donation target

Our **Leading The Kimball Way** leadership development program brought together a diverse group of leaders for personal reflection, shared learning, and practical application rooted in our values. Participants explored Leading Self, Leading Teams, and Leading at the Enterprise by building deeper self-awareness, strengthening team effectiveness, and expanding enterprise-wide thinking.

Through facility tours, interactive sessions, and peer collaboration, leaders connected key concepts to real-world application, meaningful dialogue, challenging one another's perspectives, and strengthening connections across the organization, all while reinforcing a shared commitment to leading with purpose.



~5,600
Employees worldwide

8 years
Average tenure of employees globally


↑15
Basis point improvement year over year for our employee Guiding Principles Survey score

FINANCIAL PERFORMANCE


Profits are the Ultimate Measure

As we expected, fiscal 2026 was a year of transition in a challenging environment. Guidance for fiscal 2027 projects a return to top-line growth, plus the accretive impact of Helvoet Polymer Technologies, and we will be leveraging the balance sheet to support those efforts.

Revenue and EPS Growth
(In millions)



Debt
(In millions)



\$1,431M

Net sales

4.6%

Adjusted operating income*

\$72M

Cash from operations

82 Days

Cash conversion days

\$117M

The lowest debt level in over four years

*Adjusted Operating Income is a Non-GAAP measure — refer to Reconciliation of Non-GAAP Results on the Company website.



“As a CFO who takes great pride in the condition of our balance sheet, I am pleased that we exited the fiscal year in a position of strength, with plenty of dry powder in the form of borrowing capacity and available cash to strategically invest.”

— Jana T. Croom,
Chief Financial Officer




Performance Graph

The following performance graph is not deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C under the Exchange Act or to the liabilities of Section 18 of the Exchange Act and will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent the Company specifically incorporates it by reference into such a filing.

The graph below compares the cumulative total return to Share Owners of the Company’s common stock for the five-year period commencing June 30, 2021 and ending June 30, 2026 to the cumulative total return of the Nasdaq Stock Market (U.S.) and the Russell 2000 Electronic Components subindex for the same period

of time. We are currently a member of the Russell 2000 Electronic Components subindex and believe that this market capitalization-weighted index reflects issuers with broadly similar market capitalizations that operate in our industry. We believe this subindex provides a more meaningful comparison of the cumulative return of our stock than any other lines of business or published industry index or peer groups.

The graph assumes \$100 is invested in the Company’s stock and each of the two indexes at the closing market quotations on June 30, 2021 and that dividends, if any, are reinvested. The performance shown on the graph is not necessarily indicative of future price performance.



	06/30/2021	06/30/2022	06/30/2023	06/30/2024	06/30/2025	06/30/2026
Kimball Electronics, Inc.	\$100.00	\$92.46	\$127.09	\$101.10	\$88.45	\$117.76
Nasdaq Stock Market (U.S.)	\$100.00	\$76.53	\$96.57	\$125.19	\$144.83	\$195.24
Russell 2000 Electronic Components subindex	\$100.00	\$132.31	\$149.73	\$181.66	\$246.14	\$610.83



A New Name for a Broader Future: From Electronics to Solutions

Fiscal 2026 marked a defining moment in the evolution of our company as we launched the transition from **Kimball Electronics** to **Kimball Solutions**, reflecting the business we have become and the future we are building. For more than 65 years, our reputation has been grounded in manufacturing excellence, operational discipline, and lasting customer relationships.

Today, our capabilities extend far beyond electronics manufacturing services to include design engineering, supply chain solutions, precision plastics, advanced manufacturing, higher-level assembly, and full product lifecycle support. The Kimball Solutions name more accurately represents the breadth of value we deliver and our commitment to helping customers solve complex challenges across the medical, industrial, and automotive markets. The timing of the rebrand underscores the Company's expanded capabilities across the full product lifecycle, from design engineering and supply chain management to advanced manufacturing, precision plastics, and full product assembly. It also reflects our continued investments in diverse capabilities that position us for long-term success.

The first phase of the rebrand was completed on July 1, 2026, at our Jasper and Indianapolis operations. The remaining facilities will adopt the Kimball Solutions name on a staggered timeline throughout 2026 and 2027, pending all local regulatory and legal requirements, culminating with the completed official corporate entity name change on July 1, 2027, subject to approval by Kimball's Share Owners. If the name change is approved, our common stock is expected to trade under the new ticker symbol "KMBL" (which we have already reserved) when we complete our corporate entity name change.

More than a new name, Kimball Solutions represents our evolution into a full end-to-end manufacturing solutions partner while remaining firmly rooted in the quality, reliability, and customer focus that have defined our company for generations. As we honor our heritage and build on decades of trusted partnerships, the Kimball Solutions brand reflects our confidence in the future and our commitment to delivering innovative manufacturing solutions with a continued focus on customer-centric, problem-solving partnerships.

"Kimball Solutions better represents who we are today and where we are going. While our heritage in electronics manufacturing remains strong, our customers increasingly rely on us for more comprehensive, end-to-end solutions that solve complex challenges across industries."

— Richard D. Phillips
Chief Executive Officer



Kimball
Solutions

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K**

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 001-36454



KIMBALL ELECTRONICS, INC.

(Exact name of registrant as specified in its charter)

Indiana

*(State or other jurisdiction of
incorporation or organization)*

1205 Kimball Boulevard, Jasper, Indiana

(Address of principal executive offices)

35-2047713

(I.R.S. Employer Identification No.)

47546

(Zip Code)

(812) 634-4000

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each Class</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered</u>
Common Stock, no par value	KE	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒	Emerging growth company	☐
Non-accelerated filer	☐	Smaller reporting company	☐		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the common stock held by non-affiliates, as of December 31, 2025 (the last business day of the Registrant's most recently completed second fiscal quarter), was \$667.3 million based on 98.1% of common stock held by non-affiliates.

The number of shares outstanding of the Registrant's common stock as of August 6, 2026 was 23,966,995 shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the Annual Meeting of Share Owners to be held on November 13, 2026, are incorporated by reference into Part III.

KIMBALL ELECTRONICS, INC.

FORM 10-K INDEX

Page No.

PART I

Item 1.	Business	3
Item 1A.	Risk Factors	11
Item 1B.	Unresolved Staff Comments	20
Item 1C.	Cybersecurity	20
Item 2.	Properties	21
Item 3.	Legal Proceedings	21
Item 4.	Mine Safety Disclosures	21
Information about Our Executive Officers		22

PART II

Item 5.	Market for Registrant’s Common Equity, Related Share Owner Matters and Issuer Purchases of Equity Securities	23
Item 6.	[Reserved]	23
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 8.	Financial Statements and Supplementary Data	33
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	72
Item 9A.	Controls and Procedures	72
Item 9B.	Other Information	72
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	72

PART III

Item 10.	Directors, Executive Officers and Corporate Governance	73
Item 11.	Executive Compensation	73
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Share Owner Matters	74
Item 13.	Certain Relationships and Related Transactions, and Director Independence	74
Item 14.	Principal Accounting Fees and Services	74

PART IV

Item 15.	Exhibits, Financial Statement Schedules	75
Item 16.	Form 10-K Summary	75
SIGNATURES		78

PART I

Item 1 - *Business*

General

As used herein, the terms “Company,” “Kimball Electronics,” “we,” “us,” or “our” refer to Kimball Electronics, Inc., the Registrant, and its subsidiaries. Reference to a year relates to a fiscal year, ended June 30 of the year indicated, rather than a calendar year unless the context indicates otherwise. Additionally, references to the first, second, third, and fourth quarters refer to those respective quarters of the fiscal year indicated.

Forward-Looking Statements

This document contains certain forward-looking statements. These are statements made by management, using their best business judgment based upon facts known at the time of the statements or reasonable estimates, about future results, plans, or future performance and business of the Company. Such statements involve risk and uncertainty, and their ultimate validity is affected by a number of factors, both specific and general. They should not be construed as a guarantee that such results or events will, in fact, occur or be realized as actual results may differ materially from those expressed in these forward-looking statements. The statements may be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” “estimates,” “forecasts,” “seeks,” “likely,” “future,” “may,” “might,” “should,” “would,” “could,” “will,” “potentially,” “can,” “goal,” “predict,” “probable,” and similar expressions. It is not possible to foresee or identify all factors that could cause actual results to differ from expected or historical results. We make no commitment to update these factors or to revise any forward-looking statements for events or circumstances occurring after the statement is issued, except as required by law.

The risk factors discussed in Item 1A - Risk Factors of this report could cause our results to differ materially from those expressed in forward-looking statements. Among those factors are the risks related to (i) our recently announced acquisition of Helvoet, (ii) the ongoing impact of tariffs, sanctions, and other trade policy changes, (iii) our development and use of artificial intelligence, (iv) the volume, mix, and cadence of orders from our largest customers, (v) evolving sustainability, cybersecurity, AI, and privacy laws and regulations, (vi) shifts in U.S. political, tax, and regulatory policy and (vii) supply chain disruptions. There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. Any such risks could cause our results to differ materially from those expressed in forward-looking statements.

At any time when we make forward-looking statements, we desire to take advantage of the “safe harbor” which is afforded such statements under the Private Securities Litigation Reform Act of 1995 where factors could cause actual results to differ materially from forward-looking statements.

Overview

Kimball Electronics was founded in 1961 and incorporated in 1998. We deliver a package of value that includes durable, high-reliability electronics, higher level and final assemblies, and contract development and manufacturing organization (“CDMO”) solutions. Through our Kimball Solutions platform, we provide integrated manufacturing solutions that combine electronics manufacturing services, medical disposables, drug delivery solutions, precision molded plastics, and end-to-end product lifecycle support. Our CDMO solutions support the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. The acquisition of Helvoet Polymer Technologies B.V. (“Helvoet”) on July 1, 2026, which occurred after our fiscal year end and is therefore reported as a subsequent event in Note 22 - Subsequent Event of Notes to Consolidated Financial Statements, expanded our capabilities in precision molded plastics, complex tooling, and medical device component manufacturing, enhancing our ability to provide comprehensive solutions to customers across the medical and pharmaceutical markets. Customers and industry trade publications regularly award us for our design, engineering, and manufacturing expertise that, coupled with robust processes and procedures, help us ensure that we deliver the highest levels of quality, reliability, and innovative service throughout the entire life cycle of our customers’ products. Our Customer Relationship Management (“CRM”) model is key to providing our customers convenient access to our highly integrated global footprint, enabled by our largely standardized operating system and procedures.

In 2026, we introduced the Kimball Solutions brand to represent our expanded portfolio of non-electronic manufacturing solutions, including medical disposables, drug delivery systems, precision molded plastics, clean room assembly, micro fluidics, sterilization management, and related CDMO capabilities. The Kimball Solutions brand complements our long-standing electronics manufacturing services business and reflects our strategy to provide customers with a broader package of value through integrated manufacturing solutions. We intend to change our name to Kimball Solutions, Inc., subject to Share Owners’ approval at our 2026 Annual Meeting of Share Owners scheduled for November 13, 2026. If approved, we expect that

our common stock will continue to trade on The Nasdaq Stock Market LLC and that our current ticker symbol (KE) would change to KMBL. Unless and until any name change becomes effective, we will continue to operate as Kimball Electronics, Inc. under our current ticker symbol.

Our corporate headquarters is located at 1205 Kimball Boulevard, Jasper, Indiana. We manufacture products for our customers at facilities located in the United States, China, India, Mexico, The Netherlands, Poland, Romania, and Thailand. As discussed above, we completed the acquisition of Helvoet Polymer Technologies B.V. (“Helvoet”) on July 1, 2026, and these subsidiaries manufacture products in India and The Netherlands.

Reporting Segment

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and assessing performance. Each of our business units qualifies as an operating segment with its results regularly reviewed by our chief operating decision maker, the Chief Executive Officer. Our operating segments meet the aggregation criteria under the accounting guidance for segment reporting. As of June 30, 2026, all of our operating segments provided contract manufacturing services, including engineering and supply chain support, for the production of electronic assemblies and other products including medical devices, medical disposables, and precision molded plastics primarily in automotive, medical, and industrial applications, to the specifications and designs of our customers. The nature of the products, the production process, the type of customers, and the methods used to distribute the products have similar characteristics across all our operating segments. Each of our operating segments serves customers in multiple markets, and many of our customers’ programs are manufactured and serviced by multiple operating segments. We leverage global processes such as component procurement and customer pricing that provide commonality and consistency among the various regions in which we operate. All of our operating segments have similar long-term economic characteristics, and as such, have been aggregated into one reportable segment.

Our Business Strategy

We intend to achieve sustained, profitable growth in the markets we serve by supporting the global growth initiatives of our customers as a multifaceted manufacturing solutions company through:

- Leveraging Our Global Footprint – responding to increasing customer demand for geographic diversification, supply chain resiliency, and manufacturing optionality through our facilities in North America, Europe, and Asia, while evaluating opportunities to expand into additional strategic regions;
- Expanding Our Package of Value – enhancing our core contract manufacturing services capabilities while expanding our offerings in complex system assembly, medical disposables, drug delivery systems, specialized manufacturing processes, precision molded plastics, and integrated CDMO solutions with particular emphasis on medical and pharmaceutical applications;
- Expanding Our Markets – exploring opportunities and making investments that will broaden existing or establish new markets.

Through Kimball Solutions, we have expanded beyond our traditional EMS foundation to offer an integrated portfolio of EMS and CDMO solutions. We are increasingly positioning the Company as a strategic manufacturing partner capable of supporting customers across both electronic and non-electronic product categories. By combining our global EMS expertise with medical disposables, precision molded plastics, clean room assembly, sterilization management, and drug delivery capabilities, we provide customers with a broader range of solutions throughout the product lifecycle.

Our Business Offerings

For 40 years, we have manufactured safety-critical electronic assemblies for automotive customers, developing invaluable expertise that extends beyond the automotive industry to benefit our medical and industrial customers as well. Because they operate in industries that demand rigorous engineering controls and that commonly require long product life cycles, our customers rely on our track record of quality, international standard certifications, financial stability, social responsibility, and commitment to long-term relationships. By harnessing our experience and expertise in design and process validation, traceability, process and control change, as well as lean manufacturing, we have achieved substantial growth and diversification.

Many of our customers are multinational companies operating across multiple global regions, and they maximize their supplier relationship by partnering with us at multiple facilities across these locations and regions. We leverage key supply chain advantages and our streamlined operations to cost-effectively manufacture both electronic and non-electronic products, from high volume-low mix to high mix-low volume, within a single production facility for customers from all three of our end market verticals. Our robust new product introduction process and our extensive manufacturing capabilities, including precision

molded plastics, specialized medical manufacturing, clean room assembly, and drug delivery solutions give us the ability to execute to the various quality and reliability expectations of each of our customers. Our CRM model and our strategic approach to expanding our global footprint aligns with our customers' preferences in our three end market verticals allowing us to support their global growth initiatives.

Our customers benefit from consistent supply chain processes across all regions thanks to our global component sourcing, procurement, quoting, and customer pricing operations. Our central sourcing organization employs global procurement strategies that ensure consistent component availability and a uniform pricing approach by leveraging our collective global purchasing volume. Our unified, global quoting model allows us to seamlessly respond to our customers' production needs anywhere across our global footprint.

We combine cross-functional teams from multiple facilities in quality, operational excellence, quoting, and design engineering support with our business development team members located in-region with our global customers. The diverse skill sets on these teams provide a robust conduit critical for executing our customers' objectives and building strong customer relationships. Our robust customer scorecard process provides valuable feedback to all levels of our company, driving continuous improvement initiatives, strengthening our award-winning service, and fostering deep customer loyalty. Our customers trust and value our people, our deep-rooted Guiding Principles, and our sustainability leadership.

We offer our services globally on a contract basis, and we manufacture products to our customers' specifications. Our services primarily include:

- Production and testing of printed circuit board assemblies (PCBAs);
- High-level and final assembly of medical, automotive, and industrial products;
- Design services and support, including innovative Design for Excellence solutions;
- Supply chain services and support;
- Rapid prototyping and new product introduction support;
- Product design and process validation and qualification;
- Industrialization and automation of manufacturing processes;
- Reliability testing (testing of products under a series of extreme environmental conditions);
- Aftermarket services;
- Production and assembly of medical devices, medical disposables including packaging, and other non-electronic products;
- Drug delivery devices and solutions with and without electronics;
- Class 7 and 8 clean room assembly, cold chain and product sterilization management;
- Design engineering and production of precision molded plastics; and
- Complete product life cycle management.

These services are delivered through a combination of our electronics manufacturing services (EMS) and contract development and manufacturing organization (CDMO) offerings, enabling customers to consolidate multiple manufacturing and supply chain requirements with a single strategic supplier.

We take pride in our attentive approach to understanding and adapting to our customers' ever-changing needs and preferences. We continuously seek opportunities to grow and diversify our business and the value we deliver to customers while enhancing our global presence.

We value our customers and their unique needs and expectations. Our customer focus and dedication to unparalleled excellence in engineering and manufacturing has resulted in proven success in the contract manufacturing industry. Personal relationships are important to us, and we strive to build long-term global partnerships. Our commitment to support our customers is backed by our history and demonstrated performance for over the past 60 years.

Marketing Channels

Manufacturing services, including engineering and supply chain support, are marketed by our business development team. We use a CRM model to provide our customers with convenient access to both our global footprint and all of our services throughout the entire product life cycle.

Major Competitive Factors

Key competitive factors in the markets we serve include quality and reliability, engineering design services, production flexibility, on-time delivery, customer lead time, test capability, competitive pricing, and global presence. Numerous contract manufacturing service providers compete globally for business from existing and potential customers. We also face competition from our customers' own capacity and capabilities to in-source production. The proliferation of electronic components in today's advanced products and the continuing trend by original equipment manufacturers in the electronics industry to subcontract the assembly process to companies with a core competency in this area drive growth in our industry. The nature of the EMS/CDMO industries is such that the start-up of new customers and new programs to replace expiring programs occurs frequently. New customers and program start-ups generally cause margin dilution early in the life of a program, which is often recovered as the program becomes established and matures. Our continuing success depends upon our ability to replace expiring customers/programs with new customers/programs.

We, and the industry in general, have special conditions affecting working capital that are significant for understanding our business, including fluctuating inventory levels, which may increase in conjunction with the start-up of new programs and component availability. Additionally, the nature of the contract manufacturing business is such that customers may be required to make advance payments for certain inventory purchases and share in the risk of excess and obsolete inventory.

Our Competitive Strengths

Our evolution from a traditional EMS provider into an integrated manufacturing solutions company expands our competitive strengths. We leverage our experience in producing safety critical electronic assemblies for automotive customers for 40 years to create valuable and innovative solutions for customers in different industries. Our strengths include:

- Core competency of producing durable electronics;
- Body of knowledge in the design and manufacture of products that require high levels of quality control, reliability, and durability;
- Highly integrated, global footprint supporting electronics manufacturing services (EMS) and contract development and manufacturing organization (CDMO) offerings;
- Fully integrated engineering, manufacturing and supply chain services as the contract development and manufacturing organization ("CDMO") including medical disposables, drug delivery systems, precision molded plastics clean room assembly, sterilization management, micro fluidics, and other non-electronic products;
- CRM model and our customer scorecard process;
- Ability to provide our customers with valuable design input for improved manufacturability, reliability, and cost;
- Quality systems, industry certifications, and regulatory compliance;
- Integrated supply chain solutions and competitive bid processes that result in competitive raw material pricing;
- Unique ability to combine high-reliability electronics manufacturing with precision molded plastics and medical CDMO capabilities under a single global operation model;
- Expanded precision molded plastics expertise and manufacturing capabilities through the acquisition of Helvoet; and
- Complete product life cycle management.

Competitors

Numerous manufacturers in the EMS industry compete for business from existing and potential customers. Our competition includes EMS companies such as Benchmark Electronics, Inc., Flex Ltd., Jabil Inc., Plexus Corp., and Sanmina Corporation as well as specialized providers of medical device manufacturing, drug delivery solutions, and precision molded plastics.

Locations

As of August 19, 2026, we have eleven manufacturing facilities with three located in Indiana (two of which are fully operational), two in Mexico, and one located in each of China, India, The Netherlands, Poland, Romania, and Thailand. We continually assess our capacity needs and evaluate our operations to optimize our service levels for supporting our customers' needs around the globe. In 2025, we executed a lease for a third manufacturing facility in Indiana to expand our medical CDMO footprint. When the leased facility is fully operational, it will replace the existing Indianapolis, Indiana facility, reducing our number of manufacturing facilities by one. See Item 1A - Risk Factors for information regarding financial and operational risks related to our international operations.

Seasonality

Consolidated sales revenue is generally not affected by seasonality.

Customers

While the total electronic assemblies market has broad applications, our customers are concentrated in the automotive, medical, and industrial end markets.

Sales by industry as a percent of net sales for each of the three years in the period ended June 30, 2026 were as follows:

	Year Ended June 30		
	2026	2025	2024
Automotive	46%	47%	46%
Medical	29%	27%	25%
Industrial	25%	26%	29%
Total	100%	100%	100%

Included in our sales were a significant amount to Nexteer Automotive, Philips, and ZF, which accounted for the following portions of net sales:

	Year Ended June 30		
	2026	2025	2024
Nexteer Automotive	18%	19%	16%
Philips	11%	*	*
ZF	11%	11%	13%

* amount is less than 10% of total

The nature of the contract manufacturing business is such that start-up of new programs to replace expiring programs occurs frequently. Our agreements with customers are often not for a definitive term and are amended and extended, but generally continue for the relevant product's life cycle, which can be difficult to predict at the beginning of a program. Typically, our customer agreements do not commit the customer to purchase our services until a short time before we begin performing those services. Our customers generally have the right to cancel a particular program subject to contractual provisions governing termination, the final product runs, excess or obsolete inventory, and end-of-life pricing, which reduce the additional costs that we incur when a manufacturing services agreement is terminated.

Raw Materials

Raw materials utilized in the manufacture of contract electronic products are generally readily available from both domestic and foreign sources, although from time to time the industry experiences shortages of certain components due to supply and demand forces, combined with rapid product life cycles of certain components. In addition, unforeseen events such as natural disasters and global events, like pandemics, can and have disrupted portions of the supply chain. We believe that maintaining close communication with suppliers helps minimize potential disruption in our supply chain.

The EMS industry has experienced component shortages, component allocations, and shipping delays, particularly with semiconductors, in recent fiscal years. Further component shortages or allocations could increase component costs and potentially interrupt our operations and negatively impact our ability to meet commitments to customers. We take various actions to attempt to mitigate the risk and minimize the impact to our customers as well as the adverse effect component shortages, component allocations, or shipping delays could have on our results. Through contractual pricing arrangements and negotiations with our customers, we attempt to mitigate the adverse effect that cost increases could have on our results.

Raw materials are normally acquired for specific customer orders and often are not interchangeable among products. Inherent risks associated with rapid technological changes within our industry are mitigated by procuring raw materials, for the most part, based on firm orders. In certain instances, such as when lead times dictate, we enter into contractual agreements for material in excess of the levels required to fulfill customer orders. In turn, material authorization agreements with customers cover a portion of the exposure for material that we must purchase prior to having a firm order. We may also purchase additional inventory to support new product introductions, transfers of production between manufacturing facilities, and to mitigate the potential impact from component shortages.

Intellectual Property

Our primary intellectual property consists of proprietary manufacturing technology and processes, including manufacturing know-how, process methods, quality and testing methodologies, systems, tools, and related confidential information used to deliver our manufacturing services. We protect these assets primarily through trade secret, copyright, trademark, contractual, internal policy, information security, and cybersecurity measures rather than patents.

In the ordinary course of providing services to our customers, we receive and use their specifications, designs, data, and other confidential or proprietary information. We use this customer-owned or customer-licensed intellectual property only as permitted under applicable agreements and solely to provide services to those customers. We maintain policies, nondisclosure agreements and other contractual safeguards, and internal procedures designed to protect our intellectual property and the intellectual property and confidential information of our customers and suppliers. Unless otherwise agreed with a customer, we retain rights to independently developed and generally applicable manufacturing processes, process improvements, methods, systems, tools, know-how, and other proprietary information that are not specific to a customer's product design or customer-owned technology. We also use nondisclosure agreements and other contractual arrangements with customers, suppliers, employees, and third parties to protect confidential information and proprietary rights.

We own and use trademarks and trade names, including Kimball Electronics and Kimball Solutions, in connection with our business and protect them where appropriate. Although our business is not principally dependent on consumer brand recognition, we protect our trademarks and trade names where appropriate. We do not believe that any individual patent, trademark, license, or other intellectual property right is material to our business as a whole.

Sustainability Commitment

We are committed to responsible, sustainable environmental, social, and governance philosophies and practices, which have been a part of our fabric since our founding in 1961. Our approach is guided by long-standing principles that emphasize environmental stewardship, workplace safety, ethical business conduct, and meaningful community engagement. These principles are embedded in our operations and culture across all global locations. To illustrate how our employees uphold these values in their daily work, we published our most recent annual Guiding Principles Report in March 2026. The Report details our sustainability priorities and performance, and highlights how our sustainability efforts support long-term stakeholder relationships and global business success. It reflects several long-standing Guiding Principles of the Company: our customer is our business; our people are the company; the environment is our home; we strive to help our communities be great places to live; profitability and financial resources give us the freedom to shape our future and achieve our vision. The Report is posted on our website at <https://www.kimballelectronics.com/sustainability>. The Company's website and the information contained therein, or incorporated therein, are not intended to be incorporated into this Annual Report on Form 10-K.

Environmental Stewardship and Energy Use

Our operations are subject to various foreign, federal, state, and local laws and regulations with respect to environmental and ecological matters. We believe that we are in substantial compliance with present laws and regulations and that there are no material liabilities related to such items. We believe that continued compliance with foreign, federal, state, and local laws and regulations which have been enacted relating to the protection of the environment will not have a material effect on our capital expenditures, earnings, or competitive position. Management believes capital expenditures for environmental control equipment will not represent a material portion of total capital expenditures. Our management systems support our process for identifying, monitoring, and managing significant environmental aspects of our operations, including energy use, waste, water, emissions, and regulatory compliance.

Our operations use energy, primarily in the form of electricity, and we manage energy use as a significant environmental aspect under our environmental management systems. Federal, foreign, and state regulations may control the allocation of energy sources available to us, but to date we have experienced no interruption of production due to such regulations. We continue to work toward our goal to source 100% renewable electricity by 2030, subject to the availability of renewable electricity, energy attribute instruments, cost considerations, regulatory requirements, and operational needs.

We participate in CDP climate change and water security questionnaires to quantify our environmental practices and demonstrate progress toward reducing our environmental impact. We also disclose environmental metrics and related sustainability information in our annual Guiding Principles Report, and certain quantitative environmental metrics disclosed in that report are subject to limited third-party assurance. Our participation in CDP, our annual Guiding Principles Report, and other public sustainability communications reflect our commitment to transparency, continuous improvement, and environmental stewardship, consistent with our belief that "the environment is our home" and our dedication to excellence, leadership, and responsibility in the communities where we operate.

Additionally, our annual Guiding Principles Report is prepared with reference to, and/or aligned with, the Global Reporting Initiative (GRI) Standards, the United Nations (UN) Sustainable Development Goals (SDG) and Global Compact (UNGC), the Sustainable Accounting Standards Board (SASB) Electronic Manufacturing Services & Original Design Manufacturing Standard, and the Task Force on Climate-related Financial Disclosures (TCFD) framework. We are members of the Responsible Minerals Initiative. Where applicable, our environmental and responsible-sourcing programs also support customer and regulatory requirements relating to product content, responsible minerals, and other supply-chain environmental matters. We publish our sustainability report and our responses to the CDP climate change and water security questionnaires annually on our website at kimballelectronics.com/sustainability. Information in those reports may be prepared using standards, assumptions, methodologies, and materiality concepts that differ from those used in our SEC filings. The contents of the sustainability reports and CDP questionnaire responses are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC.

Refer to the discussion in Item 1A - Risk Factors for further details of the legal and regulatory initiatives related to environmental matters including climate change that could adversely affect our business, results of operations, and financial condition.

Responsible Sourcing and Supply Chain Integrity

We are committed to the use of a socially responsible supply chain to reduce the risk of human rights violations and the use of conflict minerals (tin, tungsten, tantalum and gold, or “3TG”) from the Democratic Republic of Congo and certain adjoining countries. Our efforts include requiring our suppliers to undertake reasonable due diligence within their supply chain to ensure that the 3TG in the materials we source from them do not directly or indirectly contribute to significant adverse human rights impacts, as well as conducting due diligence before allowing a potential supplier to become one of our preferred suppliers.

Our responsible sourcing program also includes broader efforts to integrate ethical and environmental considerations into procurement practices, improve material efficiency, and monitor resource use across our operations and supply chain. We request the return of reporting forms related to conflict minerals from our suppliers under the Responsible Minerals Initiative, or RMI, Conflict Minerals Survey. Further, we seek to remove any suppliers that continue to fail to meet our supplier and conflict minerals policies after being provided the opportunity to remedy non-compliance via implementation of a corrective action plan. We also conduct recurring, annual training for all employees and certain select contractors on export compliance, anti-corruption and anti-slavery, and insider trading. In addition, Kimball Electronics is a member of the RMI, which is evaluating the supply chain risks of conflict minerals and other minerals (e.g., cobalt, mica) and studying how to mitigate those risks.

Human Rights

As reflected in our Vision and Guiding Principles, Kimball Electronics is committed to the highest standards of conduct in its business dealings. We are a human-centered company that fully supports human rights. For us, human rights are more than just being compliant--they are about doing the right thing. Our Guiding Principles outline the critical role Kimball plays as a corporate citizen for our customers, our people, our partners, our environment, our Share Owners, and our communities. Our human rights beliefs are deeply rooted in our Guiding Principles and expressed in our Global Human Rights Policy, which is supported by annual review that explains some of the practical actions that we take each year to implement our Policy.

Kimball has been built upon the tradition of pride in craftsmanship, mutual trust, personal integrity, respect for dignity of the individual, a spirit of cooperation, and a sense of family and good humor. We seek to enhance this culture as we grow. We believe that no company should prosper while violating the basic human rights of others whether through unlawful slavery, servitude, forced or compulsory labor, or otherwise exploitative means. We believe in upholding principles of human rights, fair remuneration and economic inclusion, fair labor practices, worker safety, and observing fair labor practices within our organization and our supply chain.

Contributing to Our Communities

One of our Guiding Principles is to strive to help our communities be great places to live. We live this Guiding Principle and further the goals of our Human Rights Policy and our Global Policy on Philanthropic Contributions and Non-Commercial Sponsorships when we contribute and encourage our employees to contribute to our local communities. Our contributions are intended to support the communities in which we operate, those who may not be in a position to directly benefit from employment with us or from our primary business activities, or those who can benefit from the value derived from our support or collaboration. See the Giving section of our Guiding Principles Report for more information about the ways that we supported a wide range of charitable and non-commercial causes through donations of time, talent, and treasure that align with our Guiding Principles.

Our People are the Company: Inclusion, Engagement, and Accountability; Human Capital Management

We believe in creating quality for life. We believe our people are the company. We believe lasting relationships create our global success. We believe our people are our competitive edge for our service, quality, and value. Our people are the reason for our success. Kimball Electronics has been built upon the tradition of pride in craftsmanship, mutual trust, personal integrity, respect for dignity of the individual, a spirit of cooperation, and a sense of family and good humor. We seek to enhance this culture as we grow. We believe in the inherent value of all individuals.

Because our people are the reason for our success, central to our long-term strategy is attracting, developing, and retaining the best talent globally and strengthening collaboration. We are committed to pay equity and apply the principle of equal pay for work of equal value in all regions where we operate. As of June 30, 2026, Kimball Electronics employed approximately 5,600 people worldwide, with approximately 1,000 located in the United States and approximately 4,600 located in foreign countries. Three of our Independent Directors are female along with 50% of the Board's leadership and 43% of our executive leadership team.

We value and work to promote a diverse, equitable, and inclusive work environment. We are committed to holding ourselves accountable, taking action to continuously improve our policies and practices, and upholding the principles that encompass diversity, equity, inclusion, and belonging as outlined in our Diversity, Equity, Inclusion, and Belonging ("DEI&B") statement. Our strategy is to achieve excellence in customer service, employee relations, and business objectives through creativity, responsiveness, and innovation as a result of increased well-being, sense of belonging, and meaningful work for our employees. Consistent with our Guiding Principles, we hold ourselves accountable for continuously improving our people-focused policies and practices, in compliance with applicable laws in each jurisdiction where we operate. We provide a report on the diversity of our employees to our Board and in our Guiding Principles Report.

The average tenure within our workforce is 8 years, and we work hard to mitigate turnover risk by consistently and formally surveying our workforce about how well we are living up to our *People* Guiding Principles by asking them to anonymously rate us on a scale from 1 (low) to 10 (high). We currently have a score of 8.28 across our enterprise. We believe this is evidence that we truly operate our business as our people are the company. We consistently have a participation rate in our Guiding Principles survey of approximately 88%. Upon completion of this survey every year, each local management team receives qualitative and quantitative feedback and are responsible for crafting improvement plans based on our people's inputs. These commitments are further detailed in our 2025 Guiding Principles Report, available at <https://www.kimballelectronics.com/sustainability>.

Our U.S. operations are not subject to collective bargaining arrangements. Certain foreign operations are subject to collective bargaining arrangements, many mandated by government regulation or customs of the particular countries. We believe that our employee relations are good.

For additional information, see our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K.

Available Information

The Company makes available free of charge through its website, <https://investors.kimballelectronics.com>, its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission ("SEC"). All reports the Company files with the SEC are also available via the SEC website, <http://www.sec.gov>. The Company's website and the information contained therein, or incorporated therein, are not intended to be incorporated into this Annual Report on Form 10-K.

Item 1A - Risk Factors

The following important risk factors, among others, could affect future results and events, causing results and events to differ materially from those expressed or implied in forward-looking statements made in this report and presented elsewhere by management from time to time. Such factors, among others, may have a material adverse effect on our business, financial condition, and results of operations and should be carefully considered. Additional risks and uncertainties that we do not currently know about, we currently believe are immaterial, or we have not predicted may also affect our business, financial condition, or results of operations. Because of these and other factors, past performance should not be considered an indication of future performance.

Business and Operational Risks

Concentration among a small number of key customers, and our customers' ordering behavior, could materially reduce our revenues, profitability, and manufacturing efficiency.

Losses of key customers within specific industries or significant volume reductions from key customers are both risks. For fiscal year 2026, sales to our three largest customers — Nexteer Automotive, Philips, and ZF — accounted for approximately 40% of our net sales in the aggregate, and sales to Nexteer Automotive alone accounted for approximately 18% of our net sales. Over the past two fiscal years, we experienced the loss of a major automotive program from a significant customer, which was unrelated to Kimball's performance, and we cannot assure you that similar program losses will not occur in the future. For example, our automotive customers, including Nexteer Automotive and ZF, are subject to significant cyclical, technological, and regulatory pressures. If our automotive customers reduce production volumes, delay or cancel programs, in-source manufacturing, or shift purchasing to competitors, our results of operations could be materially adversely affected.

Our continuing success is dependent upon replacing expiring contract customers/programs with new customers/programs. See "Customers" in Item 1 - Business for disclosure of the net sales as a percentage of consolidated net sales for each of our significant customers during fiscal years 2026, 2025, and 2024. Regardless of whether our agreements with our customers, including our significant customers, have a definite term, our customers typically do not commit to firm production schedules for more than one quarter.

Many factors outside of our control impact our customers and their ordering behavior, including global pandemics, recessions in end markets, changing technologies and industry standards, commercial acceptance for products, shifting market demand, product obsolescence, changing sourcing strategies, and our customers' loss of business. Our customers generally have the right to cancel a particular product, subject to contractual provisions governing the final product runs, excess or obsolete inventory, recovery of dedicated investments, and end-of-life pricing. New customer relationships also present risk because we do not have an extensive product or customer relationship history. As many of our costs and operating expenses are relatively fixed, a reduction in customer demand, particularly a reduction in demand for a product that represents a significant amount of revenue, can harm our gross profit margins and results of operations.

Significant declines in the level of purchases by key customers or the loss of a significant number of customers could have a material adverse effect on our business. As many of our costs and operating expenses are relatively fixed, a reduction in customer demand, particularly a reduction in demand for a product that represents a significant amount of revenue, can harm our gross profit margins and results of operations.

Consolidation among our customers exposes us to increased risks, including reduced revenue and dependence on a smaller number of customers. Consolidation in industries that utilize our services may occur as companies combine to achieve further economies of scale and other synergies, which could result in an increase in excess manufacturing capacity as companies seek to divest manufacturing operations or eliminate duplicative product lines. Excess manufacturing capacity may increase pricing and competitive pressures for our industry as a whole and for us in particular. In addition, the nature of the contract manufacturing industry is such that the start-up of new customers and new programs to replace expiring programs occurs frequently, and new customers and program start-ups generally cause margin dilution early in the life of a program.

We cannot assure you that our current or future customers will not terminate their manufacturing service arrangements with us or significantly change, reduce, cancel, or delay the amount of services ordered. Such changes, delays and cancellations have led to, and may lead in the future to declines in our production, increases in excess or obsolete inventory that we may not be able to sell to customers or third parties, and reductions in the efficient use of our manufacturing facilities. In the past, we have also been required to increase staffing and other expenses in order to meet anticipated demand. On occasion, customers have required rapid increases in production for one or more of their products, which stresses our resources and may have an adverse effect on our financial position, results of operations, or cash flows.

Supply chain disruptions could increase our inventory costs, interrupt our operations, or prevent us from purchasing sufficient materials, parts, and components necessary to meet customer demand at competitive prices, in a timely manner, or at all.

We depend on suppliers globally to provide timely delivery of materials, parts, and components for use in our products. We have experienced, and may again experience in the future, shortages of some of the materials, parts and components that we use, particularly with semiconductors. These shortages can result from strong demand for those components or from problems experienced by suppliers, such as shortages of raw materials and shipping delays for such components with common carriers. These unanticipated component shortages have and, when they occur, may continue to result in curtailed production or delays in production, which prevent us from making scheduled shipments to customers.

Our integrated supply chain solutions for purchasing components and materials is a competitive strength and key to our strategy as a CDMO. Inflation and prices from suppliers have increased and may continue to rise. When prices rise for these or other similar reasons, they impact our margins and results of operations if we are not able to pass the increases through to our customers or otherwise offset them through cost savings. Many of our customer contracts permit periodic prospective adjustments to pricing based on decreases and increases in component prices and other factors; however, we could bear the risk of component price increases that occur between any such re-pricing or, if such re-pricing is not permitted or accepted by customers, during the balance of the term of the particular customer contract. There can be no assurance that we will continue to be able to purchase the components and materials needed to manufacture customer products at favorable prices. Accordingly, certain component price increases could adversely affect our gross profit margins and results of operations.

We have also experienced, and may again experience in the future, such shortages due to the effects of and responses to industry-wide conditions, pandemics, natural disasters, and other events outside our control, including macroeconomic events, trade restrictions, political crises, social unrest, terrorism, and conflicts (including the Russian invasion of, and ongoing war in, Ukraine, the conflict involving the United States, Israel, and Iran and the related regional instability in the Middle East, evolving trade and sanctions regimes affecting semiconductor supply, and the risk of prolonged reliance on select regions (including Taiwan and mainland China) for certain critical components). We cannot reasonably predict the full extent to which these events may impact our supply chain, because any impacts will depend on future developments that are highly uncertain and continuously evolving, including new information that may emerge concerning new or existing pandemics, further actions by governmental entities or others in response to the types of events described above, and how quickly and to what extent normal economic and operating conditions can resume.

Suppliers adjust their capacity as demand fluctuates, and component shortages and/or component allocations could occur in addition to longer lead times. Certain components we purchase are primarily manufactured in select regions of the world and issues in those regions could cause manufacturing delays. Maintaining strong relationships with key suppliers of components critical to the manufacturing process is essential. Our production of a customer's product has and could again be negatively impacted by any quality, reliability or availability issues with any of our component suppliers. Component shortages may also increase our cost of goods sold because we may be required to pay higher prices for components in short supply and redesign or reconfigure products to accommodate substitute components. These and other price increases, including increased tariffs, could have an adverse impact on our profitability if we cannot offset such increases with other cost reductions or by price increases to customers. If a component shortage is threatened or anticipated, we have and may in the future purchase such components in greater quantities and over longer lead times to avoid a delay or interruption in our operations. Purchasing additional components in this way may cause us to incur additional inventory carrying costs and may cause us to experience inventory obsolescence, both of which may not be recoverable from our customers and could adversely affect our gross profit margins and results of operations. If suppliers fail to meet commitments to us in terms of price, delivery, or quality, or if the supply chain is unable to react timely to increases in demand, it could interrupt our operations and negatively impact our ability to meet commitments to customers.

The substantial investments required to start up and expand facilities and new customer programs may adversely affect our margins and profitability.

We continue to expand our global operations by increasing our product and service offerings, including as a CDMO, and scaling our infrastructure at certain facilities to support our business. This expansion increases the complexity of our business and places significant strain on our management, personnel, operations, systems, technical performance, financial resources, and internal financial control and reporting functions. We may not be able to manage these expansions effectively or successfully, which could damage our reputation, limit our growth, and negatively affect our operating results.

Start-ups of new customer programs require the coordination of the design and manufacturing processes, as well as substantial investments in resources and equipment. The design and engineering required for certain new programs can take an extended period of time, and further time may be required to achieve customer acceptance. Accordingly, the launch of any particular

program may be delayed, less successful than we originally anticipated, or not successful at all. Additionally, even after acceptance, most of our customers do not commit to long-term production schedules, and we are unable to forecast the level of customer orders with certainty over a given period of time. If our customers do not purchase anticipated levels of products, we may not recover our up-front investments, may not realize profits, and may not effectively utilize expanded fixed manufacturing capacities. All of these types of manufacturing inefficiencies could have an adverse impact on our financial position, operating margins, results of operations, or cash flows.

We may not realize the anticipated benefits of the Helvoet acquisition or other future acquisitions.

On July 1, 2026, we completed our acquisition of Helvoet. Helvoet is our largest acquisition to date, expanded our manufacturing footprint into India and, additionally, the Netherlands, and materially expanded our precision molded plastics, complex tooling, and medical device component manufacturing capabilities. The success of the Helvoet acquisition depends on our ability to integrate Helvoet's operations, employees, customers, information systems, financial and internal controls, and manufacturing processes with those of the Company on the timelines we currently expect, and to retain Helvoet's key personnel and customer relationships.

Integration efforts may be complicated by differences in operating practices, geographic distances, differing regulatory regimes (including in India and the European Union), the need to remediate any control deficiencies identified in the integration process, and the diversion of management attention from ongoing operations. If we are unable to integrate Helvoet successfully or realize the strategic, operational, or financial benefits we expect, or if unanticipated integration costs, liabilities, or delays arise, we may not achieve the return on investment or the growth we anticipate and our business, results of operations, and financial condition could be materially adversely affected. Some of these risks are heightened by our decision to fund a portion of the purchase price from our credit facilities. Similar risks would apply to future acquisitions we may complete.

Our international operations make us vulnerable to financial and operational risks associated with doing business in foreign countries.

We derive a substantial majority of our revenues from our operations outside the United States, primarily in China, Mexico, Poland, Romania, and Thailand. Our international operations are subject to a number of risks, which may include the following:

- global, regional, or local economic and political instability;
- foreign currency fluctuations including currency controls and inflation, which may adversely affect our ability to do business in certain markets and reduce the U.S. dollar value of revenues, profits, or cash flows we generate in non-U.S. markets;
- warfare, riots, terrorism, general strikes, or other forms of violence and/or geopolitical disruption, including the Russian invasion of Ukraine and the ongoing war there;
- compliance with laws and regulations, including the U.S. Foreign Corrupt Practices Act, applicable to operations outside of the U.S.;
- potentially adverse tax consequences, including changes in tax rates and the manner in which multinational companies are taxed in the United States and other countries; and
- foreign labor practices.

These risks could have an adverse effect on our financial position, results of operations, or cash flows. Certain foreign jurisdictions restrict the amount of cash that can be transferred to the United States or impose taxes and penalties on such transfers of cash if we seek to repatriate these funds.

Changes to U.S. tariff measures and other potential changes in international trade relations implemented by the U.S. or other countries could have a material adverse effect on our business, financial condition, cash flows and results of operations.

Our supply chain is heavily reliant on raw materials and components manufactured and assembled in various countries, including China. These supply chain operations are subject to tariff and other international trade regulations in each of the countries where we operate. For example, when imported into the U.S., such raw materials and components are subject to applicable rates of duty. The U.S. government has recently made statements and taken certain actions that have created significant uncertainty about the future relationship between the U.S. and various other countries regarding trade policies, treaties, government regulations, and tariffs, including implementing tariffs on certain countries and implementing and subsequently pausing and, sometimes, reimplementing such tariffs on others. Because of these statements and actions, we are exposed to the possibility of supply disruptions and increased costs and expenses. Significant uncertainty exists about the future relationship between the U.S. and other countries regarding trade policies, treaties, and tariffs.

During fiscal year 2026, tariffs implemented under various U.S. trade authorities increased costs within our supply chain. We have generally recovered, and expect to continue recovering, a significant portion of these costs through contractual pass-through and repricing mechanisms. Although we may not be able to fully recover tariff-related costs, any unrecovered amounts are not expected to be material to our results of operations or cash flows. Changes in tariff policies, trade restrictions, or other international trade measures could nevertheless adversely affect our costs, our customers, our supply chain, or demand for our services.

We cannot predict with certainty the future trade policy of the U.S. or other countries, and we cannot reasonably predict the full extent to which these events may impact our supply chain, because any impacts will depend on future trade policy, treaty, and tariff developments that are highly uncertain and continuously evolving. Relevant factors include whether such tariffs are ultimately implemented, the timing and duration of implementation and the amount, scope, and nature of such tariffs and potential exclusions from the application of those tariffs. These tariffs and other unfavorable government policies on international trade (such as export controls) may increase the cost of manufacturing our customers' products, affect the demand for our manufacturing services, or restrict our access to raw materials and components used in the manufacture of our customers' products, each of which could negatively impact our financial condition and results of operations. Further, such developments, or the perception that any such developments could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the U.S. Any of these factors could depress economic activity and adversely impact the price and demand for our customers' products, increase our costs, and affect our customers and suppliers, any of which could have a material adverse effect on our business, financial condition and results of operations.

We operate in a highly competitive industry and may not be able to compete successfully.

Numerous manufacturers within the contract manufacturing industry compete globally for business from existing and potential customers. Some of our competitors have greater resources and more geographically diversified international operations than we do. We also face competition from the manufacturing operations of our customers, who are continually evaluating the merits of manufacturing products internally against the advantages of outsourcing to contract manufacturing service providers. In the past, some of our customers have decided to in-source a portion of their manufacturing from us in order to utilize their excess internal manufacturing capacity. The competition may further intensify as more companies enter the markets in which we operate, as existing competitors expand capacity, and as the industry consolidates.

In relation to customer pricing pressures, if we cannot achieve the proportionate reductions in costs, profit margins may suffer. The high level of competition in the industry impacts our ability to implement price increases or, in some cases, even maintain prices, which also could lower profit margins. In addition, as end markets dictate, we are continually assessing excess capacity and developing plans to better utilize manufacturing operations, including consolidating and shifting manufacturing capacity to lower cost venues as necessary.

We may not achieve the organic growth on which our strategy depends.

Our strategy to achieve sustained, profitable growth depends on our ability to expand our existing customer relationships, secure new customer programs, launch those programs on time and on budget, successfully introduce new categories of manufacturing services (including through our Kimball Solutions CDMO offerings), and expand our global manufacturing footprint (including the ramp of our new Indianapolis, Indiana medical CDMO facility). New program start-ups typically require significant investment in capacity, tooling, and working capital, and generally generate lower margins early in a program's life. If we fail to execute on these initiatives, if new programs experience delays or higher start-up costs than we anticipate, or if we cannot secure and retain the customer demand needed to fill our expanded capacity, our revenue growth, margin performance, and returns on invested capital could be adversely affected.

Our business may be harmed due to failure to successfully implement information technology solutions or a lack of reasonable safeguards to maintain data security, including adherence to evolving global data privacy laws, cross-border data transfer, AI-specific regulations, and physical security measures.

The operation of our business depends on effective information technology systems, including data management, analytics, and artificial intelligence and machine learning technologies (collectively, "AI") platforms and applications. See also 'Risks related to our development and use of artificial intelligence' below. These systems are subject to the risk of security breach or cybersecurity threat, including misappropriation of assets or other sensitive information, such as confidential business information and personally identifiable data relating to employees, customers, and other business partners, or data corruption which could cause operational disruption. The unpredictability of AI, machine learning, and similar systems that automate certain operational tasks bring the potential for unintended consequences and unexpected disruptions in business operations, financial losses, and reputational damage, including if such systems produce incorrect or biased outputs, expose confidential data to third-party AI providers, or generate outputs that infringe third-party intellectual property or violate applicable privacy

or AI-specific laws (such as the EU AI Act, Colorado AI Act, and other emerging AI legislation). As we could be the target of cyber and other security threats, which are becoming increasingly sophisticated, we must continuously monitor and develop our information technology networks and infrastructure to prevent, detect, address, and mitigate the risk of unauthorized access, misuse, computer viruses, and other events that could have a security impact. Information systems require an ongoing commitment of significant resources to research new technologies and processes, maintain and enhance existing systems, and develop new systems in order to keep pace with changes in information processing technology and evolving industry standards as well as to protect against cyber risks and security breaches. While we provide employee awareness training around phishing, malware, and other cyber threats to help protect against these cyber and security risks, we cannot ensure the measures we take to protect our information technology systems will be sufficient.

Implementation delays, poor execution, or a breach of information technology systems could disrupt our operations, damage our reputation, or increase costs related to the mitigation of, response to, or litigation arising from any such issue. Similar risks exist with our third-party vendors. Any problems caused by these third parties, including those resulting from disruption in communications services, cyber attacks, or security breaches, have the potential to hinder our ability to conduct business.

Because we operate in the United States, Mexico, China, India, The Netherlands, Poland, Romania, and Thailand, we are subject to a wide and evolving range of data privacy, employee-monitoring, and cross-border data-transfer laws, including the EU and UK General Data Protection Regulations, the ePrivacy Directive, Mexico's Federal Personal Data Protection Law, India's Digital Personal Data Protection Act, and analogous laws in U.S. states and other jurisdictions in which we operate. AI-specific laws — including the EU Artificial Intelligence Act and state-level AI laws such as Colorado's Artificial Intelligence Act — increasingly overlap with these privacy regimes and impose their own compliance obligations on our development, deployment, or use of AI systems.

Compliance with these laws is complex, costly, and increasingly requires cross-functional coordination among legal, IT, human resources, and business owners. Non-compliance, or perceived non-compliance, with any of these laws could result in significant civil penalties, injunctions, litigation, contract remediation obligations, and reputational harm, any of which could materially adversely affect our business, financial condition, and results of operations.

Our development, deployment, and use of artificial intelligence technologies could expose us to operational, legal, reputational, and competitive risks.

We use, and expect to continue to use and expand our use of AI, across our business, including in engineering design services, manufacturing process optimization, predictive maintenance, quality analytics, supply chain forecasting, back office productivity tools, and certain administrative functions. Some of these tools are developed internally, and others are provided by third-party suppliers, including through generally available large language models and cloud services.

Our use of AI presents a variety of risks, including operational risks (such as system errors, unreliable or biased outputs, and disruptions to business processes); intellectual property risks (including uncertainty regarding ownership of AI-generated outputs and possible infringement of third-party rights); data privacy and confidentiality risks (including the possibility that confidential customer or supplier information could be exposed through third-party AI tools); cybersecurity risks (including AI-enabled attacks such as deepfake impersonation, prompt injection, model poisoning, and automated phishing); competitive risks (including if our competitors deploy AI more effectively or at lower cost); and reputational risks (including if AI is misused or produces harmful, biased, or inaccurate outputs).

AI-specific laws and regulations are developing rapidly and are increasingly divergent across jurisdictions. Examples include the European Union Artificial Intelligence Act, the Colorado Artificial Intelligence Act, and other state-level AI laws in the United States, as well as evolving guidance from the U.S. Securities and Exchange Commission on AI-related disclosure. Complying with these laws and regulations could increase our costs, require changes to our AI systems, or limit our ability to deploy AI technologies. Failure to comply, or perceived failure to comply, could result in enforcement actions, litigation, or reputational harm. In addition, the U.S. Securities and Exchange Commission has focused on so-called 'AI washing,' or overstating the capabilities or business impact of AI, and we could be subject to claims if any of our public statements about AI are considered misleading.

Our use of AI also depends on our ability to attract and retain personnel with the relevant technical skills, to invest in the necessary infrastructure, and to safeguard our customers' and suppliers' proprietary information. Any of these risks could adversely affect our business, financial condition, results of operations, or reputation.

We depend on attracting and retaining executive officers, key employees, skilled personnel, and sufficient labor to efficiently operate our business.

Our ability to execute our strategy depends on attracting, developing, and retaining employees with the technical, engineering, and operational skills needed to run an increasingly automated, digitized, and data-driven manufacturing environment, including engineers, data and analytics professionals, cybersecurity and artificial intelligence specialists, skilled operators supporting our Industry 4.0 initiatives, and quality and regulatory personnel supporting our operations. Competition for these skills is intense and can be compounded by broader labor market pressures — including localized labor shortages, wage inflation, evolving employee expectations regarding workplace flexibility, and demographic shifts in the regions where we operate. If we are unable to attract and retain qualified personnel, to develop the technical and leadership capabilities of our existing workforce, or to manage the labor and retention effects of restructuring actions such as the closure of our Tampa facility, our ability to serve our customers, execute our strategic initiatives, and maintain operational efficiency could be adversely affected.

Regulatory and Litigation Risks

Failure to protect our intellectual property could undermine our competitive position.

Competing effectively depends, to a significant extent, on maintaining the proprietary nature of our intellectual property. We attempt to protect our intellectual property rights worldwide through a combination of keeping our proprietary information secret and utilizing trademark, copyright, and trade secret laws, as well as licensing agreements and third-party non-disclosure and assignment agreements. Because of the differences in foreign laws concerning proprietary rights, our intellectual property rights do not generally receive the same degree of protection in foreign countries as they do in the United States, and therefore, in some parts of the world, we have limited protections, if any, for our intellectual property. If we are unable to adequately protect our intellectual property embodied in our solutions, designs, processes, and products, the competitive advantages of our proprietary technology could be reduced or eliminated, which would harm our business and could have a material adverse effect on our results of operations and financial position.

Anti-takeover provisions in our organizational documents and Indiana law could delay or prevent a change in control.

Certain provisions of our Amended and Restated Articles of Incorporation and the Amended and Restated By-Laws may delay or prevent a merger or acquisition that a Share Owner may consider favorable. For example, the Amended and Restated Articles of Incorporation authorizes our Board of Directors to issue one or more series of preferred stock, prevents Share Owners from acting by written consent without unanimous consent, and requires a supermajority Share Owner approval for certain business combinations with related persons. These provisions may discourage acquisition proposals or delay or prevent a change in control, which could harm our stock price. Indiana law also imposes some restrictions on potential acquirers.

Failure to satisfy applicable customer, industry, and regulatory quality standards could adversely affect our customer relationships, results of operations, and reputation.

We make substantial investments in comprehensive, company-wide quality systems, certifications, and controls designed to satisfy customer requirements and to comply with the various product and quality-system regulations applicable to our operations. If we fail to meet these requirements, we may incur costs associated with product defects, warranty and product liability claims, production interruptions, government investigations, fines, and penalties, and our failure to comply could delay or prevent our customers' ability to obtain or maintain product approvals or to receive products from us on schedule. Any of the foregoing could adversely affect our reputation, customer relationships, financial position, results of operations, or cash flows. Although we maintain product liability and other insurance coverage that we believe is generally consistent with industry practice, our coverage may not be adequate to protect us fully against substantial claims arising from warranty or product-defect liabilities.

Our medical CDMO operations — including our expanded footprint in Indianapolis, Indiana and our new Helvoet operations in India and the Netherlands — are subject to additional quality and regulatory requirements, including the U.S. Food and Drug Administration's Quality Management System Regulation (formerly the Quality System Regulation) and current Good Manufacturing Practices (cGMP), the European Union Medical Device Regulation (2017/745) and In Vitro Diagnostic Regulation (2017/746), ISO 13485, and comparable regimes in China, India, and Thailand. Failures to comply, delays in obtaining or maintaining product-specific registrations or notified body certifications, or negative outcomes from FDA or comparable inspections could result in warning letters, import alerts, consent decrees, product recalls, or the temporary suspension of production, any of which could adversely affect our reputation, customer relationships, financial position, results of operations, or cash flows. Because we also handle customer-owned drug substances and drug products in support of drug delivery programs, our failure or our customers' failure to comply with applicable drug cGMP, controlled-substance handling, or pharmacovigilance obligations could adversely affect our medical CDMO business.

Climate change, evolving sustainability regulation, and stakeholder expectations regarding environmental, social, and governance matters could increase our costs, impose new compliance obligations, and expose us to enforcement, litigation, and reputational risk.

Customers, investors, and other stakeholders continue to focus on environmental issues — including climate change, greenhouse gas emissions, water use, waste, and hazardous materials — and on broader sustainability topics. We have made public commitments to significantly reduce our greenhouse gas emissions and waste intensity and to increase our use of renewable electricity and recycled water by 2030, and we may adopt additional voluntary sustainability initiatives in the future. Our failure or perceived failure to achieve these commitments, or to satisfy other sustainability expectations of our customers, investors, employees, or other stakeholders, could adversely affect our reputation, our customer and investor relationships, our ability to attract and retain employees, our results of operations, and our attractiveness as an investment or business partner, and could expose us to government enforcement actions and private litigation.

Increased frequency and severity of extreme weather events, sea-level rise, and heightened water stress associated with climate change could damage our facilities or those of our suppliers and customers, disrupt our supply chain, and reduce demand for our services. Our past and present operations are also subject to extensive federal, state, local, and foreign environmental laws and regulations governing discharges to air, water, and land, the handling and disposal of solid and hazardous waste, the use of hazardous materials in production, and the remediation of contamination associated with releases of hazardous substances. Compliance with more stringent laws or regulations, or stricter interpretation of existing requirements, could require material expenditures, and any investigations or remedial efforts could result in material liabilities.

We are also subject to a rapidly evolving set of climate- and sustainability-related disclosure regimes. The European Union's Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS) apply, or under certain circumstances could apply, to our EU operations and, in some cases, to our global business. We prepare our annual Guiding Principles Report with reference to the ESRS as outlined by the CSRD, and continued compliance with the CSRD and ESRS, together with the European Union's ongoing 'Omnibus' simplification proposals and evolving climate-related disclosure regimes in California and other U.S. states, could require significant effort and resources, particularly if the requirements do not align with existing initiatives. Transition to a lower-carbon economy could also require material investments in renewable energy, energy efficiency, and retrofitting or constructing facilities with lower-emission technology, and increases in the cost of energy, water, or other resources used in our operations or in the freight and logistics services on which we depend could reduce our profitability.

In addition, our customers have adopted, and may continue to adopt, procurement policies and sustainability goals that impose environmental, social, and governance requirements on their suppliers, including us, and an increasing number of investors have adopted sustainability policies for their portfolio companies. These practices, together with the divergent and rapidly evolving investor policies, voluntary sustainability frameworks, and regulatory regimes described above, may be difficult or expensive to comply with, may conflict with one another, and could adversely affect our reputation, business, or financial condition. Given the political significance and continuing uncertainty around these issues, we cannot predict how climate change and related legal, regulatory, and market developments will ultimately affect our operations and financial condition.

Compliance with government legislation and regulations may significantly increase our operating costs in the United States and abroad.

Legislation and regulations promulgated by the U.S. federal and foreign governments could significantly impact our profitability by burdening us with forced cost choices that either cannot be recovered by increased pricing or, if we increase our pricing, could negatively impact demand for our products. For example:

- The Dodd-Frank Wall Street Reform and Consumer Protection Act contains provisions to improve transparency and accountability concerning the supply of certain minerals, known as "conflict minerals," originating from the Democratic Republic of Congo ("DRC") and adjoining countries. These rules could adversely affect the sourcing, supply, and pricing of materials used in our products, as the number of suppliers who provide conflict-free minerals may be limited. We may also suffer reputational harm if we determine that certain of our products contain minerals not determined to be conflict-free or if we are unable to modify our products to avoid the use of such materials. We may also face challenges in satisfying customers who may require that our products be certified as containing conflict-free minerals or that we adopt more stringent guidelines like those fostered by the Responsible Business Alliance ("RBA") and Responsible Materials Initiative ("RMI").
- We are subject to a variety of federal, state, local and foreign environmental, health and safety, product stewardship and producer responsibility laws and regulations, including those arising from global pandemics or relating to the use, generation, storage, discharge and disposal of hazardous chemicals used during our manufacturing process, those governing worker health and safety, those requiring design changes, supply chain investigation or conformity

assessments, and those relating to the recycling or reuse of products we manufacture. These include EU regulations and directives, such as the Restrictions on Hazardous Substances (“RoHS”), the Waste Electrical and Electronic Equipment (“WEEE”) directives, and the Registration, Evaluation, Authorization, and Restriction of Chemicals (“REACH”) regulation, and similar regulations in China (the Management Methods for Controlling Pollution for Electronic Information Products or “China RoHS”). If we fail to comply with any present or future regulations or timely obtain any needed permits, we could become subject to liabilities, and we could face fines or penalties, the suspension of production, or prohibitions on sales of products we manufacture. In addition, such regulations could restrict our ability to expand our facilities or could require us to acquire costly equipment, or to incur other significant expenses, including expenses associated with the recall of any non-compliant product or with changes in our operational, procurement and inventory management activities.

Shifts in U.S. political, tax, trade, and regulatory policy could adversely affect our business and results of operations.

Since January 2025, changes in the U.S. presidential administration have led to a series of executive orders, agency reorganizations, and rapidly evolving policy priorities that affect areas critical to our operations, including tariffs and trade policy, immigration enforcement, environmental and workplace regulation, the pace and scope of federal regulatory enforcement, and the composition of the federal workforce. These developments have introduced increased legal, regulatory, reputational, and operational uncertainty for companies that operate cross-border supply chains, including us.

The One Big Beautiful Bill Act, signed into law on July 4, 2025, made the 21% corporate tax rate permanent and made a variety of other changes to the U.S. tax code, some of which may affect our effective tax rate, cash taxes, deferred tax assets and liabilities (including in respect of GILTI, Section 163(j), and Section 174 research and experimental expenditures), and the value of our tax incentives. Further changes in U.S. tax law, or in tax laws in the foreign jurisdictions in which we operate, could adversely affect our results of operations.

Heightened fiscal and political uncertainty in the United States, including the risk of future government shutdowns, delays or terminations of federal programs, and increased scrutiny of federal contractors, could also have direct or indirect effects on our customers, our suppliers, and our results of operations, even though we do not primarily sell to the U.S. government. Any of these developments could materially adversely affect our business, financial condition, and results of operations.

Financial Risks

We are exposed to the credit risk of our customers.

The instability of market conditions drives an elevated risk of potential bankruptcy of customers resulting in a greater risk of uncollectible outstanding accounts receivable. Accordingly, we intensely monitor our receivables and related credit risks. The realization of these risks could have a negative impact on our profitability.

Failure to effectively manage working capital may adversely affect our cash flow from operations.

We closely monitor inventory and receivable efficiencies and continuously strive to improve these measures of working capital, but customer financial difficulties, cancellation or delay of customer orders, shifts in customer payment practices, transfers of production among our manufacturing facilities, additional inventory purchases to mitigate potential impact from component shortages, or manufacturing delays could adversely affect our cash flow from operations.

We could incur losses due to asset impairment.

As business conditions change, we must continually evaluate and work toward the optimum asset base. It is possible that certain assets such as, but not limited to, facilities, equipment, intangible assets, or goodwill could be impaired at some point in the future depending on changing business conditions. Our July 1, 2026 acquisition of Helvoet is expected to result in the recognition of additional goodwill and identifiable intangible assets during fiscal year 2027, and if the integration of Helvoet, its financial performance, its customer relationships, or the projected cash flows we ascribe to those assets do not meet our expectations, we could be required to recognize impairment charges with respect to those or other long-lived assets. Such impairment could have an adverse impact on our financial position and results of operations.

Fluctuations in our effective tax rate could have a significant impact on our financial position, results of operations, or cash flows.

Our effective tax rate is highly dependent upon the geographic mix of earnings across the jurisdictions where we operate. Changes in tax laws or tax rates in those jurisdictions could have a material impact on our operating results. Judgment is required in determining the worldwide provision for income taxes, other tax liabilities, interest, and penalties. We base our tax position upon the anticipated nature and conduct of our business and upon our understanding of the tax laws of the various countries in which we have assets or conduct activities. Our tax position, however, is subject to review and possible challenge

by taxing authorities and to possible changes in law (including adverse changes to the manner in which the United States and other countries tax multinational companies or interpret their tax laws). We cannot determine in advance the extent to which some jurisdictions may assess additional tax or interest and penalties on such additional taxes. In addition, our effective tax rate may be increased by changes in the valuation of deferred tax assets and liabilities, changes in our cash management strategies, changes in local tax rates, or countries adopting more aggressive interpretations of tax laws.

Several countries where we operate provide tax incentives to attract and retain business. We have obtained incentives where available and practicable. Our taxes could increase if certain incentives were retracted, they were not renewed upon expiration, we no longer qualify for such programs, or tax rates applicable to us in such jurisdictions were otherwise increased. In addition, our growth may cause our effective tax rate to increase, depending on the jurisdictions in which we expand our business or acquire operations. Given the scope of our international operations and our international tax arrangements, changes in tax rates and the manner in which multinational companies are taxed in the United States and other countries could have a material impact on our financial results and competitiveness.

Certain of our subsidiaries provide financing, products, and services to, and may undertake certain significant transactions with, other subsidiaries in different jurisdictions. Moreover, several jurisdictions in which we operate have tax laws with detailed transfer pricing rules which require that all transactions with non-resident related parties be priced using arm's length pricing principles and that contemporaneous documentation must exist to support such pricing. Due to inconsistencies among jurisdictions in the application of the arm's length standard, our transfer pricing methods may be challenged and, if not upheld, could increase our income tax expense. In addition, the Organization for Economic Cooperation and Development continues to issue guidelines and proposals related to transfer pricing and profit shifting that may result in legislative changes that could reshape international tax rules in numerous countries and negatively impact our effective tax rate.

We are exposed to foreign currency risk.

During fiscal year 2026, the U.S. dollar continued to depreciate against several of the currencies to which we have significant exposure, including the Euro, Polish zloty, and Romanian leu, and had a favorable 2% impact on our net sales for the year. Continued volatility in the U.S. dollar, including as a result of shifting U.S. monetary and fiscal policy, could materially affect our revenues, costs, and results of operations. Fluctuations in exchange rates could impact our operating results. Our risk management strategy includes the use of derivative financial instruments to hedge certain foreign currency exposures. Any hedging techniques we implement contain risks and may not be entirely effective. Exchange rate fluctuations could also make our products more expensive than competitors' products not subject to these fluctuations, which could adversely affect our revenues and profitability in international markets.

A failure to comply with the financial covenants under our credit facilities could adversely impact us.

Our primary credit facility requires us to comply with certain financial covenants. We believe the most significant covenants under our credit facilities are the ratio of consolidated total indebtedness minus unrestricted cash not to exceed \$25 million to adjusted consolidated EBITDA, as defined in our primary credit facility, and the interest coverage ratio. More detail on these financial covenants is discussed in Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. As of June 30, 2026, we had \$116.6 million in borrowings under our credit facilities and had total cash and cash equivalents of \$88.9 million. In the future, a default on the financial covenants under our credit facilities could cause an increase in the borrowing rates or make it more difficult for us to secure future financing, which could adversely affect our financial condition.

We are exposed to inflation, interest rate, and other banking and capital market risks.

High levels of inflation in the U.S. and other countries where we operate have and may continue to increase our costs and may impact pricing and customer demand, both of which may impact our revenues and earnings. We have exposure to interest rate risk on our borrowings under our credit facilities. The interest rates of these borrowings are based on a spread plus applicable base rate, including the Secured Overnight Financing Rate ("SOFR"), the Euro Interbank Offered Rate ("EURIBOR"), the prime rate of a reference bank, or the federal funds rate. An adverse change in the base rates upon which our interest rates are determined could have a material adverse effect on our financial position, results of operations, or cash flows. Rising interest rates have increased our costs of borrowing. Additionally, volatility in capital markets could present challenges to us if we need to raise funds in the equity market. This, in turn, may cause us to adopt strategies that may be less capital-intensive. Volatility in the credit markets, including due to evolving U.S. Federal Reserve monetary policy in response to inflation, employment, and tariff-related economic conditions, may have an adverse effect on our ability to obtain debt financing.

Our reliance on customer supply-chain financing and receivables purchase agreements exposes us to program-availability and counterparty risks.

During fiscal year 2026, we sold \$315.8 million of accounts receivable under customer supply chain financing arrangements and \$171.3 million of accounts receivable under receivables purchase agreements ("RPAs") with third-party banking

institutions. These programs enable us to accelerate cash collection but expose us to a variety of risks, including the potential loss or non-renewal of a program by a customer or financial institution, adverse changes in the pricing (including base rate volatility) or terms of these programs, and concentration of counterparty risk at particular banks.

If one or more of these programs becomes unavailable or economically unattractive, our working capital, cash flows, and interest expense could be adversely affected, and we may need to draw on our credit facilities or reduce our share repurchase or capital expenditure activities to bridge any resulting funding gap.

General Risk Factors

Facility catastrophes, pandemics, and other business-interruption events may impact our production schedules and profitability.

Natural disasters, pandemics, or other catastrophic events, including severe weather (including cyclones, hurricanes, and floods) as well as terrorist attacks, power interruptions, fires, and pandemics, could disrupt operations and likewise our ability to produce or deliver products. Our manufacturing operations require significant amounts of energy, including natural gas. Employees are an integral part of our business, and events such as a pandemic could reduce the availability of employees reporting for work. In the event we experience a temporary or permanent interruption in our ability to produce or deliver product, revenues could be reduced, and business could be materially adversely affected. In addition, catastrophic events, or the threat thereof, can adversely affect U.S. and world economies, and could result in reduced demand for our customers' products and delayed or lost revenue for our services. We maintain insurance to help protect us from costs relating to some of these matters, but it may not be sufficient or paid in a timely manner to us in the event of such an interruption.

Item 1B - Unresolved Staff Comments

None.

Item 1C - Cybersecurity

We depend on information systems and technology in substantially all aspects of our business, including communications among our employees and with suppliers and customers. We recognize the significance of developing, implementing, and maintaining cybersecurity measures to safeguard our information systems and products and protect the confidentiality, integrity, and availability of our data.

Cybersecurity Risk Management and Strategy

We maintain a risk-based cybersecurity program and related processes designed to assess, identify and manage material risks from cybersecurity threats, including risks relating to our information technology systems, business operations, confidential information, customer and supplier information and personal data. These processes are integrated into our enterprise risk management and internal audit activities.

Our cybersecurity program is informed by recognized cybersecurity standards and practices, including ISO 27001. The Company has achieved and maintains ISO 27001 certification for the scope covered by that certification.

We use a combination of internal personnel, external service providers and third-party advisors to support our cybersecurity risk management processes. These resources may include managed security monitoring, vulnerability assessments, penetration testing, third-party assessments, employee training, phishing awareness activities, incident response planning, disaster recovery, and business continuity planning. We also maintain processes designed to assess and manage cybersecurity risks associated with certain third parties, including through third-party risk assessments and other vendor due diligence/oversight processes.

We maintain cybersecurity insurance intended to address certain cybersecurity-related risks, subject to policy terms, limits and exclusions.

Governance

Board's Oversight Role

The Board of Directors oversees risks from cybersecurity threats directly and through the Audit Committee. The Audit Committee has primary responsibility for overseeing cybersecurity risk and receives reports at each of its regular quarterly meetings from management and, as appropriate, internal and external cybersecurity resources regarding cybersecurity risk management, threat trends, program initiatives and incident response preparedness. The full Board receives cybersecurity updates at least twice each year. The Board and Audit Committee receive additional updates as appropriate based on the nature and severity of cybersecurity matters.

Management's Role

At the management level, cybersecurity risk oversight is led by our Chief Legal and Administrative Officer, who has more than 30 years of experience managing enterprise risk and leading IT strategy and is responsible for spearheading the ongoing

development and execution of our cybersecurity strategy and governance. Our Chief Legal and Administrative Officer is supported by a team of enterprise infrastructure and security risk professionals who are responsible for identifying, assessing, monitoring, managing, and communicating our cybersecurity risks. This cross-functional team includes experienced leaders in IT infrastructure and operational technology (OT) environments, including in system design, network monitoring, endpoint protection, and security response.

Management uses cross-functional incident response and disclosure escalation processes designed to support timely evaluation, escalation, and communication of cybersecurity incidents, including assessment of potential materiality and disclosure obligations.

Incident Response, Business Continuity, and the Effect of Cybersecurity Threats

We maintain incident response, disaster recovery and business continuity plans designed to support escalation, containment, recovery and business continuity in the event of a cybersecurity incident. We periodically evaluate and test elements of these plans through assessments, exercises and other preparedness activities.

Like many other companies, from time to time, we detect attempts by third parties to gain access to our systems and networks, and the frequency of such attempts could increase in the future. As of the date of this Annual Report, we have not identified risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect the Company, including its business strategy, results of operations or financial condition. However, cybersecurity threats continue to evolve, and there can be no assurance that our processes, controls, or third-party service providers will prevent or timely detect all cybersecurity incidents or mitigate all related risks. For additional information regarding cybersecurity risks, see Item 1A - Risk Factors - *“Our business may be harmed due to failure to successfully implement information technology solutions or a lack of reasonable safeguards to maintain data security, including adherence to evolving global data privacy laws, cross-border data transfer, AI-specific regulations, and physical security measures.”*

Item 2 - Properties

We have eleven manufacturing facilities, ten of which are owned and one (in Indiana) is leased, with three located in Indiana (two of which are fully operational), two in Mexico, and one located in each of Poland, Romania, The Netherlands, India, China, and Thailand. These facilities occupy approximately 2,057,000 square feet in aggregate. The Netherlands and India manufacturing facilities were acquired on July 1, 2026, see Note 22 - Subsequent Event of Notes to Consolidated Financial Statements for more information. We lease a facility in the Netherlands to accommodate our support services there. In addition, we own a 42,000 square-foot building to house our headquarters located in Jasper, Indiana. Our Tampa facility, excluded from above, was sold during fiscal year 2026, see Note 4 - Restructuring Activities of Notes to Consolidated Financial Statements for more information.

Generally, our manufacturing facilities are utilized at normal capacity levels on a multiple shift basis. At times, certain facilities utilize reduced shifts due to demand and sales fluctuations. We continually assess our capacity needs and evaluate our operations to optimize our service levels by geographic region. We executed a lease in fiscal year 2025 for a third manufacturing facility in Indiana to expand our medical CDMO footprint and production has not started. When the leased facility is fully operational, it will replace the existing Indianapolis, Indiana facility. See Item 1A - Risk Factors for information regarding financial and operational risks related to our international operations.

Significant loss of income resulting from a facility catastrophe would be partially offset by business interruption insurance coverage.

We hold a land lease for our facility in China that expires in fiscal year 2056 and one for our facility in Thailand that expires in fiscal year 2030. See Note 1 - Business Description and Summary of Significant Accounting Policies of Notes to Consolidated Financial Statements for additional information concerning leases. In addition, we own approximately 83 acres of land which includes land where our facilities reside.

Item 3 - Legal Proceedings

We and our subsidiaries are not parties to any pending legal proceedings, other than ordinary routine litigation and claims incidental to the business. The outcome of current routine pending litigation and claims, individually and in the aggregate, is not expected to have a material adverse impact on our business or financial condition. We are also required to disclose any pending or contemplated environmental proceeding by a governmental authority where potential monetary sanctions could reach \$300,000 or more. No such proceeding is presently pending.

Item 4 - Mine Safety Disclosures

Not applicable.

Information about Our Executive Officers

Our executive officers as of August 19, 2026 are as follows:

Name	Age	Office and Area of Responsibility
Richard D. Phillips	56	Chief Executive Officer and Director
Adam M. Baumann	45	Chief Accounting Officer
Jana T. Croom	49	Chief Financial Officer
Jessica L. DeLorenzo	41	Chief Human Resources Officer
Douglas A. Hass	50	Chief Legal & Administrative Officer, Secretary
Steven T. Korn	62	Chief Operating Officer
Andrew D. Regrut	63	Vice President, Investor Relations, Strategic Development, and Treasurer
Kathy R. Thomson	57	Chief Commercial Officer

Executive officers are appointed annually by the Board of Directors. The following is a brief description of the business experience during the past five or more years of each of our executive officers.

Mr. Phillips was appointed Chief Executive Officer and Director effective March 1, 2023. Mr. Phillips was most recently the President and Chief Executive Officer from 2019 until 2022 for Elkay Manufacturing Company. Previously, Mr. Phillips served as the President, Chief Executive Officer, and Board member from 2017 through 2019, for Essendant, Inc.

Mr. Baumann was appointed Chief Accounting Officer effective July 1, 2023. He joined Kimball Electronics in April 2019 as Assistant Corporate Controller and served as our Corporate Controller since March 2021. Mr. Baumann was previously employed by Vectren Corporation from 2009 to 2019.

Ms. Croom is our Chief Financial Officer effective July 1, 2021. Ms. Croom joined Kimball Electronics in January 2021 in the role of Vice President, Finance. Prior to joining Kimball Electronics, she held the position of Vice President, Financial Planning and Analysis for NiSource Inc. since August 2019. Previously at NiSource Inc., she served as Director of Operations Planning since March 2017 and Director of Regulatory Affairs since April 2014. Ms. Croom currently serves on the Board of First Energy Corp.

Ms. DeLorenzo was appointed Vice President, Human Resources in June 2018, and her title was changed to Chief Human Resources Officer in 2025 to better reflect the evolution of her role at the Company. Ms. DeLorenzo joined Kimball Electronics in 2015 in the position of Director, Organizational Development.

Mr. Hass was appointed Chief Legal and Administrative Officer and Secretary in 2025, having previously served as our Chief Legal and Compliance Officer and Secretary since 2022. He joined Kimball Electronics in 2020 as Associate General Counsel and Assistant Secretary. From 2016 through 2020, Mr. Hass served as General Counsel and Secretary of Nasdaq-listed Lifeway Foods. Mr. Hass had assumed the leadership of information technology and computing systems, including cybersecurity, following the departure of our former Chief Information Officer on January 1, 2025. Mr. Hass currently serves on the Board of Columbus Insurance, Ltd.

Mr. Korn was appointed to the role of Chief Operating Officer effective July 1, 2023. Previously, Mr. Korn was our President, Global Electronics Manufacturing Services Operations since July 2020, and Vice President, North American Operations since 2007.

Mr. Regrut was appointed to the role of Vice President, Investor Relations, Strategic Development, and Treasurer effective November 14, 2025. He joined Kimball Electronics in March 2021 as Head of Investor Relations. Prior to joining Kimball Electronics, he held the position of Vice President, Investor Relations, for Big Lots, Inc. from 2012 to 2021.

Ms. Thomson was appointed to the role of Chief Commercial Officer effective July 1, 2023. Previously, Ms. Thomson was our Vice President, Global Business Development and Design Services since August 2018. Prior to joining Kimball Electronics, she held the position of Vice President of Business Development for Creation Technologies since 2012.

PART II

Item 5 - Market for Registrant's Common Equity, Related Share Owner Matters and Issuer Purchases of Equity Securities

Market Information

The Company's common stock trades on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC ("Nasdaq") under the symbol: KE.

Dividends

Since our inception, we have not paid any dividends on our common stock, and we currently do not have plans to pay dividends in fiscal year 2027. Our Board of Directors (the "Board") regularly reviews our capital allocation strategy.

Share Owners

On August 6, 2026, the Company's common stock was owned by approximately 872 Share Owners of record.

Securities Authorized for Issuance Under Equity Compensation Plans

The information required by this item concerning securities authorized for issuance under equity compensation plans is incorporated by reference to Item 12 - Security Ownership of Certain Beneficial Owners and Management and Related Share Owner Matters of Part III.

Issuer Purchases of Equity Securities

On October 21, 2015, our Board approved an 18-month stock repurchase plan (the "Plan"), authorizing the repurchase of up to \$20 million worth of our common stock. Then, separately on each of September 29, 2016, August 23, 2017, November 8, 2018, November 10, 2020, November 15, 2024, and May 13, 2026 the Board extended and increased the Plan to allow the repurchase of up to an additional \$20 million worth of common stock with no expiration date, which brought the total authorized stock repurchases under the Plan to \$140 million.

During fiscal year 2026, the Company repurchased \$11.9 million of common stock under the Plan. The following table contains information about our purchases of equity securities during the three months ended June 30, 2026.

Period	Total Number of Shares Purchased	Average Price Paid per Share ⁽¹⁾	Total Number of Shares Purchased as Part of Publicly Announced Plan	Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plan ⁽¹⁾
April 1, 2026 - April 30, 2026	—	\$ —	—	\$ 6,526,922
May 1, 2026 - May 31, 2026	77,475	\$ 25.21	77,475	\$ 24,573,506
June 1, 2026 - June 30, 2026	5,887	\$ 25.42	5,887	\$ 24,423,858
Total	<u>83,362</u>	<u>\$ 25.23</u>	<u>83,362</u>	

(1) Excludes 1% U.S. excise tax on share repurchases which is recognized as part of the cost basis of the shares acquired in the Consolidated Statements of Share Owners' Equity.

Item 6 - [Reserved]

Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements contained within this document are considered forward-looking under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects,” “estimates,” “forecasts,” “likely,” “future,” “may,” “might,” “should,” “would,” “could,” “will,” “can,” “potentially,” “probable,” and similar expressions. These forward-looking statements are subject to risks and uncertainties including, but not limited to, global economic conditions, geopolitical environment and conflicts such as war, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of Kimball Electronics are located within Item 1A - Risk Factors.

Business Overview

We are a global, multifaceted manufacturing solutions provider. We provide electronics manufacturing services (“EMS”), including engineering and supply chain support, to customers in the automotive, medical, and industrial end markets. We further produce higher level and final assemblies and offer contract development and manufacturing organization (“CDMO”) solutions which include the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. Our manufacturing services, including engineering and supply chain support, utilize common production and support capabilities globally. We are well recognized by our customers and the industry for our excellent quality, reliability, and innovative service. We have participated in the CIRCUITS ASSEMBLY Service Excellence Awards for the past twelve consecutive years, winning awards for excellence each year of participation and recently receiving top honors in all seven award categories. CIRCUITS ASSEMBLY is a leading brand and technical publication for electronics manufacturers worldwide.

The contract manufacturing services industry is very competitive. As a mid-sized player, we can expect to be challenged by the agility and flexibility of the smaller, regional players, and we can expect to be challenged by the scale and price competitiveness of the larger, global players. We enjoy a unique market position between these extremes which allows us to compete with the larger scale players for high-volume projects, but also maintain our competitive position in the generally lower volume durable electronics market space. We expect to continue to effectively operate in this market space; however, one significant challenge will be maintaining our profit margins. Pricing remains competitive in the market even as production efficiencies and material pricing advantages for most projects drive costs and prices down over the life of the projects, a characteristic of our business and the market that we expect to continue.

We monitor the current economic and industry conditions for uncertainties that may pose a threat to our future growth or cause disruption in business strategy, execution, and timing in the markets in which we compete.

Beginning in February 2025, the U.S. implemented tariffs on a variety of countries and commodities under the International Emergency Economic Powers Act (“IEEPA”), and certain countries have imposed or are considering retaliatory tariffs on U.S. exports. The global tariff landscape is highly dynamic, including legal challenges and administrative processes related to tariffs and potential refunds. Increased tariffs have and may continue to impact end customer demand. We have recovered, and expect to continue recovering, a significant portion of our tariff-related costs from our customers, although recovery may lag the timing of cost occurrence. In the fourth quarter of fiscal year 2026, following the Supreme Court ruling that the IEEPA tariffs must be vacated, we began receiving refunds on IEEPA tariffs, a significant portion of which will be returned to our customers. While we may not be able to fully recover tariff costs, we expect any unrecovered amounts, after giving effect to our contractual pass-through and repricing mechanisms, to be immaterial to our results of operations and cash flows.

We are closely monitoring ongoing geopolitical tensions in the Middle East, including the recent conflict involving the U.S., Israel, and Iran, and the related regional instability. We are specifically monitoring the impacts to global macroeconomic conditions, supply chain disruptions, freight and component cost increases, and the related impact to end customer demand.

Net sales in fiscal year 2026 decreased 4% compared to fiscal year 2025, driven primarily by decreases in the automotive and industrial vertical markets partially offset by an increase in the medical market.

We have a strong focus on cost control balanced with managing the future growth prospects of our business. We expect to make investments that will strengthen or add new capabilities to our package of value as a multifaceted manufacturing solutions company, including through entering into a lease on a new facility for our Indianapolis operations, and our recently announced acquisition of Helvoet. Managing working capital in conjunction with fluctuating demand levels is likewise key. In addition, a long-standing component of our profit-sharing incentive bonus plan is its link to our financial performance, which results in varying amounts of compensation expense as profits change.

In fiscal year 2025, the Company announced that its Board of Directors had approved a plan to cease operations at our Tampa facility, which was completed by the end of the fiscal year 2025, and the sale of the land and building was completed in fiscal year 2026. The decision was another important step towards sharpening our strategic focus, while leveraging our global footprint and streamlining the operating structure. Production activities on existing customer programs were transferred out of Tampa, with the majority of the work going to our plants in North America, primarily our newly expanded facility in Mexico and Jasper. As we continue to monitor the progression of tariffs and the geopolitical economic environment, additional restructuring efforts may be necessary. In fiscal year 2027, we expect the following known trends and uncertainties to affect our results of operations: (i) integration of Helvoet, including one-time integration costs, purchase-accounting adjustments, and expected revenue and cost synergies; (ii) start-up costs and depreciation associated with our new Indianapolis, Indiana medical CDMO facility as it replaces our existing Indianapolis operations; (iii) continued uncertainty regarding U.S. and foreign tariff policy; (iv) ongoing demand pressure in the automotive vertical, partially offset by expected growth in the medical vertical; and (v) potential changes to our effective tax rate arising from the geographic mix of earnings and from the continued implementation of the One Big Beautiful Bill Act. We continue to work with our customers to optimize our global footprint.

We continue to maintain a strong balance sheet as of the end of fiscal year 2026, which included a current ratio of 2.1, a debt-to-equity ratio of 0.2, and Share Owners' equity of \$585 million. Refer to the Future Liquidity section of Liquidity and Capital Resources below for further discussion of our liquidity.

The continuing success of our business is dependent upon our ability to replace expiring customers/programs with new customers/programs. We monitor our success in this area by tracking the number of customers and the percentage of our net sales generated from them by years of service as depicted in the table below. While variation in the size of program awards makes it difficult to directly correlate this data to our sales trends, we believe it does provide useful information regarding our customer loyalty and new business growth.

Customer Service Years	Year End		
	2026	2025	2024
More than 10 Years			
% of Net Sales	77%	77%	76%
# of Customers	26	36	38
5 to 10 Years			
% of Net Sales	17%	17%	18%
# of Customers	12	13	15
Less than 5 Years			
% of Net Sales	6%	6%	6%
# of Customers	12	9	12
Total			
% of Net Sales	100%	100%	100%
# of Customers	50	58	65

Our total number of customers declined by eight from 2025 to 2026. Those customers accounted for approximately 1% of our consolidated net sales in fiscal year 2025.

A detailed discussion of risk factors and uncertainties that could have an effect on our performance are located within Item 1A - Risk Factors.

Presentation of Results of Operations and Liquidity and Capital Resources

A discussion regarding our financial condition and results of operations for fiscal year 2026 compared to fiscal year 2025 is presented below. A discussion regarding our financial condition and results of operations for fiscal year 2025 compared to fiscal year 2024 can be found under captions entitled "Results of Operations - Fiscal Year 2025 Compared with Fiscal Year 2024" and "Liquidity and Capital Resources" in the section entitled "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the year ended June 30, 2025 filed with the SEC on August 22, 2025, which is available free of charge through the SEC's website at <http://www.sec.gov> or the Company's website, <https://investors.kimballelectronics.com>. The Company's website and the information contained therein, or incorporated therein, are not intended to be incorporated into this Annual Report on Form 10-K.

Results of Operations - Fiscal Year 2026 Compared with Fiscal Year 2025

	At or For the Year Ended June 30				
(Amounts in Millions, Except for Per Share Data)	2026	as a % of Net Sales	2025	as a % of Net Sales	% Change
Net Sales	\$ 1,431.4		\$ 1,486.7		(4)%
Gross Profit	\$ 117.5	8.2%	\$ 104.4	7.0%	13%
Selling and Administrative Expenses	61.1	4.3%	50.3	3.4%	22%
Restructuring Expense	5.0	0.3%	11.0	0.7%	(55)%
(Gain on Disposal) Asset Impairment	(14.7)	(1.0)%	(2.4)	(0.2)%	(516)%
Operating Income	66.1	4.6%	45.5	3.1%	45%
Other Income (Expense)	(12.8)		(19.3)		
Provision for Income Taxes	25.3		9.2		173%
Net Income	<u>\$ 28.0</u>		<u>\$ 17.0</u>		65%
Diluted Earnings per Share	\$ 1.13		\$ 0.68		66%
Open Orders	\$ 643		\$ 642		— %

Net Sales by Vertical Market

	For the Year Ended June 30		
(Amounts in Millions)	2026	2025	% Change
Automotive	\$ 656.9	\$ 708.5	(7)%
Medical	412.8	396.2	4%
Industrial	361.7	382.0	(5)%
Total Net Sales	<u>\$ 1,431.4</u>	<u>\$ 1,486.7</u>	(4)%

Beginning in the first quarter 2026, sales to certain customers previously included in the automotive vertical, specifically those customers more aligned with commercial vehicle applications versus passenger vehicles, are now reflected in the industrial vertical to better reflect the nature of the programs. Prior periods have been recast to conform to current period presentation. For the year ended June 30, 2025, \$29.4 million of the industrial net sales were previously categorized as automotive.

Net sales in fiscal year 2026 decreased by 4% compared to net sales in fiscal year 2025. Foreign currency fluctuations had a favorable 2% impact on net sales in fiscal year 2026 compared to fiscal year 2025. By end market vertical, our market verticals fluctuated as follows:

- Sales to customers in the automotive market were down in the current fiscal year when compared to the prior fiscal year resulting from the loss of a major automotive program that was unrelated to Kimball, the continued pressure on customer demand partially as a result of tariffs primarily impacting North America, partially offset by improvements in Europe.
- Sales to customers in the medical market increased when compared to the prior fiscal year. Fiscal year 2025 was favorably impacted by \$24 million in non-recurring consignment inventory sales to a customer for completed programs. Offsetting the decreases from the non-recurring consignment inventory sales in the prior year were a step-up in sales with our largest medical customer in addition to some new program wins.
- In the industrial end market vertical, sales to customers decreased when compared to fiscal year 2025 primarily as a result of decline in residential HVAC partially offset by an increase in smart metering in Europe.

Sales to Nexteer Automotive, Philips, and ZF accounted for the following portions of our net sales:

	Year Ended June 30	
	2026	2025
Nexteer Automotive	18%	19%
Philips	11%	*
ZF	11%	11%

* amount is less than 10% of total

Gross profit as a percent of net sales improved in fiscal year 2026 when compared to fiscal year 2025 as we experienced volume leverage in Europe, cost efficiencies from global restructuring and the closure of our Tampa facility, and favorable foreign exchange rates.

For fiscal year 2026, selling and administrative expenses increased as a percent of net sales and in absolute dollars when compared to fiscal year 2025, driven by higher wages and benefits, increased profit-sharing bonus expense and stock compensation driven by improved performance, and increased professional fees relating to business transformation. Fiscal year 2026 also included a \$2.0 million recovery received during the first three months of fiscal year 2026 resulting from a customer terminating a program.

In fiscal year 2026 and 2025, we recorded pre-tax restructuring expense of \$5.0 million and \$11.0 million, primarily for employee-related costs as we undertook restructuring efforts to align our cost structure with reduced end market demand levels and incurred costs related to the Tampa closure.

At June 30, 2025, we ceased operations at our Tampa facility. At that time, the related land, building, and equipment were classified as held for sale. On April 22, 2026, the Company completed the sale of the Tampa land and buildings recording a gain on sale of \$15.0 million. See Note 4 - Restructuring Activities of Notes to Consolidated Financial Statements for more information. We completed the divestiture of GES on July 31, 2024 and recorded a gain on disposal of \$2.4 million during fiscal year 2025. See Note 3 - Sale of GES of Notes to Consolidated Financial Statements for more information.

Other Income (Expense) consisted of the following:

	Year Ended June 30	
	2026	2025
(Amounts in Thousands)		
Interest Income	\$ 1,232	\$ 771
Interest Expense	(8,504)	(14,745)
Foreign Currency/Derivative Gain (Loss)	(1,263)	(1,751)
Gain (Loss) on SERP Investments	666	614
Factoring fees / AR program discounts	(3,862)	(2,415)
Credit facilities fees and bank charges	(910)	(1,018)
Other	(195)	(762)
Other Income (Expense), net	<u>\$ (12,836)</u>	<u>\$ (19,306)</u>

Interest expense has decreased in the year ended June 30, 2026 compared to the year ended June 30, 2025 due to lower borrowings on credit facilities and lower interest rates. The Foreign Currency/Derivative Gain (Loss) resulted from net foreign currency exchange rate movements during the periods. The losses in fiscal year 2026 and 2025 were driven by the weakening of the U.S. dollar versus foreign currencies that we have exposure to in our business. The revaluation to fair value of the SERP investments recorded in Other Income (Expense) is offset by the revaluation of the SERP liability recorded in Selling and Administrative Expenses, and thus there is no effect on net income.

Our income before income taxes and effective tax rate were comprised of the following U.S. and foreign components:

(Amounts in Thousands)	Year Ended June 30, 2026		Year Ended June 30, 2025	
	Income (Loss) Before Taxes	Effective Tax Rate	Income (Loss) Before Taxes	Effective Tax Rate
United States	\$ 2,551	157.8%	\$ (9,681)	11.8%
Foreign	\$ 50,670	41.9%	\$ 35,910	28.9%
Total	<u>\$ 53,221</u>	47.5%	<u>\$ 26,229</u>	35.2%

The consolidated effective tax rate for fiscal year 2026 was driven higher primarily by the recognition of dividend withholding taxes from foreign subsidiaries as well as the inclusion of GILTI income which resulted in additional U.S. tax on foreign earnings.

The consolidated effective tax rate for fiscal year 2025 was driven higher by the limitation on the deductibility of business interest expense under Section 163(j) and the inclusion of GILTI income which resulted in additional U.S. tax on foreign earnings.

Our overall effective tax rate will fluctuate depending on the geographic distribution of our worldwide earnings. See Note 12 - Income Taxes of Notes to Consolidated Financial Statements for more information.

We recorded net income of \$28.0 million in fiscal year 2026, or \$1.13 per diluted share, an increase of 64.6% from fiscal year 2025 net income of \$17.0 million, or \$0.68 per diluted share.

Open orders were flat as of June 30, 2026 compared to June 30, 2025. The total reported for June 30, 2025 has been revised to \$642 million, from the \$702 million originally reported, to more accurately reflect the calculation of open order activity impacting all three verticals. Open orders are the aggregate sales price of production pursuant to unfulfilled customer orders, which may be delayed or canceled by the customer subject to contractual termination provisions. The majority of open orders as of June 30, 2026 are expected to be filled within the next twelve months. Open orders at a point in time may not be indicative of future sales trends due to the contract nature of our business and the variability of order lead times among our customers.

Liquidity and Capital Resources

Working capital at June 30, 2026 was \$360.9 million compared to working capital of \$381.0 million at June 30, 2025. The current ratio was 2.1 at June 30, 2026 and 2.2 at June 30, 2025, respectively. The debt-to-equity ratio was 0.2 at June 30, 2026 and 0.3 at June 30, 2025. Our short-term liquidity available, represented as cash and cash equivalents plus the unused amount of our credit facilities, some of which are uncommitted, totaled \$403.8 million at June 30, 2026 and \$373.5 million at June 30, 2025.

Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding (“DSO”) plus Contract Asset Days (“CAD”) plus Production Days Supply on Hand (“PDSOH”) less Accounts Payable Days (“APD”) and less Advances from Customers Days (“ACD”). CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital. The following table summarizes our CCD for the quarterly periods indicated.

	Three Months Ended				
	June 30, 2026	March 31, 2026	December 31, 2025	September 30, 2025	June 30, 2025
DSO	53	56	59	54	56
CAD	19	20	20	18	18
PDSOH	89	91	92	85	84
APD	62	62	65	59	55
ACD	17	15	15	15	18
CCD	<u>82</u>	<u>90</u>	<u>91</u>	<u>83</u>	<u>85</u>

We define Days Sales Outstanding as the average of monthly trade accounts and notes receivable divided by an average day’s net sales, Contract Asset Days as the average monthly contract assets divided by an average day’s net sales, Production Days Supply on Hand as the average of monthly gross inventory divided by an average day’s cost of sales, Accounts Payable Days as the average of monthly accounts payable divided by an average day’s cost of sales, and Advances from Customers Days as the average of monthly customer deposits divided by an average day’s cost of sales. Over the past several quarters, we have improved our CCD metrics by better aligning our working capital with the lower sales levels.

Cash Flows

The following table reflects the major categories of cash flows for the fiscal years ended June 30, 2026 and 2025.

(Amounts in Millions)	Year Ended June 30	
	2026	2025
Net cash provided by operating activities	\$ 72.3	\$ 183.9
Net cash used for investing activities	\$ (25.9)	\$ (14.7)
Net cash used for financing activities	\$ (47.1)	\$ (160.9)

Cash Flows from Operating Activities

Net cash provided by operating activities for the fiscal year ended June 30, 2026 was primarily driven by net income adjusted for non-cash items as well as changes in operating assets and liabilities. Net income adjusted for non-cash items generated operating cash flow of \$62.8 million in fiscal year 2026. Changes in operating assets and liabilities generated cash flow of \$9.5 million in fiscal year 2026 driven primarily by cash provided by accounts payable of \$20.0 million, which was driven by the improvement of payment terms, and accrued expenses and taxes payable which provided cash of \$13.3 million, driven by improved performance which resulted in increased accrued taxes and accrued compensation. Partially offsetting cash provided by accounts payable and accrued expenses was an increase in inventory which used cash of \$19.9 million, which was due to longer lead times on certain components as well as ramp up of new programs.

Net cash provided by operating activities for the fiscal year ended June 30, 2025 was primarily driven by change in receivables, which provided cash of \$71.8 million due to lower sales levels and increased use of factoring programs, and inventories, which provided cash of \$74.6 million due to working down previously inflated inventory levels from strategic inventory builds to mitigate part shortages. Net income adjusted for non-cash items also generated operating cash flow of \$56.5 million in fiscal year 2025.

Cash Flows from Investing Activities

Net cash used for investing activities during fiscal year 2026 includes \$51.7 million cash used for capital investments including for the new medical facility in Indianapolis as well as to support new business awards and facility improvements, partially offset by the \$21.7 million of proceeds from the sale of the Tampa facility. See Note 4 - Restructuring Activities of Notes to Consolidated Financial Statements for more information on the Tampa facility sale.

Net cash used for investing activities during fiscal year 2025 includes \$33.7 million cash used for capital investments primarily to support new business awards and replacement of older machinery, partially offset by the \$18.5 million of proceeds from the sale of GES. See Note 3 - Sale of GES of Notes to Consolidated Financial Statements for more information on the divestiture of GES.

Cash Flows from Financing Activities

Net cash used for financing activities for the fiscal year ended June 30, 2026 resulted largely from payments of \$30.9 million on our credit facilities to reduce debt.

Net cash used for financing activities for the fiscal year ended June 30, 2025 resulted largely from net payments on our credit facilities of \$147.3 million.

Credit Facilities

The Company maintains a U.S. primary credit facility (the “primary credit facility”) which was scheduled to mature on May 4, 2027. The primary credit facility provides for \$300 million in revolving borrowings, with an option to increase the amount available for borrowing to \$450 million at the Company’s request, subject to the consent of each lender participating in such increase. On December 20, 2024, the Company entered into an amended and restated credit agreement which resulted in the addition of a term loan borrowing, allowing for term loan borrowings of \$100 million repayable in scheduled quarterly installments, and is scheduled to mature on December 20, 2029.

On April 30, 2026, the Company entered into an amended and restated credit agreement (the “restated primary credit facility”). The restated primary credit facility continues to provide for revolving borrowings of \$300 million, with the option to increase the amount available for revolving borrowings by an additional \$150 million at the Company’s request, subject to the consent of each lender participating in such increase. The amended and restated credit agreement is scheduled to mature on April 30, 2031. The terms for the term loan borrowings remain largely unchanged in the restated primary credit facility. It is still scheduled to mature on December 20, 2029 for such term loan borrowings and the quarterly payment schedule for such term

loan borrowings. This facility is maintained for working capital and general corporate purposes of the Company. We were in compliance with the financial covenants of the primary credit facility during the period ended June 30, 2026.

We also maintain foreign credit facilities for working capital and general corporate purposes at specific foreign locations rather than utilizing funding from intercompany sources. These foreign credit facilities can be canceled at any time by either the bank or us and generally include renewal clauses. As of June 30, 2026, we maintained foreign credit facilities at our Thailand operation, our China operation, our Netherlands subsidiary, and our Poland operation.

See Note 9 - Credit Facilities of Notes to Consolidated Financial Statements for more information on our credit facilities, including the terms of the credit facilities such as interest, commitment fees, debt covenants, and the amended primary credit facility.

Factoring Arrangements

We participate in our customers' supply chain financing arrangements in order to extend terms for the customer without negatively impacting our cash flow. These arrangements in all cases do not contain recourse provisions which would obligate us in the event of our customers' failure to pay. Receivables are considered sold when they are transferred beyond the reach of Kimball Electronics and its creditors, the purchaser has the right to pledge or exchange the receivables, and we have surrendered control over the transferred receivables. During the fiscal years ended June 30, 2026 and 2025, we sold, without recourse, \$315.8 million and \$338.4 million of accounts receivable, respectively.

In addition to our customers' supply chain financing arrangements, we have also entered into receivables purchase agreements ("RPA's") with third-party banking institutions for certain domestic receivables. We sell our entire interest in certain receivables for 100% of face value, less a discount. We are required to remit amounts collected as a servicer under the RPA's timely to the financial institution that purchased the receivables. Our risks with respect to receivables we service include commercial disputes regarding such receivables, and under one of the RPA's, no greater than 5% of sold and outstanding receivables in the event of customer insolvency. In the fiscal years ended June 30, 2026 and 2025, under these programs, we sold \$171.3 million and \$19.4 million of receivables, respectively. See Note 1 - Business Description and Summary of Significant Accounting Policies of Notes to Consolidated Financial Statements for more information regarding our factoring arrangements.

Future Liquidity

As of June 30, 2026, following several quarters of strong cash generated from operating activities and debt reduction, we are in a much improved liquidity position with \$88.9 million in cash and unused borrowings in USD equivalent under all of our credit facilities of \$314.9 million. Additionally, considering expected future sources of liquidity from cash generated from operations, we are positioned to meet our working capital and other operating needs for at least the next twelve months.

We expect to continue to prudently invest in capital expenditures that would help us continue our growth as a multifaceted manufacturing solutions company, including for capacity expansions and potential acquisitions such as the recent announcement of the Helvoet acquisition. In July 2026, the Company paid a purchase price of approximately 90.0 million Euro, or approximately \$103.0 million which was funded with a combination of the Company's cash and existing lines of credit. See Note 22 - Subsequent Event of Notes to Consolidated Financial Statements for more information regarding our recent acquisition.

At June 30, 2026, our capital expenditure commitments were approximately \$7.7 million, consisting primarily of capital related to new program wins as well as for facility improvements. We anticipate our available liquidity will be sufficient to fund these capital expenditures.

We have purchase obligations that arise in the normal course of business for items such as raw materials, services, and software acquisitions/license commitments. In certain instances, such as when lead times dictate, we enter into contractual agreements for material in excess of the levels required to fulfill customer orders. In turn, material authorization agreements with customers cover a portion of the exposure for material that we must purchase prior to having a firm order.

At June 30, 2026, our foreign operations held cash totaling \$85 million. Most of our accumulated unremitted foreign earnings have been invested in active non-U.S. business operations. The Company continually evaluates its global cash needs. If such funds were repatriated or we determined that all or a portion of such foreign earnings are no longer permanently reinvested, we may be subject to applicable non-U.S. income and withholding taxes. Determination of the amount of any potential future unrecognized deferred tax liability on such unremitted earnings is not practicable and is recorded in the period when any foreign earnings are determined to be no longer permanently reinvested.

The Company's Repurchase Plan allows the repurchase of up to \$140 million of our common stock. Purchases may be made under various programs, including in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions, all in accordance with applicable securities laws and regulations. The Repurchase Plan has no expiration date but may be suspended or discontinued at any time. The extent to which the Company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements, and other corporate considerations, as determined by the Company's management team. The Company expects to finance the purchases with existing liquidity. The Company has repurchased \$115.6 million of common stock under the Repurchase Plan through June 30, 2026.

Our ability to generate cash from operations to meet our liquidity obligations could be adversely affected in the future by factors such as general economic and market conditions, lack of availability of raw material components in the supply chain, a decline in demand for our services, loss of key contract customers, unsuccessful integration of acquisitions and new operations, global health emergencies, and the related uncertainties around the financial impact, and other unforeseen circumstances. In particular, should demand for our customers' products and, in turn, our services decrease significantly over the next 12 months, the available cash provided by operations could be adversely impacted.

Fair Value

During fiscal year 2026, no level 1 or level 2 financial instruments were affected by a lack of market liquidity. For level 1 financial assets, readily available market pricing was used to value the financial instruments. Our foreign currency derivative assets and liabilities, which were classified as level 2, were independently valued using observable market inputs such as forward interest rate yield curves, current spot rates, and time value calculations. To verify the reasonableness of the independently determined fair values, these derivative fair values were compared to fair values calculated by the counterparty banks. Our own credit risk and counterparty credit risk had an immaterial impact on the valuation of the foreign currency derivatives. See Note 14 - Fair Value of Notes to Consolidated Financial Statements for additional information.

Off-Balance Sheet Arrangements

As of June 30, 2026, we do not have any material off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Kimball Electronics' Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America. These principles require the use of estimates and assumptions that affect amounts reported and disclosed in the Consolidated Financial Statements and related notes. Actual results could differ from these estimates and assumptions. Management uses its best judgment in the assumptions used to value these estimates, which are based on current facts and circumstances, prior experience, and other assumptions that are believed to be reasonable. Management believes the following critical accounting policies reflect the more significant judgments and estimates used in preparation of our Consolidated Financial Statements and are the policies that are most critical in the portrayal of our financial position and results of operations. Management has discussed these critical accounting policies and estimates with the Audit Committee of the Company's Board of Directors and with the Company's independent registered public accounting firm.

Revenue recognition - Kimball Electronics recognizes revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services and products. The majority of our revenue is recognized over time as manufacturing services are performed where we manufacture a product with no alternative use and have an enforceable right to payment for performance completed to date. The remaining revenue is recognized when the customer obtains control of the manufactured product.

Taxes - Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. We evaluate the recoverability of our deferred tax assets each quarter by assessing the likelihood of future taxable income and available tax planning strategies that could be implemented to realize our deferred tax assets. If recovery is not likely, we provide a valuation allowance based on our best estimate of future taxable income in the various taxing jurisdictions and the amount of deferred taxes ultimately realizable. Future events could change management's assessment.

We operate within multiple taxing jurisdictions and are subject to tax audits in these jurisdictions. These audits can involve complex issues, which may require an extended period of time to resolve. However, we believe we have made adequate provision for income and other taxes for all years that are subject to audit. As tax positions are effectively settled, the tax

provision will be adjusted accordingly. The liability for uncertain income tax and other tax positions, including accrued interest and penalties on those positions, was \$1.6 million and \$1.5 million at June 30, 2026 and June 30, 2025, respectively.

New Accounting Standards

See Note 1 - Business Description and Summary of Significant Accounting Policies of Notes to Consolidated Financial Statements for information regarding New Accounting Standards.

Item 7A - *Quantitative and Qualitative Disclosures About Market Risk*

Foreign Exchange Rate Risk: Kimball Electronics operates internationally and thus is subject to potentially adverse movements in foreign currency rate changes. Our principal foreign currency exposures include the Euro, Polish zloty, Romanian leu, Chinese renminbi, Thai baht, and Mexican peso. Our risk management strategy includes the use of derivative financial instruments to hedge certain foreign currency exposures. Derivatives are used only to manage underlying exposures and are not used in a speculative manner. Further information on derivative financial instruments is provided in Note 15 - Derivative Instruments of Notes to Consolidated Financial Statements. We estimate that a hypothetical 10% adverse change in foreign currency exchange rates from levels at June 30, 2026 relative to non-functional currency balances of monetary instruments, to the extent not hedged by derivative instruments, would not have a material impact on profitability in an annual period. Actual future gains and losses could have a material impact in an annual period depending on changes or differences in market rates and interrelationships, hedging instruments, timing, and other factors.

Interest Rate Risk: Our primary exposure to market risk for changes in interest rates relates to our primary credit facility, described further in Note 9 - Credit Facilities of Notes to Consolidated Financial Statements, as the interest rates paid for borrowings are determined at the time of borrowing based on market indices. Therefore, although we can elect to fix the interest rate at the time of borrowing, the facility does expose us to market risk for changes in interest rates. We estimate that a hypothetical 10% change in interest rates on borrowing levels at June 30, 2026 would not have a material impact of profitability in an annual period. The interest rate on all borrowings at June 30, 2026 are based on the Secured Overnight Financing Rate ("SOFR").

Item 8 - Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	<u>Page No.</u>
Management’s Report on Internal Control Over Financial Reporting	34
Report of Independent Registered Public Accounting Firm (PCAOB No. 34)	35
Consolidated Balance Sheets as of June 30, 2026 and 2025	38
Consolidated Statements of Income for Each of the Three Years in the Period Ended June 30, 2026	39
Consolidated Statements of Comprehensive Income for Each of the Three Years in the Period Ended June 30, 2026	40
Consolidated Statements of Cash Flows for Each of the Three Years in the Period Ended June 30, 2026	41
Consolidated Statements of Share Owners’ Equity for Each of the Three Years in the Period Ended June 30, 2026 ..	42
Notes to Consolidated Financial Statements	43

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

The management of Kimball Electronics, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting and for the preparation and integrity of the accompanying financial statements and other related information in this report. The consolidated financial statements of the Company and its subsidiaries, including the footnotes, were prepared in accordance with accounting principles generally accepted in the United States of America and include judgments and estimates, which in the opinion of management are applied on an appropriately conservative basis. We maintain a system of internal and disclosure controls intended to provide reasonable assurance that assets are safeguarded from loss or material misuse, transactions are authorized and recorded properly, and that the accounting records may be relied upon for the preparation of the financial statements. This system is tested and evaluated regularly for adherence and effectiveness by employees who work within the internal control processes and by our staff of internal auditors.

The Audit Committee of the Board of Directors, which is comprised of directors who are not employees of the Company, meets regularly with management, our internal auditors, and the independent registered public accounting firm to review our financial policies and procedures, our internal control structure, the objectivity of our financial reporting, and the independence of the independent registered public accounting firm. The internal auditors and the independent registered public accounting firm have free and direct access to the Audit Committee, and they meet periodically, without management present, to discuss appropriate matters.

Because of inherent limitations, a system of internal control over financial reporting may not prevent or detect misstatements and even when determined to be effective, can only provide reasonable assurance with respect to financial statement preparation and presentation.

These consolidated financial statements are subject to an evaluation of internal control over financial reporting conducted under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer. Based on that evaluation, conducted under the criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission, management concluded that our internal control over financial reporting was effective as of June 30, 2026.

/s/ RICHARD D. PHILLIPS

Richard D. Phillips
Chief Executive Officer
August 19, 2026

/s/ JANA T. CROOM

Jana T. Croom
Chief Financial Officer
August 19, 2026

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Share Owners and the Board of Directors of Kimball Electronics, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Kimball Electronics, Inc. and subsidiaries (the “Company”) as of June 30, 2026 and 2025, the related consolidated statements of income, comprehensive income, share owners’ equity, and cash flows for each of the three years in the period ended June 30, 2026, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). We also have audited the Company’s internal control over financial reporting as of June 30, 2026, based on the criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2026, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2026, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

Basis for Opinions

The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying management’s report on internal control over financial reporting. Our responsibility is to express an opinion on these financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Revenue Recognition—Contracts Recognized Over Time— Refer to Notes 1 and 2 to the financial statements

Critical Audit Matter Description

The majority of the Company's revenue is recognized over time as manufacturing services are performed when the Company manufactures a product to customer specifications with no alternative use and for which the Company has an enforceable right to payment for performance completed to date. The Company generally recognizes revenue over time to depict the Company's progress towards meeting its performance obligations, using costs based input methods, in which judgment is required to evaluate assumptions including the anticipated margins to estimate the corresponding amount of revenue to recognize.

The timing differences of revenue recognition, billings to the Company's customers, and cash collections from the Company's customers result in billed accounts receivable and unbilled accounts receivable. Contract assets on the consolidated balance sheets relate to unbilled accounts receivable and occur when revenue is recognized over time as manufacturing services are provided and the billing to the customer has not yet occurred as of the balance sheet date, which are generally transferred to receivables in the next fiscal quarter due to the short-term nature of the manufacturing cycle.

We identified the Company's revenue recognition over time for contracts with customers as a critical audit matter because of the judgments required to evaluate assumptions, including the anticipated margins to estimate the corresponding amount of revenue to recognize and contract assets to record. This required an increased extent of audit effort due to the significant number of contracts on which the Company recognizes revenue over time and a high degree of auditor judgment when performing procedures to audit management's estimate of anticipated margins used to recognize revenue over time and evaluating the results of those procedures.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to management's estimates of the anticipated margins used to recognize revenue over time and record contract assets included the following, among others:

- We tested the effectiveness of controls over the Company's recognition of revenue over time and the related contract asset balance, including management's process for estimating the anticipated margins for manufactured products. We evaluated management's ability to estimate revenue accurately by comparing actual margins to management's historical estimates for completed contracts.
- We selected a sample of contracts with customers and performed the following:
 - Evaluated whether the contracts with customers were properly included or excluded in management's calculation of over time contract revenue based on the terms and conditions of each contract, including whether the Company determined the product has no alternative use and that the Company has an enforceable right to payment for performance completed to date.
 - Compared the transaction prices to the consideration expected to be received based on current rights and obligations under the contracts and any modifications that were agreed upon with the customers.
 - Tested the accuracy and completeness of the costs incurred to date for the respective performance obligations by comparing the quantities on hand and standard cost per the calculation to the Company's perpetual inventory information and testing any manufacturing variances and purchase price adjustments.
 - Evaluated the calculation of the amount of revenue to recognize for the performance obligation by:
 - Evaluating the reasonableness of management's anticipated margins used in the Company's calculation of revenue.

- Evaluating the appropriateness and consistency of the methods and assumptions used by management to develop the estimates of anticipated margin at completion.
- We tested the mathematical accuracy of management's calculation of revenue recognized over time and the related contract asset balance.

/s/ Deloitte & Touche LLP

Indianapolis, Indiana

August 19, 2026

We have served as the Company's auditor since 2014.

KIMBALL ELECTRONICS, INC.
CONSOLIDATED BALANCE SHEETS
(Amounts in Thousands, Except for Share Data)

	<u>June 30, 2026</u>	<u>June 30, 2025</u>
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 88,925	\$ 88,781
Receivables, net of allowances of \$536 and \$102, respectively	218,840	222,623
Contract assets	70,497	71,812
Inventories	271,906	273,500
Prepaid expenses and other current assets	42,836	36,027
Assets held for sale	—	6,861
Total current assets	<u>693,004</u>	<u>699,604</u>
Property and Equipment, net of accumulated depreciation of \$354,854 and \$334,465, respectively	274,192	264,804
Goodwill	6,191	6,191
Other Intangible Assets, net of accumulated amortization of \$28,253 and \$28,227, respectively	1,921	2,427
Other Assets, net	116,762	104,286
Total Assets	<u>\$ 1,092,070</u>	<u>\$ 1,077,312</u>
LIABILITIES AND SHARE OWNERS' EQUITY		
Current Liabilities:		
Current portion of long-term debt	\$ 8,202	\$ 17,400
Accounts payable	234,361	218,805
Advances from customers	30,672	35,867
Accrued expenses	58,860	46,489
Total current liabilities	<u>332,095</u>	<u>318,561</u>
Other Liabilities:		
Long-term debt under credit facilities, less current portion	108,000	129,650
Other long-term liabilities	66,843	59,217
Total other liabilities	<u>174,843</u>	<u>188,867</u>
Share Owners' Equity:		
Preferred stock-no par value		
Shares authorized: 15,000,000		
Shares issued: None	—	—
Common stock-no par value		
Shares authorized: 150,000,000		
Shares issued: 29,430,000		
Shares outstanding: 23,967,000 and 24,218,500, respectively	—	—
Additional paid-in capital	325,787	323,309
Retained earnings	361,508	333,548
Accumulated other comprehensive income (loss)	(4,672)	1,063
Treasury stock, at cost:		
Shares: 5,463,000 and 5,211,500, respectively	(97,491)	(88,036)
Total Share Owners' Equity	<u>585,132</u>	<u>569,884</u>
Total Liabilities and Share Owners' Equity	<u>\$ 1,092,070</u>	<u>\$ 1,077,312</u>

See Notes to Consolidated Financial Statements

KIMBALL ELECTRONICS, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Amounts in Thousands, Except for Per Share Data)

	Year Ended June 30		
	2026	2025	2024
Net Sales	\$ 1,431,378	\$ 1,486,727	\$ 1,714,510
Cost of Sales	1,313,910	1,382,323	1,574,253
Gross Profit	117,468	104,404	140,257
Selling and Administrative Expenses	61,155	50,270	66,626
Other General Income	—	—	(892)
Restructuring Expense	4,977	10,990	2,386
Goodwill Impairment	—	—	5,820
(Gain on Disposal) Asset Impairment	(14,721)	(2,391)	17,040
Operating Income	66,057	45,535	49,277
Other Income (Expense):			
Interest income	1,232	771	638
Interest expense	(8,504)	(14,745)	(22,839)
Non-operating income (expense), net	(5,564)	(5,332)	(1,877)
Other expense, net	(12,836)	(19,306)	(24,078)
Income Before Taxes on Income	53,221	26,229	25,199
Provision for Income Taxes	25,261	9,245	4,688
Net Income	<u>\$ 27,960</u>	<u>\$ 16,984</u>	<u>\$ 20,511</u>
Earnings Per Share of Common Stock:			
Basic	\$ 1.14	\$ 0.68	\$ 0.82
Diluted	\$ 1.13	\$ 0.68	\$ 0.81
Average Number of Shares Outstanding:			
Basic	24,501	24,782	25,079
Diluted	24,768	25,017	25,278

See Notes to Consolidated Financial Statements

KIMBALL ELECTRONICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Amounts in Thousands)

	Year Ended June 30, 2026			Year Ended June 30, 2025			Year Ended June 30, 2024		
	Pre-tax	Tax	Net of Tax	Pre-tax	Tax	Net of Tax	Pre-tax	Tax	Net of Tax
Net Income			\$ 27,960			\$ 16,984			\$ 20,511
Other Comprehensive Income (Loss):									
Foreign currency translation adjustments	\$ (5,737)	\$ —	\$ (5,737)	\$ 16,523	\$ —	\$ 16,523	\$ (2,620)	\$ 192	\$ (2,428)
Postemployment actuarial change	114	78	192	113	(69)	44	(916)	275	(641)
Derivative gain (loss)	3,968	(991)	2,977	(82)	18	(64)	2,621	(524)	2,097
Reclassification to (earnings) loss:									
Derivatives	(4,495)	1,163	(3,332)	2,960	(762)	2,198	(7,530)	1,670	(5,860)
Amortization of actuarial change	217	(52)	165	222	(53)	169	94	(23)	71
Other Comprehensive Income (Loss)	<u>\$ (5,933)</u>	<u>\$ 198</u>	<u>\$ (5,735)</u>	<u>\$ 19,736</u>	<u>\$ (866)</u>	<u>\$ 18,870</u>	<u>\$ (8,351)</u>	<u>\$ 1,590</u>	<u>\$ (6,761)</u>
Total Comprehensive Income			<u>\$ 22,225</u>			<u>\$ 35,854</u>			<u>\$ 13,750</u>

See Notes to Consolidated Financial Statements

KIMBALL ELECTRONICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in Thousands)

	Year Ended June 30		
	2026	2025	2024
Cash Flows From Operating Activities:			
Net income	\$ 27,960	\$ 16,984	\$ 20,511
Adjustments to reconcile net income to net cash provided by:			
Depreciation and amortization	38,705	36,994	38,030
(Gain)/loss on sales of assets	506	(1,139)	(15)
Deferred income taxes	530	(6,243)	(8,852)
Goodwill impairment	—	—	5,820
(Gain on disposal) asset impairment	(14,721)	(2,391)	17,040
Stock-based compensation	8,232	6,519	7,185
Other, net	1,568	5,802	2,928
Change in operating assets and liabilities:			
Receivables	(6,030)	71,769	8,485
Contract assets	1,155	4,508	2,478
Inventories	(19,937)	74,646	64,219
Prepaid expenses and other assets	(2,198)	(466)	(6,412)
Accounts payable	20,037	(2,790)	(102,574)
Advances from customers	3,181	(6,119)	34,922
Accrued expenses and taxes payable	13,279	(14,137)	(10,548)
Net cash provided by operating activities	72,267	183,937	73,217
Cash Flows From Investing Activities:			
Capital expenditures	(51,488)	(33,276)	(46,074)
Proceeds from sales of assets	4,012	383	499
Purchases of capitalized software	(187)	(399)	(966)
Net proceeds from disposal	21,674	18,507	—
Other, net	42	85	20
Net cash used for investing activities	(25,947)	(14,700)	(46,521)
Cash Flows From Financing Activities:			
Proceeds from credit facilities	43,000	100,000	—
Payments on credit facilities	(76,000)	(237,500)	—
Additional net change in revolving credit facilities	2,052	(9,830)	13,450
Repurchases of common stock	(11,872)	(12,032)	(2,847)
Payments related to tax withholding for stock-based compensation	(3,340)	(1,013)	(1,479)
Debt issuance costs	(890)	(499)	(150)
Net cash (used for) provided by financing activities	(47,050)	(160,874)	8,974
Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash	904	2,325	(755)
Net Increase in Cash, Cash Equivalents, and Restricted Cash	174	10,688	34,915
Cash, Cash Equivalents, and Restricted Cash at Beginning of Year ⁽¹⁾	89,467	78,779	43,864
Cash, Cash Equivalents, and Restricted Cash at End of Year ⁽¹⁾	<u>\$ 89,641</u>	<u>\$ 89,467</u>	<u>\$ 78,779</u>
Supplemental Disclosure of Cash Flow Information			
Cash paid during the year for:			
Income taxes	\$ 14,218	\$ 12,825	\$ 27,265
Interest expense	\$ 9,037	\$ 18,147	\$ 19,444
Non-cash investing activity:			
Unpaid purchases of property and equipment at the end of the year	\$ 2,826	\$ 4,000	\$ 1,442

⁽¹⁾ The following table reconciles cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents, and restricted cash per the consolidated statements of cash flows. The restricted cash included in Prepaid expenses and other current assets on the consolidated balance sheet represents funds held by the Company for a foreign subsidiary's employee savings plan.

	Year Ended June 30		
	2026	2025	2024
Cash and Cash Equivalents	\$ 88,925	\$ 88,781	\$ 77,965
Restricted Cash included in Prepaid expenses and other current assets	\$ 716	\$ 686	\$ 814
Total Cash, Cash Equivalents, and Restricted Cash at end of period	<u>\$ 89,641</u>	<u>\$ 89,467</u>	<u>\$ 78,779</u>

See Notes to Consolidated Financial Statements

KIMBALL ELECTRONICS, INC.
CONSOLIDATED STATEMENTS OF SHARE OWNERS' EQUITY
(Amounts in Thousands, Except for Share Data)

	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Share Owners' Equity
Amounts at June 30, 2023	\$ 315,482	\$ 296,053	\$ (11,046)	\$ (76,495)	\$ 523,994
Net income		20,511			20,511
Other comprehensive income (loss)			(6,761)		(6,761)
Issuance of non-restricted stock (18,000 shares)	235			222	457
Compensation expense related to stock compensation plans	6,773				6,773
Performance and restricted share issuance (108,000 and 19,000 shares, respectively)	(3,027)			1,549	(1,478)
Repurchase of Common Stock (136,000 shares) (including excise tax)				(3,035)	(3,035)
Amounts at June 30, 2024	\$ 319,463	\$ 316,564	\$ (17,807)	\$ (77,759)	\$ 540,461
Net income		16,984			16,984
Other comprehensive income (loss)			18,870		18,870
Issuance of non-restricted stock (26,000 shares)	180			320	500
Compensation expense related to stock compensation plans	6,035				6,035
Performance and restricted share issuance (83,000 and 27,000 shares, respectively)	(2,379)			1,341	(1,038)
Charitable donation of common stock (2,000 shares)	10			20	30
Repurchase of Common Stock (653,000 shares) (including excise tax)				(11,958)	(11,958)
Amounts at June 30, 2025	\$ 323,309	\$ 333,548	\$ 1,063	\$ (88,036)	\$ 569,884
Net income		27,960			27,960
Other comprehensive income (loss)			(5,735)		(5,735)
Issuance of non-restricted stock (21,000 shares)	309			274	583
Compensation expense related to stock compensation plans	7,676				7,676
Performance and restricted share issuance (123,000 and 51,000 shares, respectively)	(5,524)			2,184	(3,340)
Charitable donation of common stock (1,000 shares)	17			13	30
Repurchase of Common Stock (447,000 shares) (including excise tax)				(11,926)	(11,926)
Amounts at June 30, 2026	<u>\$ 325,787</u>	<u>\$ 361,508</u>	<u>\$ (4,672)</u>	<u>\$ (97,491)</u>	<u>\$ 585,132</u>

See Notes to Consolidated Financial Statements

KIMBALL ELECTRONICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 Business Description and Summary of Significant Accounting Policies

Business Description:

Kimball Electronics, Inc. (also referred to herein as “Kimball Electronics,” the “Company,” “we,” “us,” or “our”) is a global, multifaceted manufacturing solutions provider. We provide electronics manufacturing services (“EMS”), including engineering and supply chain support, to customers in the automotive, medical, and industrial end markets. We further produce higher level and final assemblies and offer contract development and manufacturing organization (“CDMO”) solutions which include the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. Our design and manufacturing expertise coupled with robust processes and procedures help us ensure that we deliver the highest levels of quality, reliability, and service throughout the entire life cycle of our customers’ products. We deliver award-winning service across our highly integrated global footprint, which is enabled by our largely common operating system, procedures, and standardization. We are well recognized by customers and industry trade publications for our excellent quality, reliability, and innovative service. We intend to change our name to Kimball Solutions, Inc., subject to Share Owners’ approval, to reflect our strategic focus as a full-service provider.

Principles of Consolidation:

The Consolidated Financial Statements include the accounts of all domestic and foreign subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts included in the Consolidated Financial Statements and related note disclosures. While efforts are made to assure estimates used are reasonably accurate based on management’s knowledge of current events, actual results could differ from those estimates.

Segment Information:

Kimball Electronics has business units located in the United States, China, Mexico, Poland, Romania, and Thailand, and each of these business units qualify as operating segments.

Our operating segments meet the aggregation criteria under the current accounting guidance for segment reporting. As of June 30, 2026, all of our operating segments provide contract manufacturing services, including engineering and supply chain support, for the production of electronic assemblies and other products including precision molded plastics and drug delivery devices. Our contract manufacturing services support primarily automotive, medical, and industrial applications, to the specifications and designs of our customers. The nature of the products, the production process, the type of customers, and the methods used to distribute the products have similar characteristics across all our operating segments. Each of our operating segments service customers in multiple markets, and many of our customers’ programs are manufactured and serviced by multiple operating segments. We leverage global processes such as component procurement and customer pricing that provide commonality and consistency among the various regions in which we operate. All of our operating segments have similar long-term economic characteristics, and as such, have been aggregated into one reportable segment. See Note 17 - Segment Reporting for more information.

Revenue Recognition:

We recognize revenue in accordance with the standard issued by the Financial Accounting Standards Board (“FASB”), Revenue from Contracts with Customers and all the related amendments. Our revenue from contracts with customers is generated primarily from manufacturing services provided for the production of electronic assemblies, components, medical devices, medical disposables, and precision molded plastics built to customers’ specifications. Our customer agreements are generally not for a definitive term but continue for the relevant product’s life cycle. Typically, our customer agreements do not commit the customer to purchase our services until a purchase order or a contractually binding forecast is provided, which are generally short term in nature. Customer purchase orders and contractually binding forecasts primarily have a single performance obligation. Generally, the prices stated in the customer purchase orders or committed to in contractually binding forecasts are agreed upon prices for the manufactured product and do not vary over the term of the order or the contractually binding forecast period, and therefore, the majority of our contracts do not contain variable consideration. In limited circumstances, we may enter into a contract which contains minimum quantity thresholds to cover our capital costs, and we may offer our customer a rebate for specific volume thresholds or other incentives; in these cases, the rebates or incentives are accounted for as variable consideration.

The majority of our revenue is recognized over time as manufacturing services are performed as we manufacture a product to customer specifications with no alternative use and we have an enforceable right to payment for performance completed to date. The remaining revenue for manufacturing services is recognized when the customer obtains control of the product, typically either upon shipment or delivery of the product dependent on the terms of the contract, and the customer is able to direct the use of and obtain substantially all of the remaining benefits from the asset. We generally recognize revenue over time using costs based input methods, in which judgment is required to evaluate assumptions including anticipated margins to estimate the corresponding amount of revenue to recognize. Costs used as a basis for estimating anticipated margins include material, direct and indirect labor, and appropriate applied overheads. Anticipated margins are determined based on historical or quoted customer pricing. Costs based input methods are considered a faithful depiction of our efforts and progress toward satisfying our performance obligations for manufacturing services and for which we believe we are entitled to payment for performance completed to date. The cumulative effect of revisions to estimates related to net contract revenues or costs are recorded in the period in which the revisions to estimates are identified and the amounts can be reasonably estimated.

We have elected to account for shipping and handling activities related to contracts with customers as costs to fulfill our promise to transfer the associated services and products. Accordingly, we record customer payments of shipping and handling costs as a component of net sales and classify such costs as a component of cost of sales. We recognize sales net of applicable sales or value add taxes. Based on estimated product returns and price concessions, a reserve for returns and allowances is recorded at the time revenue is recognized, resulting in a reduction of net revenue.

Direct incremental costs to obtain and fulfill a contract are capitalized as a contract asset only if they are material, expected to be recovered, and are not accounted for in accordance with other guidance. Incidental items that are immaterial in the context of the contract are recognized as expense in the period incurred.

Cash and Cash Equivalents:

Cash equivalents consist primarily of highly liquid investments with original maturities of three months or less at the time of acquisition. Cash and cash equivalents consist of bank accounts and money market funds. Bank accounts are stated at cost, which approximates fair value, and money market funds are stated at fair value.

Trade Accounts Receivable:

The Company's trade accounts receivable are recorded per the terms of the agreement or sale, and accrued interest is recognized when earned. Our policy for estimating the allowance for credit losses on trade accounts receivable includes analysis of such items as aging, credit worthiness, payment history, and historical bad debt experience. Management uses these specific analyses in conjunction with an evaluation of the general economic and market conditions to estimate expected credit losses. Management believes that historical loss information generally provides a basis for its assessment of expected credit losses. Trade accounts receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. Adjustments to the allowance for credit losses are recorded in Selling and Administrative Expenses on our Consolidated Statements of Income.

In the ordinary course of business, customers periodically negotiate extended payment terms on trade accounts receivable. Customary terms require payment within 30 to 45 days, with any terms beyond 45 days being considered extended payment terms. We participate in our customers' supply chain financing arrangements for certain of our accounts receivable in order to extend terms for the customer without negatively impacting our cash flow. These arrangements in all cases do not contain recourse provisions which would obligate us in the event of our customers' failure to pay. Receivables are considered sold when they are transferred beyond the reach of Kimball Electronics and its creditors, the purchaser has the right to pledge or exchange the receivables, and we have surrendered control over the transferred receivables. During fiscal years 2026, 2025, and 2024, we sold \$315.8 million, \$338.4 million, and \$410.0 million of accounts receivable under these arrangements, respectively. Factoring fees were \$2.7 million, \$2.3 million, and \$3.4 million during fiscal years 2026, 2025, and 2024, respectively. Factoring fees are recorded in Non-operating income (expense), net on our Consolidated Statements of Income for the fiscal years ended June 30, 2026 and June 30, 2025. Prior to fiscal year 2025, factoring fees were recorded in Selling and Administrative Expenses.

We are also a party to receivables purchase agreements ("RPA's") with third-party banking institutions for the sale of trade receivables generated from sales to certain customers, subject to acceptance by, and a funding commitment from, the banks that are a party to the RPA's. Receivables sold pursuant to the RPA's are serviced by us.

Under the RPA's, we sell our entire interest in certain receivables at the invoice amount less a discount. Upon sale, these receivables are removed from the Consolidated Balance Sheets and cash received is presented as cash provided by operating activities in the Consolidated Statements of Cash Flows. We are required to remit amounts collected as a servicer under the RPA's timely to the financial institution that purchased the receivables. Our risks with respect to receivables we service include

commercial disputes regarding such receivables and, under one of the RPA's, no greater than 5% of sold and outstanding receivables in the event of customer insolvency.

In fiscal years 2026 and 2025, under the RPA's, we sold \$171.3 million and \$19.4 million of receivables and incurred discount fees of \$1.1 million and \$0.1 million, respectively, recorded in Non-operating income (expense), net on our Consolidated Statements of Income. Receivables sold under the RPA and subject to our servicing that remained outstanding and uncollected as of June 30, 2026 and June 30, 2025 were \$49.0 million and \$19.4 million, respectively. Of the \$49.0 million outstanding and uncollected at June 30, 2026, \$22.0 million is subject to the 5% customer insolvency provision.

In limited circumstances, our China operation may receive banker's acceptance drafts from customers as payment on account. The banker's acceptance drafts are non-interest bearing and primarily mature within six months from the origination date. The Company has the ability to sell the drafts at a discount or transfer the drafts in settlement of current accounts payable prior to the scheduled maturity date. There are no drafts outstanding at June 30, 2026 and 2025, respectively. Drafts received and outstanding would be reflected in Receivables on the Consolidated Balance Sheets until the banker's drafts are sold at a discount, transferred in settlement of current accounts payable, or cash is received at maturity. Banker's acceptance drafts sold at a discount or transferred in settlement of current accounts payable during fiscal years 2026 and 2025 were \$46.3 million and \$14.3 million, respectively. No banker's acceptance drafts were sold at a discount or transferred in settlement of current accounts payable during fiscal year 2024.

In fiscal year 2024, changes to the expected timing of payments from and risk of default for a customer resulted in the recording of an allowance for credit losses of \$2.0 million in Selling and Administrative Expenses on our Consolidated Statements of Income. An additional \$0.4 million allowance was recorded in fiscal year 2026. Although the customer is not in bankruptcy and we will continue to pursue full recovery, an allowance was deemed necessary in consideration of the expected timing of payments and risk of default. The amount expected to be collected after twelve months is included in Other Assets, net on the Consolidated Balance Sheet. At June 30, 2026, the noncurrent receivable associated with this customer in Other Assets, net totaled \$2.3 million, which is net of the \$2.4 million allowance for expected credit losses. The \$2.4 million allowance for expected credit losses does not include fully reserved unpaid late payment fees. The current portion of receivables from this customer is \$1.8 million at June 30, 2026.

Inventories:

Inventories are stated at the lower of cost and net realizable value. Cost includes material, labor, and applicable manufacturing overhead. Costs associated with underutilization of capacity are expensed as incurred. Inventories are valued using the first-in, first-out ("FIFO") method. Inventories are adjusted for excess and obsolete inventory. Evaluation of excess inventory includes such factors as anticipated usage, inventory turnover, inventory levels, and product demand levels. Factors considered when evaluating obsolescence include the age of on-hand inventory and reduction in value due to damage, design changes, or cessation of product lines. Evaluation of both excess inventory and obsolescence also considers whether customer agreements specify customer obligation to pay for such inventory.

Property, Equipment, and Depreciation:

Property and equipment are stated at cost less accumulated depreciation and depreciated over the estimated useful life of the assets using the straight-line method for most assets and units of production method for certain fully dedicated machinery and equipment. Generally, maintenance and repairs are expensed as incurred. Depreciation and expenses for maintenance and repairs are included in both Cost of Sales and Selling and Administrative Expense on the Consolidated Statements of Income.

Impairment of Long-Lived Assets:

We perform reviews for impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. When an impairment is identified, the carrying amount of the asset is reduced to its estimated fair value. Assets to be disposed of are recorded at the lower of net book value or fair market value less cost to sell at the date management commits to a plan of disposal. In fiscal year 2024, we recognized \$17.0 million of impairment with the decision to divest of GES. In addition, on November 4, 2024, the Company announced that its Board of Directors has approved a plan to cease operations at our Tampa facility, which concluded with the assets being held for sale at the end of the fiscal year. No impairment was recorded on the Tampa assets as we deemed them recoverable. See Note 3 - Sale of GES and Note 4 - Restructuring Activities, respectively, for more information on the GES divestiture and Tampa Closure. Impairment of long-lived assets was not material during fiscal years 2026 and 2025.

Goodwill:

Goodwill represents the difference between the purchase price and the related underlying tangible and intangible net asset fair values resulting from business acquisitions. Annually, or if conditions indicate an earlier review is necessary, goodwill is assessed or tested at the reporting unit level. If the estimated fair value of the reporting unit is less than the carrying value, goodwill is written down to its estimated fair value. See Note 7 - Goodwill and Other Intangible Assets for more information on Goodwill.

To test GES, our automation, test, and measurement business unit, for goodwill impairment in fiscal year 2024, we used a combination of the Income Approach and the Market Approach. The discounted cash flow method (Income Approach) uses forecasted information based on management's strategic plans and projections. Discount rates are developed using a weighted average cost of capital ("WACC") methodology. The WACC represents the blended average required rate of return for equity and debt capital based on observed market return data and company specific risk factors. In the Market Approach, fair value is determined using transactional evidence for similar publicly traded equity.

During fiscal year 2024, the Company made the decision to divest of GES and committed to a plan to sell the business. As a result, the business unit met the criteria to be classified as held for sale, and goodwill and asset impairment were recorded. See Note 3 - Sale of GES for more information on the sale of GES.

Other Intangible Assets:

Other Intangible Assets reported on the Consolidated Balance Sheets consist of capitalized software. Intangible assets are reviewed for impairment, and their remaining useful lives evaluated for revision, when events or circumstances indicate that the carrying value may not be recoverable over the remaining lives of the assets. Internal-use software is stated at cost less accumulated amortization and is amortized using the straight-line method. During the software application development stage, capitalized costs include external consulting costs, cost of software licenses, and could include internal payroll and payroll-related costs for employees who are directly associated with a software project. Upgrades and enhancements are capitalized if they result in added functionality which enable the software to perform tasks it was previously incapable of performing. Software maintenance, training, data conversion, and business process reengineering costs are expensed in the period in which they are incurred.

Leases:

The Company leases certain office facilities, manufacturing facilities, warehouse facilities, and equipment under operating leases, in addition to land on which certain office and manufacturing facilities reside. These operating leases expire from fiscal year 2027 to 2056. The Company determines if a contract is or contains a lease at inception. Lease assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our estimated incremental borrowing rate, unless the implicit rate is readily determinable. The estimated incremental borrowing rate is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised. See Note 21 - Leases for more information on leases.

Research and Development:

The costs of research and development are expensed as incurred and are included in Cost of Sales on the Consolidated Statements of Income. Research and development costs were approximately \$19.1 million, \$17.5 million, and \$18.3 million in fiscal years 2026, 2025, and 2024, respectively.

Insurance and Self-insurance:

We are self-insured up to certain limits for general liability, workers' compensation, and certain domestic employee health benefits including medical, short-term disability, and dental, with the related liabilities included in the accompanying financial statements. Our policy is to estimate reserves based upon a number of factors including known claims, estimated incurred but not reported claims, and other analyses, which are based on historical information along with certain assumptions about future events. Approximately 14% of the workforce is covered under self-insured medical and short-term disability plans. At June 30, 2026 and 2025, accrued liabilities for self-insurance exposure were \$2.3 million and \$1.4 million, respectively.

The remainder of our workforce not covered by self-insured plans have medical and disability coverage through either our external plans or government plans. Insurance benefits are not provided to retired employees.

Income Taxes:

Deferred income tax assets and liabilities, recorded in Other Assets and Other long-term liabilities, respectively, in the Consolidated Balance Sheets, are recognized for the estimated future tax consequences attributable to temporary differences

between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. We evaluate the recoverability of deferred tax assets each quarter by assessing the likelihood of future taxable income and available tax planning strategies that could be implemented to realize our deferred tax assets. If recovery is not likely, we provide a valuation allowance based on our best estimate of future taxable income in the various taxing jurisdictions and the amount of deferred taxes ultimately realizable. Future events could change management's assessment.

We operate within multiple taxing jurisdictions and are subject to tax audits in these jurisdictions. These audits can involve complex uncertain tax positions, which may require an extended period of time to resolve. A tax benefit from an uncertain tax position may be recognized only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. We maintain a liability for uncertain income tax and other tax positions, including accrued interest and penalties on those positions. As tax positions are effectively settled, the tax liability is adjusted accordingly. We recognize interest and penalties related to unrecognized tax benefits in Provision for Income Taxes on the Consolidated Statements of Income. See Note 12 - Income Taxes for more information.

Concentrations of Credit Risk:

We have business and credit risks associated with our customers. The Company monitors credit quality and associated risks of receivables on an individual basis based on criteria such as financial stability of the party and collection experience in conjunction with general economic and market conditions.

A summary of significant customers' net sales and trade receivables as a percentage of consolidated net sales and consolidated trade receivables is as follows:

	Net Sales			Trade Receivables	
	Year Ended June 30			As of June 30	
	2026	2025	2024	2026	2025
Nexteer Automotive	18%	19%	16%	21%	30%
Philips	11%	*	*	13%	*
ZF	11%	11%	13%	13%	*
HL Mando	*	*	*	*	10%

*amount is less than 10% of total

Off-Balance Sheet Risk:

Off-balance sheet arrangements are limited to standby letters of credit entered into in the normal course of business as described in Note 8 - Commitments and Contingent Liabilities.

Non-operating Income and Expense:

Non-operating income (expense), net includes the impact of such items as foreign currency rate movements and related derivative gain or loss, fair value adjustments on supplemental employee retirement plan ("SERP") investments, government subsidies, credit facility fees, factoring fees, bank charges, and other miscellaneous non-operating income and expense items that are not directly related to operations. Prior to fiscal year 2025, factoring fees were recorded in Selling and Administrative Expenses on our Consolidated Statements of Income. The gain (loss) on SERP investments is offset by a change in the SERP liability that is recognized in Selling and Administrative Expense.

Components of Non-operating income (expense), net:

(Amounts in Thousands)	Year Ended June 30		
	2026	2025	2024
Foreign currency/derivative gain (loss)	\$ (1,263)	\$ (1,751)	\$ (1,425)
Gain (loss) on SERP investments	666	614	680
Factoring fees/AR program discounts	(3,862)	(2,415)	—
Credit facilities fees and bank charges	(910)	(1,018)	(873)
Other	(195)	(762)	(259)
Non-operating income (expense), net	<u>\$ (5,564)</u>	<u>\$ (5,332)</u>	<u>\$ (1,877)</u>

Foreign Currency Translation:

The Company uses the U.S. dollar and Euro as its functional currencies. Foreign currency assets and liabilities are remeasured into functional currencies at end-of-period exchange rates, except for nonmonetary assets and equity, which are remeasured at historical exchange rates. Revenue and expenses are remeasured at the weighted average exchange rate during the fiscal year, except for expenses related to nonmonetary assets, which are remeasured at historical exchange rates. Gains and losses from foreign currency remeasurement are reported in Non-operating income or expense on the Consolidated Statements of Income.

For business units whose functional currency is other than the U.S. dollar, the translation of functional currency statements to U.S. dollar statements uses end-of-period exchange rates for assets and liabilities, weighted average exchange rates for revenue and expenses, and historical rates for equity. The resulting currency translation adjustment is recorded in Accumulated Other Comprehensive Income (Loss), as a component of Share Owners' Equity.

Derivative Instruments and Hedging Activities:

Derivative financial instruments are recognized on the balance sheet as assets and liabilities and are measured at fair value. Changes in the fair value of derivatives are recorded each period in earnings or Accumulated Other Comprehensive Income (Loss), depending on whether a derivative is designated and effective as part of a hedge transaction, and if it is, the type of hedge transaction. Hedge accounting is utilized when a derivative is expected to be highly effective upon execution and continues to be highly effective over the duration of the hedge transaction. Hedge accounting permits gains and losses on derivative instruments to be deferred in Accumulated Other Comprehensive Income (Loss) and subsequently included in earnings in the periods in which earnings are affected by the hedged item. For transactions and balances denominated in currencies other than functional currencies, we use forward purchases to manage exposure to the variability of cash flows and foreign exchange contracts to hedge intercompany balances and other balance sheet positions. Cash receipts and cash payments related to derivative instruments are recorded in the same category as the cash flows from the items being hedged on the Consolidated Statements of Cash Flows. See Note 15 - Derivative Instruments for more information on derivative instruments and hedging activities.

Stock-Based Compensation:

As described in Note 11 - Stock Compensation Plans, the Company maintains the 2023 Equity Incentive Plan, which allows for the issuance of incentive stock options, stock appreciation rights, restricted shares, unrestricted shares, restricted share units, or performance shares and performance units for grant to officers and other key employees, and to members of the Board of Directors who are not employees. The Company also maintains the Kimball Electronics, Inc. Non-Employee Directors Stock Compensation Deferral Plan (the "Deferral Plan"), which allows Non-Employee Directors to elect to defer all, or a portion of, their retainer fees in stock. We recognize the cost resulting from share-based payment transactions using a fair-value-based method on a majority of our transactions. The estimated fair value of outstanding performance shares is based on the stock price at the date of the grant. Stock-based compensation expense is recognized for the portion of the award for which performance targets have been established and is expected to vest. The Company has elected to account for forfeitures by reversing the compensation costs at the time a forfeiture occurs.

New Accounting Standards:

Adopted in Fiscal Year 2026:

In December 2023, the Financial Accounting Standards Board ("FASB") issued guidance on Improvements to Income Tax Disclosures, intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted the standard for the year ended June 30, 2026. See Note 12 - Income Taxes for more information.

Not Yet Adopted:

In December 2025, FASB issued guidance on Interim Reporting, intended to improve the navigability of the guidance in ASC 270, Interim Reporting, and clarify when it applies. The guidance is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the guidance can be applied prospectively or retrospectively. We are currently evaluating the impact of the adoption of this guidance on our consolidated financial statements.

In September 2025, the FASB issued guidance on Accounting for Internal-Use Software, intended to modernize the accounting for software costs and changing the requirements for capitalization of software costs. The guidance is effective for fiscal years beginning after December 15, 2027 and for interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period, and the guidance can be applied prospectively, retrospectively, or

on a modified transition approach. We will adopt this guidance prospectively on July 1, 2026, and the adoption of this guidance will not have a material impact on our consolidated financial statements.

In November 2024, the FASB issued guidance on Expense Disaggregation Disclosures, requiring more disclosure about the types of expenses presented in our expense captions. The guidance is effective for fiscal years beginning after December 15, 2026 and for interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the guidance can be applied prospectively or retrospectively. We are currently evaluating the impact of the adoption of this guidance on our consolidated financial statements.

Note 2 Revenue from Contracts with Customers

Our revenue from contracts with customers is generated primarily from manufacturing services provided for the production of electronic assemblies, electronic and non-electronic components, medical devices, medical disposables, and precision molded plastics in automotive, medical, and industrial applications, to the specifications and designs of our customers.

The following table disaggregates our revenue by end market vertical for fiscal years 2026, 2025, and 2024:

(Amounts in Millions)	Year Ended		
	2026	2025	2024
Vertical Markets:			
Automotive ⁽¹⁾	\$ 656.9	\$ 708.5	\$ 793.3
Medical	412.8	396.2	425.7
Industrial ⁽¹⁾	361.7	382.0	495.5
Total net sales	<u>\$ 1,431.4</u>	<u>\$ 1,486.7</u>	<u>\$ 1,714.5</u>

- (1) For the years ended 2025 and 2024, \$29.4 million and \$33.1 million of the industrial net sales to certain customers previously included in the automotive vertical, specifically those customers more aligned with commercial vehicle applications versus passenger vehicles, are now reflected in the industrial vertical to better reflect the nature of the program.

For fiscal years 2026, 2025, and 2024, approximately 99%, 98%, and 96% of our net sales, respectively, were recognized over time as manufacturing services were performed under a customer contract on a product with no alternative use and we have an enforceable right to payment for performance completed to date. The remaining sales revenues were recognized at a point in time when the customer obtained control of the products.

The timing differences of revenue recognition, billings to our customers, and cash collections from our customers result in billed accounts receivable and unbilled accounts receivable. Contract assets on the Consolidated Balance Sheets relate to unbilled accounts receivable and occur when revenue is recognized over time as manufacturing services are provided and the billing to the customer has not yet occurred as of the balance sheet date, which are generally transferred to receivables in the next fiscal quarter due to the short-term nature of the manufacturing cycle. Contract assets were \$70.5 million and \$71.8 million as of June 30, 2026 and 2025, respectively.

The Company may receive payments from customers in advance of the satisfaction of performance obligations primarily for material price variances, inventory purchases, tooling, or other miscellaneous services or costs. These payments are recognized as contract liabilities until the performance obligations are completed and are included in Advances from customers, if inventory related, and Accrued expenses, if not inventory related, on the Consolidated Balance Sheets which amounted to \$40.6 million and \$41.5 million as of June 30, 2026 and 2025, respectively. Other than deposits associated with inventory purchases classified as long term, our performance obligations are generally short term in nature and therefore our contract liabilities are all expected to be settled within twelve months. See Note 5 - Inventories for further discussion.

Note 3 Sale of GES

Following approval by our Board of Directors, on July 31, 2024, we entered into a definitive agreement and closed on the sale of 100% of the equity interests in GES to Avera Test Systems, Inc., resulting in cash proceeds after costs to sell of \$18.5 million at the time of closing.

The following table summarizes net sales and income (loss) before taxes on income for GES:

(Amounts in Thousands)	Year Ended		
	2026	2025	2024
Net Sales	\$ —	\$ 2,075	\$ 45,674
Income (Loss) Before Taxes on Income ⁽¹⁾	\$ (383)	\$ 2,112	\$ (23,518)

- (1) Amounts include loss on sale adjustments of \$0.4 million in the year ended June 30, 2026, gain on sale of \$2.4 million in the year ended June 30, 2025, and \$22.9 million of pre-tax impairment charges in the year ended June 30, 2024. The years ended June 30, 2025 and June 30, 2024 also include allocated corporate overhead expenses.

Note 4 Restructuring Activities

During fiscal years 2026, 2025, and 2024, we undertook restructuring efforts to align our cost structure with reduced end market demand levels, including resizing our workforce and taking specific cost actions, and recorded restructuring expense of \$3.4 million, \$5.7 million, and \$2.4 million, respectively, which were primarily employee-related costs. The cumulative amount incurred since inception of these efforts beginning in fiscal year 2024 through June 30, 2026 was \$11.5 million. We expect to incur \$1.5 million to \$3.0 million of additional restructuring costs through fiscal year 2027. This is the final phase of this restructuring plan. No additional restructuring costs are anticipated to be recognized under this plan after fiscal year 2027.

Additionally, on November 4, 2024, the Company announced that its Board of Directors approved a plan to cease operations at our Tampa facility (“Tampa Closure Plan”). The decision was made to leverage capacity within our global footprint and streamline the operating structure. These costs are predominantly cash expenditures. We recorded restructuring expense of \$1.6 million in fiscal year 2026 for the Tampa Closure Plan. The cumulative amount incurred since inception of the Tampa Closure Plan during fiscal years 2025 and 2026 was \$6.9 million. The restructuring charges are complete at June 30, 2026.

Accrued restructuring is recorded in Accrued expenses in the Consolidated Balance Sheets. The changes in the Company’s accrued restructuring costs under the Tampa Closure Plan were as follows:

(Amounts in Thousands)	Severance and Termination Benefits	Other Exit Costs	Total
Balance at June 30, 2025	\$ 2,018	\$ —	\$ 2,018
Restructuring charges	164	1,435	1,599
Payments	(2,182)	(1,435)	(3,617)
Non-cash activity	—	—	—
Balance at June 30, 2026	\$ —	\$ —	\$ —

At June 30, 2025, Tampa’s operations had ceased, and the related land, building, and certain equipment met the criteria to be classified as held for sale, and we ceased recording depreciation on the held for sale assets. On April 22, 2026, the Company completed the sale of the Tampa land and buildings for \$21.6 million and recognized a gain on sale of \$15.0 million. The gain on sale is recorded in (Gain on Disposal) Asset Impairment on our Consolidated Statements of Income.

Note 5 Inventories

Inventories were valued using the lower of first-in, first-out (“FIFO”) cost and net realizable value. Inventory components were as follows:

(Amounts in Thousands)	2026	2025
Finished products	\$ 199	\$ 111
Work-in-process	775	628
Raw materials	270,932	272,761
Total inventory	<u>\$ 271,906</u>	<u>\$ 273,500</u>

Additionally, as of June 30, 2026 and 2025, we have raw materials inventory totaling \$57.0 million and \$39.4 million, respectively, classified as long-term included in Other Assets, net in our Consolidated Balance Sheets. Inventory classified as long term is raw materials inventory we do not expect to be consumed and sold within twelve months. As of June 30, 2026 and 2025, we have received deposits for long-term inventory totaling \$35.4 million and \$27.0 million, respectively, which is included in Other long-term liabilities in our Consolidated Balance Sheets.

Note 6 Property and Equipment

Major classes of property and equipment consist of the following at June 30, exclusive of the amounts classified as held for sale as of June 30, 2025:

(Amounts in Thousands)	2026	2025
Land	\$ 8,041	\$ 13,268
Buildings and improvements	148,194	116,899
Machinery and equipment	416,172	417,017
Machinery and equipment - fully dedicated	34,452	18,079
Construction-in-progress	22,187	34,006
Total	<u>\$ 629,046</u>	<u>\$ 599,269</u>
Less: Accumulated depreciation	<u>(354,854)</u>	<u>(334,465)</u>
Property and equipment, net	<u>\$ 274,192</u>	<u>\$ 264,804</u>

The useful lives used in computing straight-line depreciation are based on estimated service lives for classes of property, as follows:

	Years
Buildings and improvements	5 to 40
Machinery and equipment	3 to 11
Leasehold improvements	Lesser of Useful Life or Term of Lease

Effective April 1, 2025, the Company implemented a new class of asset, fully dedicated machinery and equipment, which is depreciated using the units of production method. As of June 30, 2026 and 2025, the net book value of the equipment was \$28.5 million and \$15.3 million, respectively. This equipment is highly customized for specific customer programs and has substantially no value other than production for that program. The units of production method more accurately reflects the pattern of usage and expected benefits of these assets than other depreciation methods.

Depreciation of property and equipment totaled \$38.0 million, \$36.0 million, and \$35.7 million for each of the three years in the period ended June 30, 2026, 2025 and 2024, respectively.

Note 7 Goodwill and Other Intangible Assets

A summary of goodwill is as follows:

(Amounts in Thousands)

Balance as of June 30, 2025

Goodwill	\$	19,017
Accumulated impairment		(12,826)
Goodwill, net	\$	6,191
Derecognition of Tampa goodwill		(8,575)
Derecognition of Tampa accumulated impairment		8,575

Balance as of June 30, 2026

Goodwill		10,442
Accumulated impairment		(4,251)
Goodwill, net	\$	6,191

Other Intangible Assets includes capitalized software. A summary of the capitalized software's cost and accumulated amortization is as follows:

(Amounts in Thousands)	June 30, 2026			June 30, 2025		
	Cost	Accumulated Amortization	Net Value	Cost	Accumulated Amortization	Net Value
Capitalized Software	\$ 30,174	\$ (28,253)	\$ 1,921	\$ 30,654	\$ (28,227)	\$ 2,427

The estimated useful life of internal-use software ranges from 3 to 10 years. During fiscal years 2026, 2025, and 2024, amortization expense of other intangible assets was, in millions, \$0.7, \$1.0, and \$2.3, respectively. Amortization expense in future periods is expected to be, in millions, \$0.6, \$0.4, \$0.3, \$0.2, and \$0.2 in the five years ending June 30, 2031, and \$0.2 thereafter. We have no intangible assets with indefinite useful lives which are not subject to amortization.

Note 8 Commitments and Contingent Liabilities

Guarantees:

As of June 30, 2026 and 2025, we had no guarantees issued which were contingent on the future performance of another entity. Standby letters of credit may be issued to third-party suppliers and insurance institutions and can only be drawn upon in the event of the Company's failure to pay its obligations to the beneficiary. We had a maximum financial exposure from unused standby letters of credit totaling \$0.4 million as of both June 30, 2026 and 2025. We do not expect circumstances to arise that would require us to perform under any of these arrangements and believe that the resolution of any claims that might arise in the future, either individually or in the aggregate, would not materially affect our consolidated financial statements. Accordingly, no liability has been recorded as of June 30, 2026 and 2025 with respect to the standby letters of credit. We also may enter into commercial letters of credit to facilitate payments to vendors and from customers.

Product Warranties:

The Company provides only assurance-type warranties for a limited time period, which cover primarily workmanship and assure that products comply with specifications provided by or agreed upon with the customer. We maintain a provision for limited warranty repair or replacement of products manufactured and sold pursuant to specific manufacturing contract agreements that require such provisions. We estimate this product warranty liability at the time of sale based on historical repair or replacement cost trends in conjunction with the length of the warranty offered. Management refines this warranty liability periodically based on changes in historical cost trends and in certain cases where specific warranty issues become known. This product warranty liability and expense were immaterial during fiscal years 2026, 2025, and 2024.

Note 9 Credit Facilities

Credit facilities consisted of the following:

(Amounts in Millions, in U.S. Dollar Equivalents)	Available Borrowing Capacity at June 30, 2026	Borrowings Outstanding at June 30, 2026	Borrowings Outstanding at June 30, 2025
Primary credit facility, revolving ⁽¹⁾	\$ 275.5	\$ 24.1	\$ 50.0
Primary credit facility, term ⁽¹⁾	—	92.5	97.5
Thailand overdraft credit facility ^(2,3)	10.1	—	—
China revolving credit facility ^(2,4)	7.4	—	—
Netherlands revolving credit facility ^(2,5)	10.5	—	—
Poland revolving credit facility ^(2,6)	11.4	—	—
Total credit facilities	<u>\$ 314.9</u>	<u>116.6</u>	<u>147.5</u>
Unamortized deferred debt financing fees		\$ (0.4)	\$ (0.4)
Total long-term debt		\$ 116.2	\$ 147.1
Less: current portion		(8.2)	(17.4)
Long-term debt under credit facilities, less current portion ⁽⁷⁾		<u>\$ 108.0</u>	<u>\$ 129.7</u>

- (1) The Company maintained a U.S. primary credit facility that provided for revolving borrowings of \$300 million, with the option to increase the amount available for revolving borrowings by an additional \$150 million (to a total of \$450 million) at the Company's request, subject to the consent of each lender participating in such increase, which was scheduled to mature on May 4, 2027. The U.S. primary credit facility also included a term loan borrowing facility that provides for term loan borrowings ("term borrowings") of \$100 million repayable in scheduled quarterly installments, scheduled to mature December 20, 2029.

On April 30, 2026, the Company entered into an amended and restated credit agreement (the "restated primary credit facility") among the Company, the lenders party thereto, and JPMorgan Chase Bank, N. A., as Administrative Agent, and Bank of America, N.A., as Documentation Agent. The restated primary credit facility continues to provide for revolving borrowings of \$300 million, with the option to increase the amount available for revolving borrowings by an additional \$150 million (to a total of \$450 million) at the Company's request, subject to the consent of each lender participating in such increase, now with a maturity date of April 30, 2031. The terms for the term loan borrowings remain largely unchanged in the restated primary credit facility as it continues to maintain the maturity date of December 20, 2029 for such term loan borrowings and the quarterly payment schedule for such term loan borrowings.

This facility is maintained for working capital and general corporate purposes of the Company, and the Company is permitted to use the proceeds to refinance existing indebtedness. The restated primary credit facility defines the limitations for a supply chain financing program, and as part of its rebranding, subject to Share Owners' approval, provides for updates to the Company's trade name to Kimball Solutions, Inc. and also its subsidiaries. A commitment fee is payable on the unused portion of the credit facility at a rate that ranges from 10.0 to 25.0 basis points per annum as determined by the Company's ratio of consolidated total indebtedness to adjusted consolidated EBITDA, as defined in the restated primary credit facility. Types of borrowings available on the restated primary credit facility include term loans, revolving loans, multi-currency term loans, and swingline loans.

At June 30, 2026, the Company had \$22.0 million Term Benchmark and \$2.1 million ABR, both denominated in U.S. dollars, outstanding borrowings under the restated primary credit facility. At June 30, 2025, all outstanding borrowings under the primary credit facility were Term Benchmark borrowings denominated in U.S. dollars.

The interest rate on borrowings is dependent on the class, type and currencies of borrowings and will be one of the following options:

- any Term Benchmark borrowing denominated in U.S. Dollars will utilize the Secured Overnight Financing Rate ("SOFR"), which is a rate per annum equal to the secured overnight financing rate for such business day published by the SOFR Administrator, the Federal Reserve Bank of New York, on the immediately succeeding business day, plus the Revolving Commitment Term Benchmark spread or Term Loan Benchmark spread which can range from 110.0 to 185.0 basis points based on the Company's ratio of consolidated total indebtedness to adjusted consolidated EBITDA;
- any Term Benchmark borrowing denominated in Euros will utilize the Euro Interbank Offered Rate ("EURIBOR") in effect two target days prior to the advance (adjusted upwards to reflect bank reserve costs) for

such interest period as defined in the agreement, plus the Revolving Commitment Term Benchmark spread or Term Loan Term Benchmark spread which can range from 110.0 to 185.0 basis points based on the Company's ratio of consolidated total indebtedness to adjusted consolidated EBITDA; or

- the Alternate Base Rate ("ABR"), which is defined as the highest of the fluctuation rate per annum equal to the higher of:
 - a. Prime Rate in the U.S. last quoted by the Wall Street Journal, and if this is ceased to be quoted, the highest bank prime loan rate or similar loan rate quoted by the Federal Reserve Board;
 - b. 1/2 of 1% per annum above the Federal Reserve Bank of New York (NYFRB) Rate (as defined under the Credit Agreement); or
 - c. 1% per annum above the Term SOFR Rate (as defined under the Credit Agreement);

plus the Revolving Commitment ABR spread which can range from 0.0 to 75.0 basis points based on the Company's ratio of consolidated total indebtedness to adjusted consolidated EBITDA. Under the restated primary credit facility, the ABR Spread and Benchmark Spread for term loan borrowings remain the same as for revolving commitment borrowings.

The Company's financial covenants under the restated primary credit facility are largely unchanged, with the exception of the change in the first covenant below from "unencumbered U.S. cash on hand in the United States in excess of \$15 million" to "unrestricted Cash in an amount not to exceed \$25 million," and require:

- a ratio of consolidated total indebtedness minus unrestricted cash, as defined in the restated primary credit facility, in an amount not to exceed \$25 million to adjusted consolidated EBITDA, determined as of the end of each of its fiscal quarters for the then most recently ended four fiscal quarters, to not be greater than 3.0 to 1.0, provided, however, that for each fiscal quarter end during the four quarter period following a material permitted acquisition, as defined in the restated primary credit facility, the Company will not permit this financial covenant to be greater than 3.5 to 1.0 for each such fiscal quarter end, and,
- an interest coverage ratio, defined as that ratio of consolidated EBITDA for such period to cash interest expense for such period, for any period of four consecutive fiscal quarters, to not be less than 3.5 to 1.0.

The Company had \$0.4 million in letters of credit contingently committed against the primary credit facility at both June 30, 2026 and June 30, 2025.

- (2) The Company also maintains foreign credit facilities for working capital and general corporate purposes at specific foreign locations rather than utilizing funding from intercompany sources. These foreign credit facilities can be canceled at any time by either the bank or us and generally include renewal clauses. Interest on borrowing under these facilities is charged at a rate as defined under the respective foreign credit facility.
- (3) The Company maintains a foreign credit facility for its operation in Thailand which allows for borrowings of up to \$10.1 million.
- (4) The Company maintains a foreign credit facility for its operation in China which allows for borrowings up to 50.0 million RMB (approximately \$7.4 million at June 30, 2026 exchange rates).
- (5) The Company maintains an uncommitted revolving credit facility for our Netherlands subsidiary. The Netherlands credit facility allows for borrowings of up to 9.2 million Euro (approximately \$10.5 million at June 30, 2026 exchange rates), which borrowings can be made in Euro, U.S. dollars, or other optional currency. Interest on borrowing under this facility is charged at a rate of interest dependent on the denomination of the currency borrowed.
- (6) The Company maintains a foreign credit facility for its operation in Poland which allows for borrowings up to 10.0 million Euro (approximately \$11.4 million at June 30, 2026 exchange rates).
- (7) The amount of Long-term debt under credit facilities, less current maturities reflects the borrowings on the primary credit facility that the Company intends, and has the ability, to refinance for a period longer than twelve months. The revolving borrowings on the primary credit facility matures on April 30, 2031.

As of June 30, 2026, the contractual maturities of the term borrowings on the primary credit facility were as follows:

(Amounts in Millions)	Contractual Maturities
Fiscal year:	
2027	\$ 6.25
2028	7.50
2029	8.75
2030	70.00
Total	<u>\$ 92.50</u>

The weighted-average interest rate on borrowings outstanding under the credit facilities at June 30, 2026 and June 30, 2025 were 5.0% and 5.9%, respectively. Capitalized interest expense was \$0.5 million during fiscal year 2026 and immaterial for fiscal years 2025 and 2024.

Note 10 Employee Benefit Plans

Defined Contribution Retirement Plans:

The Company maintains a trustee defined contribution retirement plan which is in effect for substantially all domestic employees meeting the eligibility requirements. The Company matches 50% of eligible employee contributions up to 6%. The Company also provides a discretionary contribution determined annually by the Talent, Culture, and Compensation Committee of the Company's Board of Directors. Total expense related to employer contributions to the domestic retirement plans was \$2.1 million, \$2.1 million, and \$4.8 million for fiscal years 2026, 2025, and 2024, respectively.

The Company also maintains a supplemental employee retirement plan ("SERP") for executives and other key employees which enables them to defer cash compensation on a pre-tax basis and restore amounts that would be otherwise payable under our tax-qualified retirement plans if the IRS did not have limits on includable compensation and maximum benefits. The SERP is structured as a rabbi trust, and therefore, assets in the SERP portfolio are subject to creditor claims in the event of bankruptcy. We recognize SERP investment assets on the balance sheet at current fair value. A SERP liability of the same amount is recorded on the balance sheet representing an obligation to distribute SERP funds to participants. As of June 30, 2026, both total investments and obligations under SERP were \$4.4 million, of which \$1.1 million were short term and \$3.3 million were long term. As of June 30, 2025, both total investments and obligations under SERP were \$4.1 million, of which \$0.5 million were short term and \$3.6 million were long term. The SERP investment assets are classified as trading, and accordingly, realized and unrealized gains and losses are recognized in the Other Income (Expense) category on our Consolidated Statements of Income. Adjustments made to revalue the SERP liability are also recognized in income as selling and administrative expenses and offset valuation adjustments on SERP investment assets. The change in net unrealized holding gains for the fiscal years ended June 30, 2026, 2025, and 2024 was approximately \$0.3 million, \$(0.1) million, and \$0.5 million, respectively.

Defined Benefit Postemployment Plans:

The Company established and maintains severance plans for all domestic employees and other postemployment plans for certain foreign subsidiaries. There are no statutory requirements for us to contribute to the plans, nor do employees contribute to the plans. The plans hold no assets. Benefits are paid using available cash on hand when eligible employees meet plan qualifications for payment. As of June 30, 2026, total obligations under these plans were \$9.2 million of which \$8.3 million were long term and \$0.9 million were short term. As of June 30, 2025, total obligations under these plans were \$8.2 million of which \$7.3 million were long term and \$0.9 million were short term. Net periodic benefit costs were not material for the fiscal years ended June 30, 2026, 2025, and 2024.

Note 11 Stock Compensation Plans

A stock compensation plan was created and adopted by the Company's Board of Directors (the "Board") on September 20, 2023 and approved by our Share Owners at our 2023 Annual Meeting on November 17, 2023. The 2023 Plan (the "Plan") allows for the issuance of up to 2 million shares and replaced our former 2014 plan. The shares under the 2023 Plan may be granted in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted awards, performance share awards, cash awards, and other equity awards. The Plan is a ten-year plan that terminates automatically on November 17, 2033. No award shall be granted pursuant to the Plan after such date, but awards theretofore granted may extend beyond that date.

On October 20, 2016, the Board approved a nonqualified deferred stock compensation plan, the Kimball Electronics, Inc. Non-Employee Directors Stock Compensation Deferral Plan (the “Deferral Plan”), which allows Non-Employee Directors to elect to defer all, or a portion of, their retainer fees in stock until retirement or termination from the Board or death. The Deferral Plan allows for issuance of up to 1.0 million shares of the Company’s common stock.

Pre-tax stock compensation charged against income in fiscal years 2026, 2025, and 2024 was \$8.2 million, \$6.5 million, and \$7.2 million, respectively. These costs are included in Selling and Administrative Expenses.

Performance Shares:

We made long-term performance share grants to leadership team members and other key employees. The Talent, Culture, and Compensation Committee of the Board approved these annual performance share grants. Grants cliff vest at the third anniversary of the award date.

Under the awards granted to leadership team members, a number of shares will be issued to each participant based on the Company’s economic profit for fiscal years 2026 through 2028 as compared to the Board approved plan. The number of shares issued could be zero if minimum thresholds are not met up to a maximum of 200%.

Under the awards granted to key employees, a number of shares will be awarded to each participant based upon a combination of the Company’s profitability based on its operating income over the performance period as defined in the Company’s operating business plans for the applicable fiscal years and the Company’s growth based on a comparison of its three-year revenue compounded annual growth rate (“CAGR”) with the Electronics Manufacturing Services Industry’s three-year revenue CAGR. The number of shares issued will be less than the targeted shares issuable if the Company does not reach 100% of one or both of the above-mentioned performance metrics, and could be zero if the Company does not reach the required minimum thresholds of both metrics. The number of shares issued will exceed the number of targeted issuable shares granted (up to a maximum of 125%) if the Company exceeds 100% of one or both of the above-mentioned incentive metrics. The Company recognizes expense, for both leadership team and key employee awards, based on management’s expectation of achievement of the specific performance metrics monitored throughout the service period of the awards.

If a participant is not employed on the date shares are issued, the performance share award is forfeited, except in the case of a Qualifying Termination (a termination of service due to death, Disability, or Retirement), as defined by the Plan.

A summary of the Company’s performance share activity during fiscal year 2026 is presented below:

	Number of Shares	Weighted Average Grant Date Fair Value
Performance shares outstanding at July 1, 2025	544,063	\$ 24.33
Granted	121,261	\$ 28.35
Vested	(182,839)	\$ 23.35
Forfeited	(3,829)	\$ 23.45
Performance shares outstanding at June 30, 2026	<u>478,656</u>	\$ 25.32

As of June 30, 2026, there was approximately \$2.7 million of unrecognized compensation cost related to performance shares, based on the latest estimated attainment of performance goals. That cost is expected to be recognized over performance periods ending August 2026 through August 2028, with a weighted average vesting period of 1.3 years. The fair value of performance shares is based on the stock price at the date of grant. During fiscal years 2026, 2025, and 2024, respectively, 182,839, 93,870, and 82,744 performance shares vested at a fair value of \$4.3 million, \$2.2 million, and \$1.6 million. The performance shares vested represent the total number of shares vested prior to the reduction of shares withheld to satisfy tax withholding obligations.

Total Shareholder Return Performance Shares:

The Talent, Culture, and Compensation Committee of the Board approved total shareholder return awards granted to leadership team members during fiscal year 2026 based on the Company’s relative total shareholder return (rTSR) for the performance period as compared to a group of peer companies selected by the Talent, Culture, and Compensation Committee of the Board. The number of shares issued could be zero if minimum thresholds are not met up to a maximum of 200%.

A summary of the Company's total shareholder return performance share activity during fiscal year 2026 is presented below:

	Number of Shares	Weighted Average Grant Date Fair Value
Total shareholder return performance shares outstanding at July 1, 2025	101,417	\$ 22.96
Granted	61,286	\$ 48.49
Vested	—	\$ —
Forfeited	(42,626)	\$ 16.88
Total shareholder return performance shares outstanding at June 30, 2026	<u>120,077</u>	<u>\$ 38.14</u>

As of June 30, 2026, there was approximately \$2.8 million of unrecognized compensation cost related to total shareholder return performance shares. That cost is expected to be recognized over performance periods ending August 2027 through August 2028, with a weighted average vesting period of 1.7 years. The fair value of total shareholder return performance shares is based on the grant date fair value calculated using a Monte Carlo simulation, with the assistance of a third-party valuation specialist. No shares vested during fiscal years 2026, 2025, and 2024.

Unrestricted Share Grants:

Unrestricted shares were granted to non-employee members of the Board as consideration for services rendered. Unrestricted share grants do not have vesting periods, holding periods, restrictions on sale, or other restrictions. The fair value of unrestricted shares is based on the stock price at the date of the award. During fiscal years 2026, 2025, and 2024, respectively, the Company granted a total of 20,555, 26,192, and 18,128 unrestricted shares at an average grant date fair value of \$28.34, \$19.09, and \$25.24 for a total fair value of \$0.6 million, \$0.5 million, and \$0.5 million. Unrestricted shares are awarded to non-employee members of the Board as compensation for director's fees, including fees that directors elected to receive as unrestricted shares in lieu of cash payment. Directors' fees are expensed over the period that directors earn the compensation. Unrestricted shares that are awarded to key employees are expensed immediately.

Restricted Shares:

Restricted shares were granted to employees as consideration for services rendered. The contractual life of the restricted shares is three years, with one-third of the interest in the restricted shares vested after year one of the grant, another one-third after year two of the grant, and the final one-third after year three of the grant.

Restricted shares are expensed over the contractual vesting period as earned. If a participant is not employed on the date shares are issued, the restricted share award is forfeited, except in the case of a Qualifying Termination (a termination of service due to death, Disability, or Retirement), as defined by the Plan. During fiscal years 2026, 2025, 2024 the Company granted restricted shares to officers and other key employees for a total fair value of \$4.8 million, \$2.9 million, and \$2.8 million.

	Number of Shares	Weighted Average Grant Date Fair Value
Restricted shares outstanding at July 1, 2025	232,617	\$ 21.63
Granted	169,851	\$ 28.35
Vested	(89,295)	\$ 22.17
Forfeited	(1,988)	\$ 23.86
Restricted shares outstanding at June 30, 2026	<u>311,185</u>	<u>\$ 25.05</u>

As of June 30, 2026, there was approximately \$3.0 million of unrecognized compensation cost related to restricted shares. The cost is expected to be recognized over vesting periods ending August 2026 through August 2028, with a weighted average vesting period of 0.9 years. The fair value of the restricted shares is based on the stock price at the date of grant. During fiscal years 2026, 2025, and 2024 respectively, 89,295, 46,497, and 20,768 restricted shares vested. The restricted shares vested represent the total number of shares vested prior to the reduction of shares withheld to satisfy tax withholding obligations.

Deferred Share Units:

Deferred share units may be granted to non-employee members of the Board under the Deferral Plan as compensation for the portion of their annual retainer fees resulting from their election to receive deferred share units in lieu of cash payment or unrestricted shares. Directors' fees are expensed over the period that directors earn the compensation. Deferred share units are participating securities and are payable in common stock in a lump sum or installments in accordance with deferral elections

upon a director's death, retirement, or termination of service with the Board. During fiscal years 2026, 2025, and 2024, respectively, 16,232, 28,288, and 26,347 deferred share units were granted to non-employee members of the Board at an average grant date fair value of \$28.34, \$19.09, and \$25.24 for a total fair value of \$0.5 million, \$0.5 million, and \$0.7 million. During fiscal year 2026, no shares of common stock were issued under the Deferral Plan.

Note 12 Income Taxes

On July 4, 2025, the One Big Beautiful Bill Act ("2025 U.S. tax reform") was enacted into law. The 2025 U.S. tax reform contains several key tax laws, including extensions and modifications of the Tax Cuts and Jobs Act. In accordance with ASC 740, Income Taxes, the Company is required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring the estimated U.S. deferred tax assets and liabilities, as well as potential impacts to previously existing valuation allowances. The legislation has multiple effective dates, with certain provisions effective in fiscal year 2026 and others implemented through fiscal year 2028. Due to the 2025 U.S. tax reform, the Company recorded a \$0.2 million tax benefit for the year as a decrease in valuation allowance on part of our deferred tax assets.

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

The components of the deferred tax assets and liabilities as of June 30, 2026 and 2025, were as follows:

(Amounts in Thousands)	2026	2025
Deferred Tax Assets:		
Receivables	\$ 751	\$ 336
Inventory	2,218	2,252
Employee benefits	341	322
Deferred compensation	8,445	7,224
Capitalized research and development	7,916	10,180
Tax credit carryforwards	9,928	9,650
Capital Loss	3,587	5,259
Net operating loss carryforward	3,916	4,676
Net foreign currency losses	131	90
Business interest carryforward	5,059	6,919
Operating Leases	3,868	—
Miscellaneous	6,280	4,672
Valuation Allowance	(16,016)	(16,418)
Total asset	<u>\$ 36,424</u>	<u>\$ 35,162</u>
Deferred Tax Liabilities:		
Property and equipment	4,082	8,101
Right-of-use Asset	2,433	—
Goodwill	594	535
Miscellaneous	3,760	1,336
Total liability	<u>\$ 10,869</u>	<u>\$ 9,972</u>
Net Deferred Income Taxes	<u>\$ 25,555</u>	<u>\$ 25,190</u>

Since fiscal year 2023, we have capitalized research and development expenses that are required to be capitalized as an amortizable asset under Section 174 of the Internal Revenue Code and amortized over a period of five years. This requirement was based on the implementation of Tax Reform effective in tax years beginning as of January 1, 2022. While this requirement was eliminated with the 2025 U.S. tax reform, the Company elected to capitalize research and development expenses in fiscal year 2026. As of June 30, 2026 and 2025, we have a net deferred tax asset from capitalized research and development expenses of \$7.9 million and \$10.2 million, respectively.

Income tax benefits associated with the net operating loss carryforwards expire from fiscal year 2030 to 2045. Income tax benefits associated with tax credit carryforwards primarily expire from fiscal year 2027 to 2046. A valuation allowance was provided as of June 30, 2026 and 2025 for deferred tax assets related to certain state credits of \$7.4 million and \$7.2 million, respectively. As of June 30, 2026 and 2025, we have full valuation allowances of \$5.0 million and \$6.9 million, respectively on the business interest carryforward deferred tax asset, following a determination that it is not more likely than not that it will be realized. As of June 30, 2026 and 2025, the Company has a deferred tax asset from the capital loss on the sale of GES for \$3.6

million and \$5.3 million, on which a valuation allowance of \$3.6 million and \$2.3 million has been provided. The capital loss deferred tax asset declined in fiscal year 2026 as a portion was utilized with the sale of the Tampa facility. The reserve increased in fiscal year 2026 as the utilization of the capital loss deferred tax asset was less than estimated at June 30, 2025, as the final sale price of the Tampa facility was less than estimated. See Note 3 - Sale of GES for further information regarding the sale of GES and Note 4 - Restructuring Activities for further information regarding the sale of the Tampa facility. Except as reserved for in the valuation allowance, we believe our deferred income taxes are more likely than not to be realized in the future.

The components of income before taxes on income are as follows:

(Amounts in Thousands)	Year Ended June 30		
	2026	2025	2024
United States	\$ 2,551	\$ (9,681)	\$ (35,055)
Foreign	50,670	35,910	60,254
Total income before taxes on income	<u>\$ 53,221</u>	<u>\$ 26,229</u>	<u>\$ 25,199</u>

The Company currently operates in international jurisdictions which expose the Company to taxation in various regions. The Company continually evaluates its global cash needs. Most of our accumulated unremitted foreign earnings have been invested in active non-U.S. business operations. The aggregate unremitted earnings of the Company's foreign subsidiaries were approximately \$472 million as of June 30, 2026. If such funds were repatriated or we determined that all or a portion of such foreign earnings are no longer permanently reinvested, we may be subject to applicable non-U.S. income and withholding taxes. Determination of the amount of any potential future unrecognized deferred tax liability on such unremitted earnings is not practicable and is recorded in the period when any foreign earnings are determined to be no longer permanently reinvested.

The provision for income taxes is composed of the following items:

(Amounts in Thousands)	Year Ended June 30		
	2026	2025	2024
Current Taxes:			
Federal	\$ (73)	\$ (2,034)	\$ 2,024
Foreign	24,196	12,097	12,372
State	429	(1,688)	587
Total payable	<u>\$ 24,552</u>	<u>\$ 8,375</u>	<u>\$ 14,983</u>
Deferred Taxes:			
Federal	\$ 3,933	\$ (3,344)	\$ (12,280)
Foreign	(2,960)	(1,701)	91
State	138	(1,261)	(3,094)
Valuation allowance	(402)	7,176	4,988
Total deferred	<u>\$ 709</u>	<u>\$ 870</u>	<u>\$ (10,295)</u>
Total provision for income taxes	<u>\$ 25,261</u>	<u>\$ 9,245</u>	<u>\$ 4,688</u>

The amount of income taxes paid (net of refunds) were:

	Year Ended June 30
(Amounts in Thousands)	2026
U.S. Federal	\$ 3,162
State	286
Foreign	
Mexico	\$ 4,226
Poland	875
Thailand	758
China	4,913
Other	\$ (2)
Total	<u>\$ 14,218</u>

The Company adopted ASU 2023-09 prospectively for the year ended June 30, 2026, and a reconciliation of the income tax provision to the amount computed applying the U.S. federal statutory tax rate of 21% to income (loss) before income taxes was as follows:

	Year Ended June 30	
	2026	
	Amount	%
Tax Computed at U.S. Statutory Tax Rate	\$ 11,176	21.0%
State and Local Income Taxes, Net of Federal Income Tax ⁽¹⁾	575	1.1
Foreign Tax Effect		
China		
Statutory rate difference between China and United States	874	1.6
Other	(433)	(0.8)
Mexico		
Impact of foreign exchange rate	699	1.3
Non-Deductible Employee Benefits	815	1.5
Inflation Adjustment	766	1.4
Fixed Assets basis difference	(623)	(1.2)
Other	670	1.3
Poland ⁽²⁾	(727)	(1.3)
Thailand ⁽²⁾	(949)	(1.8)
Romania		
Minimum Tax	809	1.5
Other	15	—
Netherlands		
Withholding Taxes ⁽³⁾	8,958	16.8
Other	18	—
Effects of Cross Border Tax Laws		
Global Intangible low-taxed income ⁽⁴⁾	2,982	5.6
Other	96	0.2
Tax Credits		
Research and Development tax credits	(206)	(0.4)
Other	165	0.3
Change in Valuation Allowance ⁽⁵⁾		
Valuation Allowance - Capital Loss	1,089	2.1
Valuation Allowance - Capitalized Interest Expense	(1,668)	(3.1)
Non Taxable or Nondeductible Items		
Executive Compensation	930	1.8
Other	(474)	(0.9)
Changes in unrecognized tax benefits	—	—
Other Adjustments	(296)	(0.5)
Total	<u>\$ 25,261</u>	<u>47.5%</u>

(1) For the year ended June 30, 2026, state taxes in California, Florida, Michigan, and Indiana comprised the majority (greater than 50%) of the tax effect in this category.

(2) All rate reconciling items for Poland and Thailand are separately below posting threshold.

(3) During fiscal year 2026, the Company recorded dividend withholding tax expense in Netherlands of \$8.9 million. This includes \$4.4 million and \$4.5 million of dividend withholding taxes and related interest from Poland and China, respectively. The dividend withholding taxes from Poland relate to a 2018 dividend, and reflect a 19% dividend withholding tax rate. The expense was recorded in fiscal year 2026 following an unfavorable court decision. The Company may pursue other means of recovery. The dividend withholding taxes from China include \$1.3 million on dividends paid in fiscal year 2026 and \$3.2 million on dividends paid from fiscal years 2021 through 2025. The withholding tax expense reflects a 10% dividend on the fiscal year 2026 dividend as well as the fiscal year 2021 through 2025 dividends, applied retroactively, following a rate settlement reached in 2026.

- (4) The effect of Global Intangible low-taxed income is presented net of foreign tax credit for the year ended June 30, 2026.
- (5) In 2026, we released \$1.9 million of valuation allowance on capitalized interest expense and recorded an additional \$1.5 million valuation allowance on capitalized loss carryforward & state income tax credits.

A reconciliation of the income tax provision, prior to the adoption of ASU 2023-09, to the amount computed applying the U.S. federal statutory tax rate of 21% to income (loss) before income taxes was as follows:

(Amounts in Thousands)	Year Ended June 30			
	2025		2024	
	Amount	%	Amount	%
Tax computed at U.S. federal statutory rate	\$ 5,508	21.0%	\$ 5,292	21.0%
State income taxes, net of federal income tax benefit	(2,810)	(10.7)	(2,433)	(9.7)
Foreign tax rate differential	2,267	8.6	592	2.3
Impact of foreign exchange rates on foreign income taxes	637	2.4	(995)	(3.9)
Valuation allowance	7,176	27.4	4,988	19.8
Asset impairment/Disposal	(4,732)	(18.0)	(2,882)	(11.4)
Research credit	(1,479)	(5.6)	(1,150)	(4.6)
Global intangible low tax income	2,913	11.1	1,339	5.3
Non-deductible compensation	244	0.9	385	1.5
Other - net	(479)	(1.9)	(448)	(1.7)
Total provision for income taxes	<u>\$ 9,245</u>	<u>35.2%</u>	<u>\$ 4,688</u>	<u>18.6%</u>

The Asset impairment/Disposal line in the table above includes, in fiscal year 2024, the tax effects of recording deferred tax assets resulting from the impairment recorded following the held for sale classification of GES. In fiscal year 2025, the line reflects the \$5.3 million tax benefit on the capital loss from the GES sale as well as the tax impact of other adjustments to GES deferred tax assets following the disposal. See Note 3 - Sale of GES for further information regarding the sale.

Changes in the unrecognized tax benefit, excluding accrued interest and penalties, during fiscal years 2026, 2025, and 2024 were as follows:

(Amounts in Thousands)	2026	2025	2024
Beginning balance - July 1	\$ 166	\$ 216	\$ 408
Tax positions related to prior fiscal years:			
Additions	17	5	10
Reductions	—	—	—
Tax positions related to current fiscal year:			
Additions	—	—	—
Reductions	—	—	—
Settlements	—	—	—
Lapses in statute of limitations	—	(55)	(202)
Ending balance - June 30	<u>\$ 183</u>	<u>\$ 166</u>	<u>\$ 216</u>
Portion that, if recognized, would reduce tax expense and effective tax rate	<u>\$ 145</u>	<u>\$ 131</u>	<u>\$ 182</u>

We do not expect the change in the amount of unrecognized tax benefits in the next 12 months to have a significant impact on our results of operations or financial position. We recognize interest and penalties related to unrecognized tax benefits in Provision for Income Taxes on the Consolidated Statements of Income.

Interest and penalties accrued for unrecognized tax benefits were \$0.6 million at each of June 30, 2026, 2025, and 2024. Expenses related to interest and penalties in fiscal years 2026, 2025, and 2024 were not material.

The Company or its wholly-owned subsidiaries file U.S. federal income tax returns and income tax returns in various state, local, and foreign jurisdictions. We are no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2023. We are subject to income tax examinations by various, state, local, and foreign jurisdiction tax authorities for years after June 30, 2020.

Note 13 Share Owners' Equity

The Company has a Board-authorized stock repurchase plan (the "repurchase plan") allowing the purchase of up to \$140 million of our common stock. Purchases may be made under various programs, including in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions, all in accordance with applicable securities laws and regulations. The Repurchase Plan has no expiration date but may be suspended or discontinued at any time.

During fiscal years 2026, 2025, and 2024, the Company repurchased \$11.9 million, \$11.9 million, and \$3.0 million respectively, of common stock under the Repurchase Plan at an average price of \$26.56 per share, \$18.19 per share, and \$22.12 per share respectively, which was recorded as Treasury stock, at cost in the Consolidated Balance Sheets. Since the inception of the Repurchase Plan, the Company has repurchased \$115.6 million of common stock at an average cost of \$16.39 per share.

Note 14 Fair Value

The Company categorizes assets and liabilities measured at fair value into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas level 3 generally requires significant management judgment. The three levels are defined as follows:

- Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
- Level 2: Observable inputs other than those included in level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
- Level 3: Unobservable inputs reflecting management's own assumptions about the inputs used in pricing the asset or liability.

There were no changes in the inputs or valuation techniques used to measure fair values during fiscal year 2026.

Financial Instruments Recognized at Fair Value:

The following methods and assumptions were used to measure fair value:

Financial Instrument	Level	Valuation Technique/Inputs Used
Derivative Assets: Foreign exchange contracts	2	Market - Based on observable market inputs using standard calculations, such as time value, forward interest rate yield curves, and current spot rates, considering counterparty credit risk
Trading securities: Mutual funds held in SERP	1	Market - Quoted market prices
Derivative Liabilities: Foreign exchange contracts	2	Market - Based on observable market inputs using standard calculations, such as time value, forward interest rate yield curves, and current spot rates adjusted for Kimball Electronics' non-performance risk

Recurring Fair Value Measurements:

As of June 30, 2026 and 2025, the fair values of financial assets and liabilities that are measured at fair value on a recurring basis using the market approach are categorized as follows:

		June 30, 2026		
		Level 1	Level 2	Total
(Amounts in Thousands)				
Assets				
Derivatives: foreign exchange contracts		\$ —	\$ 1,024	\$ 1,024
Trading securities: mutual funds held in nonqualified SERP		4,388	—	4,388
Total assets at fair value		<u>\$ 4,388</u>	<u>\$ 1,024</u>	<u>\$ 5,412</u>
Liabilities				
Derivatives: foreign exchange contracts		\$ —	\$ 330	\$ 330
Total liabilities at fair value		<u>\$ —</u>	<u>\$ 330</u>	<u>\$ 330</u>
		June 30, 2025		
		Level 1	Level 2	Total
(Amounts in Thousands)				
Assets				
Derivatives: foreign exchange contracts		\$ —	\$ 3,017	\$ 3,017
Trading securities: mutual funds held in nonqualified SERP		4,114	—	4,114
Total assets at fair value		<u>\$ 4,114</u>	<u>\$ 3,017</u>	<u>\$ 7,131</u>
Liabilities				
Derivatives: foreign exchange contracts		\$ —	\$ 1,910	\$ 1,910
Total liabilities at fair value		<u>\$ —</u>	<u>\$ 1,910</u>	<u>\$ 1,910</u>

We had no level 3 assets or liabilities as of June 30, 2026 and 2025, or any activity in level 3 assets or liabilities during fiscal years 2026, 2025, and 2024.

The nonqualified supplemental employee retirement plan ("SERP") assets consist primarily of equity funds, balanced funds, bond funds, and a money market fund. The SERP investment assets are offset by a SERP liability which represents the Company's obligation to distribute SERP funds to participants. See Note 10 - Employee Benefit Plans for further information regarding the SERP.

Financial Instruments Not Carried At Fair Value:

Financial instruments that are not reflected in the Consolidated Balance Sheets at fair value that have carrying amounts which approximate fair value include the following:

Financial Instrument	Level	Valuation Technique/Inputs Used
Notes receivable	2	Market - Price approximated based on the assumed collection of receivables in the normal course of business, taking into account non-performance risk
Borrowings under credit facilities	2	Market - Based on observable market rates, taking into account Kimball Electronics' non-performance risk

The carrying values of our cash deposit accounts, trade accounts receivable, and trade accounts payable approximate fair value due to their relatively short maturity and immaterial non-performance risk.

Note 15 Derivative Instruments**Foreign Exchange Contracts:**

We operate internationally and are therefore exposed to foreign currency exchange rate fluctuations in the normal course of business. Our primary means of managing this exposure is to utilize natural hedges, such as aligning currencies used in the supply chain with the sale currency. To the extent natural hedging techniques do not fully offset currency risk, we use derivative instruments with the objective of reducing the residual exposure to certain foreign currency rate movements. Factors considered in the decision to hedge an underlying market exposure include the materiality of the risk, the volatility of the market, the duration of the hedge, the degree to which the underlying exposure is committed to, and the availability, effectiveness, and cost of derivative instruments. Derivative instruments are only utilized for risk management purposes and are not used for speculative or trading purposes.

We use forward contracts designated as cash flow hedges to protect against foreign currency exchange rate risks inherent in forecasted transactions denominated in a foreign currency. Non-designated foreign exchange contracts are also used to hedge against foreign currency exchange rate risks related to intercompany balances and other balance sheet positions denominated in currencies other than the functional currencies. As of June 30, 2026, we had outstanding foreign exchange contracts to hedge currencies against the U.S. dollar in the aggregate notional amount of \$2.7 million and to hedge currencies against the Euro in the aggregate notional amount of 45.6 million Euro. The notional amounts are indicators of the volume of derivative activities but may not be indicators of the potential gain or loss on the derivatives.

In limited cases due to unexpected changes in forecasted transactions, cash flow hedges may cease to meet the criteria to be designated as cash flow hedges. Depending on the type of exposure hedged, we may either purchase a derivative contract in the opposite position of the undesignated hedge or may retain the hedge until it matures if the hedge continues to provide an adequate offset in earnings against the currency revaluation impact of foreign currency denominated liabilities.

The fair value of outstanding derivative instruments is recognized on the Consolidated Balance Sheets as a derivative asset or liability and presented with Prepaid expenses and other current assets and Accrued expenses, respectively. When derivatives are settled with the counterparty, the derivative asset or liability is relieved and cash flow is impacted for the net settlement. For derivative instruments that meet the criteria of hedging instruments under FASB guidance, the gain or loss on the derivative instrument is initially recorded net of related tax effect in Accumulated Other Comprehensive Income (Loss), a component of Share Owners' Equity, and is subsequently reclassified into earnings in the period or periods during which the hedged transaction is recognized in earnings. The gain or loss associated with derivative instruments that are not designated as hedging instruments or that cease to meet the criteria for hedging under FASB guidance is reported immediately in Non-operating income (expense), net on the Consolidated Statements of Income.

Based on fair values as of June 30, 2026, we estimate that approximately \$0.7 million of pre-tax derivative gain deferred in Accumulated Other Comprehensive Loss will be reclassified into earnings, along with the earnings effects of related forecasted transactions, within the next twelve months. Losses on foreign exchange contracts are generally offset by gains in operating income in the income statement when the underlying hedged transaction is recognized in earnings. Because gains or losses on foreign exchange contracts fluctuate partially based on currency spot rates, the future effect on earnings of the cash flow hedges alone is not determinable, but in conjunction with the underlying hedged transactions, the result is expected to be a decline in currency risk. The maximum length of time we had hedged our exposure to the variability in future cash flows was 12 months as of both June 30, 2026 and June 30, 2025.

See Note 14 - Fair Value for further information regarding the fair value of derivative assets and liabilities and Note 20 - Accumulated Other Comprehensive Income (Loss) for the changes in deferred derivative gains and losses.

Information on the location and amounts of derivative fair values in the Consolidated Balance Sheets and derivative gains and losses in the Consolidated Statements of Income are presented below.

Fair Values of Derivative Instruments on the Consolidated Balance Sheets

(Amounts in Thousands)	Asset Derivatives			Liability Derivatives		
	Balance Sheet Location	Fair Value As of		Balance Sheet Location	Fair Value As of	
		June 30 2026	June 30 2025		June 30 2026	June 30 2025
Derivatives Designated as Hedging Instruments:						
Foreign exchange contracts	Prepaid expenses and other current assets	\$ 1,023	\$ 2,540	Accrued expenses	\$ 327	\$ 927
Derivatives Not Designated as Hedging Instruments:						
Foreign exchange contracts	Prepaid expenses and other current assets	1	477	Accrued expenses	3	983
Total derivatives		\$ 1,024	\$ 3,017		\$ 330	\$ 1,910

The Effect of Derivative Instruments on Other Comprehensive Income (Loss)

(Amounts in Thousands)	June 30		
	2026	2025	2024
Amount of Pre-Tax Gain or (Loss) Recognized in Other Comprehensive Income (Loss) (OCI) on Derivatives:			
Foreign exchange contracts	\$ 3,968	\$ (82)	\$ 2,621

The Effect of Derivative Instruments on Consolidated Statements of Income

(Amounts in Thousands)		Year Ended June 30		
Derivatives in Cash Flow Hedging Relationships	Location of Gain or (Loss)	2026	2025	2024
Amount of Pre-Tax Gain or (Loss) Reclassified from Accumulated OCI into Income:				
Foreign exchange contracts	Cost of Sales	\$ 4,495	\$ (2,960)	\$ 7,530
Derivatives Not Designated as Hedging Instruments				
Amount of Pre-Tax Gain or (Loss) Recognized in Income on Derivatives:				
Foreign exchange contracts	Non-operating income (expense)	\$ (3,005)	\$ (1,069)	\$ 64
Total Derivative Pre-Tax Gain (Loss) Recognized in Income		\$ 1,490	\$ (4,029)	\$ 7,594

Note 16 Accrued Expenses

Accrued expenses consisted of the following:

(Amounts in Thousands)	June 30	
	2026	2025
Compensation	\$ 22,487	\$ 18,714
Non-inventory advance payments	9,976	5,636
Taxes	15,138	9,077
Interest	816	1,449
Retirement plan	335	251
Derivatives	330	1,910
Insurance	2,299	1,368
Operating leases	2,338	520
Restructuring	33	2,018
Other expenses	5,108	5,546
Total accrued expenses	<u>\$ 58,860</u>	<u>\$ 46,489</u>

Note 17 Segment Reporting

The Company's operations are managed by its Chief Executive Officer, who has been identified as our chief operating decision maker "CODM." The CODM evaluates the performance of multiple business units domestically and globally. Each of these business units qualify as operating segments, providing contract manufacturing services, including engineering and supply chain support, for the production of electronic assemblies and other products including medical devices, medical disposables, precision molded plastics, and complete device assembly primarily in automotive, medical, and industrial applications, to the specifications and designs of our customers. These operating segments are aggregated into one reportable segment, Business Unit Operations, due to similarities in the nature of the products, the production process, the type of customer, the methods used to distribute the products, and long-term economic characteristics. The accounting policies for the Business Unit Operations segment are consistent with those described in the Summary of Significant Accounting Policies.

The CODM uses operating income as the measure of profitability to evaluate income or loss generated from each operating segment and to guide decisions on capital investments and assess performance. These decisions may include capital expenditures and/or acquisitions. Expenditures for long-lived assets for fiscal years 2026, 2025, and 2024 are \$51.7 million, \$33.7 million, and \$47.0 million, respectively. The measure of segment assets is reported on the Consolidated Balance Sheet as Total Assets; however, it should be noted the discrete balance sheet information is not utilized by the CODM in assessing performance and allocating resources.

Certain corporate administrative expenses have been allocated to the Business Unit Operations Segment based upon the nature of the expenses.

The following table presents significant operations segment net sales and expenses:

(Amounts in Thousands)	Year Ended June 30		
	2026	2025	2024
Net Sales			
Business Unit Operations	\$ 1,457,293	\$ 1,519,456	\$ 1,748,218
Corporate/Eliminations	(25,915)	(32,729)	(33,708)
Total Net Sales	\$ 1,431,378	\$ 1,486,727	\$ 1,714,510
Cost of Sales (Excluding Depreciation and Amortization)	1,275,552	1,345,624	1,537,813
Selling and Administrative (Excluding Depreciation and Amortization)	60,808	49,975	65,036
Depreciation and Amortization	38,705	36,994	38,030
Other General Income	—	—	(892)
Restructuring Expense	4,977	10,990	2,386
Goodwill Impairment	—	—	5,820
(Gain on Disposal) Asset Impairment	(14,721)	(2,391)	17,040
Total Operating Income	\$ 66,057	\$ 45,535	\$ 49,277

Note 18 Geographic Information

The following geographic area data includes net sales based on the country location of the Company's business unit providing the manufacturing or other service and long-lived assets based on physical location. Long-lived assets include property and equipment and capitalized software, and amounts as of June 30, 2025 exclude the amounts classified as held for sale.

(Amounts in Thousands)	Year Ended June 30		
	2026	2025	2024
Net Sales:			
Mexico	\$ 359,707	\$ 445,717	\$ 519,279
United States	293,600	341,817	404,974
Poland	288,653	241,939	261,433
China	236,513	258,896	248,095
Thailand	158,610	132,298	171,340
Other Foreign	94,295	66,060	109,389
Total net sales	<u>\$ 1,431,378</u>	<u>\$ 1,486,727</u>	<u>\$ 1,714,510</u>

(Amounts in Thousands)	June 30	
	2026	2025
Long-Lived Assets:		
Mexico	\$ 89,290	\$ 99,687
United States	63,604	39,143
Poland	55,498	54,356
China	26,662	30,470
Thailand	24,579	25,579
Other Foreign	16,480	17,996
Total long-lived assets	<u>\$ 276,113</u>	<u>\$ 267,231</u>

Note 19 Earnings Per Share

Basic and diluted earnings per share were calculated as follows under the two-class method:

(Amounts in thousands, except per share data)	Year Ended June 30		
	2026	2025	2024
Basic and Diluted Earnings Per Share:			
Net Income	\$ 27,960	\$ 16,984	\$ 20,511
Less: Net Income allocated to participating securities	23	19	24
Net Income allocated to common Share Owners	<u>\$ 27,937</u>	<u>\$ 16,965</u>	<u>\$ 20,487</u>
Basic weighted average common shares outstanding	24,501	24,782	25,079
Dilutive effect of average outstanding stock compensation awards	267	235	199
Dilutive weighted average shares outstanding	<u>24,768</u>	<u>25,017</u>	<u>25,278</u>
Earnings Per Share of Common Stock:			
Basic	\$ 1.14	\$ 0.68	\$ 0.82
Diluted	\$ 1.13	\$ 0.68	\$ 0.81

Note 20 Accumulated Other Comprehensive Income (Loss)

The changes in the balances of each component of Accumulated Other Comprehensive Income (Loss), net of tax, were as follows:

(Amounts in Thousands)	Foreign Currency Translation Adjustments	Derivative Gain (Loss)	Post Employment Benefits Net Actuarial Gain (Loss)	Accumulated Other Comprehensive Income (Loss)
Balance at June 30, 2024	\$ (14,260)	\$ (2,395)	\$ (1,152)	\$ (17,807)
Other comprehensive income (loss) before reclassifications	16,523	(64)	44	16,503
Reclassification to (earnings) loss	—	2,198	169	2,367
Net current-period other comprehensive income (loss)	\$ 16,523	\$ 2,134	\$ 213	\$ 18,870
Balance at June 30, 2025	\$ 2,263	\$ (261)	\$ (939)	\$ 1,063
Other comprehensive income (loss) before reclassifications	(5,737)	2,977	192	(2,568)
Reclassification to (earnings) loss	—	(3,332)	165	(3,167)
Net current-period other comprehensive income (loss)	(5,737)	(355)	357	(5,735)
Balance at June 30, 2026	\$ (3,474)	\$ (616)	\$ (582)	\$ (4,672)

The following reclassifications were made from Accumulated Other Comprehensive Income (Loss) to the Consolidated Statements of Income:

Reclassifications from Accumulated Other Comprehensive Income (Loss)

(Amounts in Thousands)	Year Ended June 30		Affected Line Item in the
	2026	2025	Consolidated Statements of Income
Derivative Gain (Loss) ⁽¹⁾	\$ 4,495	\$ (2,960)	Cost of Sales
	(1,163)	762	Benefit (Provision) for Income Taxes
	\$ 3,332	\$ (2,198)	Net of Tax
Postemployment Benefits:			
Amortization of Actuarial Gain (Loss) ⁽²⁾	\$ (217)	\$ (222)	Non-operating income
	52	53	Benefit (Provision) for Income Taxes
	\$ (165)	\$ (169)	Net of Tax
Total Reclassifications for the Period	\$ 3,167	\$ (2,367)	Net of Tax

Amounts in parentheses indicate reductions to income.

(1) See Note 15 - Derivative Instruments for further information on derivative instruments.

(2) See Note 10 - Employee Benefit Plans for further information on postemployment benefit plans.

Note 21 Leases

The Company determines if a contract is or contains a lease at inception. The Company leases certain office, manufacturing, and warehouse facilities and equipment under operating leases, in addition to land on which certain office and manufacturing facilities reside. These operating leases expire from fiscal year 2027 to 2056.

Operating lease costs in fiscal years 2026, 2025, and 2024 were \$2.9 million, \$1.5 million, and \$1.9 million, respectively. During fiscal year 2025, the Company executed a lease for a facility to expand our medical CDMO footprint with the lease commencing in June 2025, including obtaining \$10.6 million operating right-of-use assets in exchange for operating lease liabilities. During fiscal year 2026, the Company received the \$4.6 million tenant allowance associated with the Indiana manufacturing facility lease, which increased the operating lease liability from June 30, 2025.

The lease assets and liabilities, which exclude leases with terms of 12 months or less, as of June 30, 2026 and 2025, were as follows:

(Amounts in Thousands)	<u>2026</u>	<u>2025</u>
Operating lease right-of-use assets (included in Other Assets)	\$ 10,933	\$ 11,779
Operating lease liability, current (included in Accrued expenses)	2,338	\$ 520
Operating lease liability, noncurrent (included in Other long-term liabilities)	\$ 14,532	\$ 11,386
Weighted average remaining lease term in years - operating leases	9.4	9.6
Weighted average discount rate - operating leases	5.3%	5.9%

Cash payments for operating leases included in the measurement of lease liabilities in fiscal years 2026, 2025, and 2024 were \$1.1 million, \$0.7 million, and \$1.4 million, respectively, and were included in Cash Flows from Operating Activities in the Consolidated Statements of Cash Flows.

Future lease payments as of June 30, 2026 are as follows:

(Amounts in Thousands)	
2027	\$ 2,392
2028	2,110
2029	2,059
2030	2,030
2031	2,060
Thereafter	10,826
Total undiscounted lease payments	\$ 21,477
Less: imputed interest	4,607
Present value of lease liabilities	<u>\$ 16,870</u>

Note 22 Subsequent Event

On June 26, 2026, we entered into a definitive agreement to acquire the shares of Helvoet Polymer Technologies B.V. and Helvoet Rubber & Plastics Technologies (India) Pvt. Ltd. (collectively referred to as “Helvoet”) from Hydratec Industries N.V. The acquisition closed on July 1, 2026, after our fiscal year end. Helvoet is a contract development and manufacturing organization based in The Netherlands and India, with a focus on microfluidics, diagnostics, and drug delivery applications.

The Company paid a cash purchase price based on an enterprise value of approximately 90.0 million Euro, or approximately \$103.0 million. The transaction price is subject to certain post-closing working capital adjustments. The acquisition was funded with a combination of the Company’s cash and existing lines of credit. The initial purchase price allocation and valuation for this acquisition was not completed at the time the financial statements were issued due to the timing of the acquisition closing. As a result, disclosures required for business combinations are not available at this time.

For the year ended June 30, 2026, we have incurred \$0.5 million in acquisition costs, recognized as Selling and Administrative Expenses on our Consolidated Statements of Income.

Item 9 - Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

None.

Item 9A - Controls and Procedures

- (a) Evaluation of disclosure controls and procedures.

Kimball Electronics maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed, the Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure controls and procedures were effective as of June 30, 2026.

- (b) Management's report on internal control over financial reporting.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 and the rules and regulations adopted pursuant thereto, the Company included a report of management's assessment of the effectiveness of its internal control over financial reporting as part of this report. The effectiveness of the Company's internal control over financial reporting as of June 30, 2026 has been audited by the Company's independent registered public accounting firm. Management's report and the independent registered public accounting firm's attestation report are included in the Company's Consolidated Financial Statements under the caption entitled "Management's Report on Internal Control Over Financial Reporting" and "Report of Independent Registered Public Accounting Firm" and are incorporated herein by reference.

- (c) Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2026 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B - Other Information

During the three months ended June 30, 2026, no officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of the Company's securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement."

Item 9C - Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

PART III

Item 10 - Directors, Executive Officers and Corporate Governance

Directors

The information required by this Item 10 with respect to Directors will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Committees

The information required by this Item 10 with respect to the Audit Committee and its financial expert and with respect to the Nominating and ESG Committee's responsibility for establishing procedures by which Share Owners may recommend nominees to the Board of Directors will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Information about Our Executive Officers

The information required by this Item 10 with respect to Executive Officers of the Registrant is included at the end of Part I of this Annual Report on Form 10-K and is incorporated herein by reference. Additional information about our Executive Officers will also appear in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K.

Compliance with Section 16(a) of the Exchange Act

The information required by this Item 10 with respect to compliance with Section 16(a) of the Securities Exchange Act of 1934 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Code of Ethics

Kimball Electronics has a code of ethics (its Code of Conduct) that applies to all of its employees, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Accounting Officer (functioning as Principal Accounting Officer). The code of ethics is posted on the Company's website at <https://investors.kimballelectronics.com> under Governance Documents. The Company's website and the information contained therein, or incorporated therein, are not intended to be incorporated into this Annual Report on Form 10-K. We will provide without charge, upon request, a copy of the Code of Conduct. Anyone wishing to obtain a copy should write to ATTN: Code of Conduct Requests, Secretary, Kimball Electronics, 1205 Kimball Boulevard, Jasper, IN 47546. It is our intention to disclose any amendments to the code of ethics on this website. In addition, any waivers of the code of ethics for directors or executive officers of the Company will be disclosed in a Current Report on Form 8-K.

Insider Trading Arrangements and Policies

Kimball Electronics has adopted insider trading policies and procedures governing the purchase, sale, and or other dispositions of the Company's securities by directors, officers, and employees that are reasonably designed to promote compliance with insider trading laws, rules, and regulations, and any listing standards applicable to us. Our insider trading policy has been filed as Exhibit 19 to this Annual Report on Form 10-K.

Item 11 - Executive Compensation

The information required by this Item 11 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Item 12 - Security Ownership of Certain Beneficial Owners and Management and Related Share Owner Matters

Security Ownership

The information required by this Item 12 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Securities Authorized for Issuance Under Equity Compensation Plans

The information required by this Item 12 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Item 13 - Certain Relationships and Related Transactions, and Director Independence

Relationships and Related Transactions

The information required by this Item 13 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Director Independence

The information required by this Item 13 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

Item 14 - Principal Accounting Fees and Services

The information required by this Item 14 will be included in our definitive Proxy Statement to be filed no later than 120 days after the end of the Company's fiscal year covered by this Annual Report on Form 10-K and is incorporated herein by reference.

PART IV

Item 15 - Exhibits, Financial Statement Schedules

(a) The following documents are filed as part of this report:

(1) Financial Statements:

The following consolidated financial statements of the Company are found in Item 8 and incorporated herein.

Management's Report on Internal Control Over Financial Reporting	34
Report of Independent Registered Public Accounting Firm (PCAOB No. 34)	35
Consolidated Balance Sheets as of June 30, 2026 and 2025	38
Consolidated Statements of Income for Each of the Three Years in the Period Ended June 30, 2026 ..	39
Consolidated Statements of Comprehensive Income for Each of the Three Years in the Period Ended June 30, 2026	40
Consolidated Statements of Cash Flows for Each of the Three Years in the Period Ended June 30, 2026	41
Consolidated Statements of Share Owners' Equity for Each of the Three Years in the Period Ended June 30, 2026	42
Notes to Consolidated Financial Statements	43

(2) Financial Statement Schedules:

II. Valuation and Qualifying Accounts for Each of the Three Years in the Period Ended June 30, 2026	80
---	----

Schedules other than those listed above are omitted because they are either not required or not applicable, or the required information is presented in the Consolidated Financial Statements.

(3) Exhibits

See the Index of Exhibits which immediately precedes the Signatures page in this Annual Report on Form 10-K for a list of the exhibits filed or incorporated herein as a part of this report.

Item 16 - Form 10-K Summary

None.

KIMBALL ELECTRONICS, INC.
INDEX OF EXHIBITS

Exhibit No.	Description	Incorporated by Reference			
		Form	Period Ending	Exhibit	Filing Date
2.1 ^{(c)(d)}	Stock Purchase Agreement By and Among Kimball Electronics, Inc. (“Seller”), The Sole Stockholder of Kimball Electronics Indiana, Inc. (“Company”); and Avera Test Systems Inc. (“Buyer”) and Company Dated as of July 31, 2024	8-K		2.1	8/1/2024
2.2 ^{(c)(d)}	Share Purchase Agreement of Helvoet Polymer Technologies B.V. and Helvoet Rubber & Plastics Technologies (India) Pvt. Ltd. between Hydratec Industries N.V., as Seller, and Kimball Electronics Netherlands, B.V., a wholly owned subsidiary of Kimball Electronics, Inc., as Purchaser, dated as of June 26, 2026	8-K		2.1	7/1/2026
3.1	Amended and Restated Articles of Incorporation of the Company	8-K		3.1	2/18/2021
3.2	Amended and Restated By-Laws of the Company	8-K		3.2	9/23/2024
4.1	Description of the Company’s Registered Securities	<i>Filed Herewith</i>			
10.1 ^(a)	Kimball Electronics, Inc. Supplemental Employee Retirement Plan (“SERP”)	10		10.8	9/4/2014
10.2 ^(a)	Kimball Electronics, Inc. Non-Employee Directors Stock Compensation Deferral Plan	8-K		10.1	10/25/2016
10.3 ^(a)	Form of Fee Deferral Election Agreement under the Kimball Electronics, Inc. Non-Employee Directors Stock Compensation Deferral Plan	10-K	6/30/2023	10.5	8/24/2023
10.4 ^(a)	Form of Annual Retainer Fee Election Agreement under the Kimball Electronics, Inc. Non-Employee Directors Stock Compensation Deferral Plan	10-K	6/30/2023	10.6	8/24/2023
10.5 ^(a)	Kimball Electronics, Inc. Leadership Team Severance and Change in Control Plan	8-K		10.2	11/21/2023
10.6 ^(a)	Kimball Electronics, Inc. 2023 Equity Incentive Plan	8-K		10.1	11/21/2023
10.7 ^(a)	Form of Stock Award Notice for Performance Shares under Kimball Electronics, Inc. 2023 Equity Incentive Plan	10-Q	9/30/2025	10.1	11/6/2025
10.8 ^(a)	Form of Stock Award Notice for Restricted Shares under Kimball Electronics, Inc. 2023 Equity Incentive Plan	10-K	6/30/2024	10.14	8/23/2024
10.9	Amended and Restated Credit Agreement, dated as of December 19, 2024, among Kimball Electronics, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Bank of America, N.A., as Documentation Agent	8-K		10.1	12/20/2024
10.10	Amended and Restated Credit Agreement, dates as of April 30, 2026, among Kimball Electronics, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Bank of America, N.A., as Documentation Agent	10-Q	3/31/2026	10.1	5/6/2026
10.11 ^(a)	2024 KE Employee Profit Sharing Bonus Plan	10-Q	12/31/2024	10.2	2/6/2025
10.12 ^(a)	Amendments to the Company’s Supplemental Employee Retirement Plan	10-Q	12/31/2024	10.3	2/6/2025
19	Insider Trading Policies and Procedures	<i>Filed Herewith</i>			
21	Subsidiaries of the Registrant	<i>Filed Herewith</i>			
23	Consent of Independent Registered Public Accounting Firm	<i>Filed Herewith</i>			
24	Power of Attorney	<i>Filed Herewith</i>			

Exhibit No.	Description	Incorporated by Reference		
		Form	Period Ending	Exhibit Filing Date
31.1	Certification filed by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	<i>Filed</i> <i>Herewith</i>		
31.2	Certification filed by Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	<i>Filed</i> <i>Herewith</i>		
32.1 ^(b)	Certification furnished by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	<i>Furnished</i> <i>Herewith</i>		
32.2 ^(b)	Certification furnished by the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	<i>Furnished</i> <i>Herewith</i>		
97	Policy Relating to Recovery of Erroneously Awarded Compensation	<i>Filed</i> <i>Herewith</i>		
101.INS	Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its Inline XBRL tags are embedded within the Inline XBRL document	<i>Filed</i> <i>Herewith</i>		
101.SCH	Inline XBRL Taxonomy Extension Schema Document	<i>Filed</i> <i>Herewith</i>		
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	<i>Filed</i> <i>Herewith</i>		
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	<i>Filed</i> <i>Herewith</i>		
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	<i>Filed</i> <i>Herewith</i>		
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	<i>Filed</i> <i>Herewith</i>		
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)	<i>Filed</i> <i>Herewith</i>		

^(a) Constitutes management contract or compensatory arrangement.

^(b) In accordance with Item 601(b)(32)(ii) of Regulation S-K, the certifications furnished in Exhibit 32.1 and 32.2 will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

^(c) Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will supplementally furnish any of the omitted schedules or exhibits to the Securities and Exchange Commission upon request.

^(d) Certain information contained in Exhibit 2.1 and Exhibit 2.2 has been excluded pursuant to Regulation S-K Item 601(b)(2) because it is both (1) not material and (2) of the type that the Company treats as private or confidential. The Registrant will supplementally furnish a copy of the unredacted exhibit to the Securities and Exchange Commission upon request; provided, however, that the Registrant may request confidential treatment.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

KIMBALL ELECTRONICS, INC.

By: /s/ JANA T. CROOM

Jana T. Croom

Chief Financial Officer

August 19, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

/s/ RICHARD D. PHILLIPS

Richard D. Phillips

Chief Executive Officer and Director

August 19, 2026

/s/ JANA T. CROOM

Jana T. Croom

Chief Financial Officer

August 19, 2026

/s/ ADAM M. BAUMANN

Adam M. Baumann

Chief Accounting Officer

August 19, 2026

SignatureGREGORY J. LAMPERT *

Gregory J. Lampert
Director

ROBERT J. PHILLIPPY *

Robert J. Phillippy
Director

HOLLY A. VAN DEURSEN *

Holly A. Van Deursen
Director

TOM G. VADAKETH *

Tom G. Vadaketh
Director

SignatureCOLLEEN C. REPPLIER *

Colleen C. Repplier
Director

GREGORY A. THAXTON *

Gregory A. Thaxton
Director

MICHELE A. M. HOLCOMB, PhD *

Michele A. M. Holcomb, PhD
Director

- * The undersigned does hereby sign this document on my behalf pursuant to powers of attorney duly executed and filed with the Securities and Exchange Commission, all in the capacities as indicated:

Date

August 19, 2026

/s/ RICHARD D. PHILLIPS

Richard D. Phillips
As Attorney-In-Fact

KIMBALL ELECTRONICS, INC.

Schedule II. - Valuation and Qualifying Accounts

Description	Balance at Beginning of Year	Additions (Reductions) to Expense	Adjustments to Other Accounts	Write-offs and Recoveries	Balance at End of Year
(Amounts in Thousands)					
Year Ended June 30, 2026					
Valuation Allowances:					
Receivables	\$ 102	\$ 156	\$ 281	\$ (3)	\$ 536
Long-Term Receivables	\$ 3,804	\$ 400	\$ 787	\$ —	\$ 4,991
Deferred Tax Asset	\$ 16,418	\$ (402)	\$ —	\$ —	\$ 16,016
Year Ended June 30, 2025					
Valuation Allowances:					
Receivables	\$ 1,002	\$ (15)	\$ (138)	\$ (747)	\$ 102
Long-Term Notes Receivable	\$ 1,936	\$ —	\$ 1,868	\$ —	\$ 3,804
Deferred Tax Asset	\$ 7,434	\$ 7,176	\$ 1,808	\$ —	\$ 16,418
Year Ended June 30, 2024					
Valuation Allowances:					
Receivables	\$ 257	\$ 1,039	\$ —	\$ (294)	\$ 1,002
Long-Term Notes Receivable	\$ —	\$ 1,936	\$ —	\$ —	\$ 1,936
Deferred Tax Asset	\$ 4,254	\$ 4,988	\$ (1,808)	\$ —	\$ 7,434

Exhibit 31.1

**CERTIFICATION PURSUANT TO
RULE 13a-14(a)/15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Richard D. Phillips, certify that:

1. I have reviewed this Annual Report on Form 10-K of Kimball Electronics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 19, 2026

/s/ RICHARD D. PHILLIPS

RICHARD D. PHILLIPS
Chief Executive Officer and Director

Exhibit 31.2

**CERTIFICATION PURSUANT TO
RULE 13a-14(a)/15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jana T. Croom, certify that:

1. I have reviewed this Annual Report on Form 10-K of Kimball Electronics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 19, 2026

/s/ JANA T. CROOM

JANA T. CROOM
Chief Financial Officer

Exhibit 32.1

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Kimball Electronics, Inc. (the “Company”) on Form 10-K for the period ended June 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard D. Phillips, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 19, 2026

/s/ RICHARD D. PHILLIPS

RICHARD D. PHILLIPS
Chief Executive Officer and Director

Exhibit 32.2

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Kimball Electronics, Inc. (the “Company”) on Form 10-K for the period ended June 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jana T. Croom, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 19, 2026

/s/ JANA T. CROOM

JANA T. CROOM
Chief Financial Officer

Leadership

Board of Directors

Robert J. Phillippy

Chairperson of the Board

Michele A. M. Holcomb, PhD.

Director

Gregory J. Lampert

Director

Richard D. Phillips

Director

Colleen C. Repplier

Director

Gregory A. Thaxton

Director

Tom G. Vadaketh

Director

Holly A. Van Deursen

Director

Executive Officers

Richard D. Phillips

Chief Executive Officer

Adam M. Baumann

Chief Accounting Officer

Jana T. Croom

Chief Financial Officer

Jessica L. DeLorenzo

Chief Human Resources Officer

Douglas A. Hass

Chief Legal & Administrative Officer,
Secretary

Steven T. Korn

Chief Operating Officer

Andrew D. Regrut

Vice President, Investor Relations,
Strategic Development, and Treasurer

Kathy R. Thomson

Chief Commercial Officer

Corporate Information

Form 10-K Report

A copy of our Annual Report on Form 10-K filed with the Securities and Exchange Commission is available on our website at investors.kimballectronics.com. We will provide without charge, upon request, a copy of the Form 10-K or our Code of Conduct. Anyone wishing to obtain a copy should write to ATTN: Secretary, Kimball Electronics, 1205 Kimball Boulevard, Jasper, IN 47546.

Transfer Agent and Registrar of the Common Stock

Share Owners with questions concerning address changes, registration changes, lost share certificates, or transferring shares may contact:

Mail

Broadridge Shareholder Services
c/o Broadridge Corporate Issuer Solutions
PO Box 1342
Brentwood, NY 11717-0718
shareholder@broadridge.com
1-303-562-9275 or
1-888-789-8606

Overnight Mail

Broadridge Shareholder Services
c/o Broadridge Corporate Issuer Solutions
1155 Long Island Avenue
Edgewood, NY 11717-8309
Attn: IWS


Website

shareholder.broadridge.com



Kimball Electronics Executive Leadership Team (above L to R):

Steve Korn, Kathy Thomson, Ric Phillips, Jessica DeLorenzo, Doug Hass,
Jana Croom, Andy Regrut





World Headquarters

Kimball Electronics, Inc.
1205 Kimball Boulevard
Jasper, IN 47546

www.kimballelectronics.com